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intrOductiOn
Prolapse is derived from the Latin word prolabi, which literally means ‘sliding forward’. 
Pelvic Organ Prolapse (abbreviated as POP) is defined as the downward descent of 
female pelvic organs, including the bladder, uterus or post-hysterectomy vaginal cuff, 
and the small or large bowel, resulting in protrusion of the vagina, uterus or both.1 
The anterior vaginal wall is the most typical compartment of the vagina to prolapse.2 
This type of prolapse usually includes descent of the bladder: when the bladder 
protrudes, this is called cystocele. Apical prolapse entails either the uterus or post-
hysterectomy vaginal cuff and can affect the small intestine (enterocele), bladder, or 
colon (sigmoidocele). Posterior vaginal wall prolapse concerns the rectum (rectocele) 
but can also include the small or large bowel.1 
Women who develop Pelvic Organ Prolapse can present with one symptom, such 
as vaginal bulging or pelvic pressure, or with several, including many bladder, bowel 
and pelvic symptoms. The hymen seems to be an important cutoff point for symptom 
development.3 Of all symptoms presented, the only one that is acknowledged 
consistently by patients with severe prolapse is the presence of a vaginal bulge that 
can be seen or felt.4, 5 
Uterovaginal support can be measured with the Pelvic Organ Prolapse 
Quantification (POP-Q) system and can broadly be classified in 4 stages, ranging 
from 0 (perfect pelvic support) to IV (total procidentia or complete vaginal eversion).6 
histOry 
Vaginal prolapse typically is a condition that affects women and is of all times. 
Soranus, a Greek physician and medical writer reported on vaginal prolapse already 
in the 2nd century AD. He believed that a vaginal prolapse could be caused by falling 
to the ground, which consequently caused the rupture of the suspending structures 
of the vagina. On the other hand, circumstances that cause severe emotional stress, 
such as the loss of a child or even a heavy storm at sea (!) were also considered to be 
causes of prolapse of the uterus or vagina. 
Some centuries before Soranus, Hippocrates had advised women with prolapse 
to be hanged upside down on a vertical standing ladder for 24 hours to enable 
gravitational forces to reduce the vaginal prolapse of these women (figure 1). After 
the ‘natural’ repositioning of the prolapsed vagina, it was stuffed with a lemon or 
pomegranate to keep the uterus and/or vagina in place. 
Digital repositions and stuffing of the vagina with a sponge soaked in diluted 
vinegar or sour wine are reported as well in ancient times.
Reinier de Graaf (Reijnerus de Graeff, 1641-1673) (figure 2), physician and 
anatomist in Delft, has devoted a chapter in his book ‘De mulierum organis 
generationi inservientibus tractatus novus’ (1672) to the diagnosis and therapy of 
the prolapsed uterus:
Soo nu de Lijf-moeder tegelijk uyt haar oude plaats nederwaarts sakt, benamen wy 
dit neder-dalen ‘t uytsakken des Lijf-moeders; ’t welk na dat het veel of weynig is, 
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soo glijt somtyts de Lijf-moeder halverweegs de Scheede, somtyts tot aan den in 
gang des selfs toe, en snapt by wylen ook wel gants by de Schamelheydt uyt, op 
allerhande manieren beleedigt; jaa soo, dat eenige genootsaakt sijn geweest deselve 
af te setten; waar van gedenk-waardige Voor-beelden sijn te sien.
De Graaf reported of some examples that demonstrate that 
Vrouwen sonder Lijf-moeder (alhoewel het weg-neemen om de veel-voudige Vaten, 
die deselve bekruypen, seer gevaarlijk is) nogtans kunnen leeven. 
After having performed a postmortem examination on a woman in the ‘Gasthuis’ in 
Delft, De Graaf reported in 1671 on the use of certain pessaries for vaginal prolapse. 
These were made of cork and covered with wax to keep the uterus or vagina in place: 
Welke met een uyt-gesakte Lijf-moeder hadt gegaen: wy vonden dan in de Scheede 
geen vleesig oft’ eenig ander uyt-wasch, maar alleen een groote wassen-bol, door 
welkers in-sitten de Scheede (die andersins, om ‘t seer verslappen der Banden 
des Lijf-moeders wierde om-gekeert en buyten uyt-hing) nu met de Lijf-moeder 
binnewaarts wierd’ op-gehouden. (Source: History of treatment of POP, unpublished 
work by A.L.Milani, H.L.Houtzager and M.E.Vierhout)
figure 1. Repositioning of utero-vaginal 
prolapse of a woman at the time of 
Hippocrates
figure 2. Reinier de Graaf, physician 
and anatomist in Delft (1641-1773)
preValence
Pelvic Organ Prolapse is a highly prevalent condition that may affect 50% of parous 
women, causing a variety of urinary, bowel and sexual symptoms that may be 
associated; however, not all of these women are bothered by this condition.7 Despite 
the fact that pelvic organ prolapse is one of the most usual indications for gynecologic 
surgery, epidemiological studies on incidence and prevalence are rare and usually 
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based on clinical populations or surgical registries. In one multicenter study of 1006 
women aged 18-83 years presenting for routine gynecological care, 24% had normal 
support and 38% stage I, 35% stage II and 2% stage III Pelvic Organ Prolapse.3 
A large Dutch cross-sectional study among community dwelling women aged 
between 45 and 85 years, demonstrated a prevalence rate of symptomatic POP of 
11.4%.8 Of these women 36.5% were diagnosed with stage I, 33% with stage II, 5% 
with stage III and only 0,5% with stage IV prolapse. However, only 6.9% of women 
diagnosed with stage I and 15.8% of those diagnosed with stage  II experienced 
vaginal bulge symptoms as opposed to 43,3% of women with stage III and 100% of 
women with stage IV prolapse.9 Thus, some loss of utero-vaginal support is present 
in most adult women, and if not symptomatic, should be considered physiological. 
causes and risk factOrs
The cause of Pelvic Organ Prolapse is likely to be multifactorial, attributable to a 
combination of risk factors. Vaginal childbirth, advancing age and increasing body-
-mass index are the most consistent risk factors, of which vaginal childbirth is the most 
frequently associated risk factor. Compared with nulliparous individuals, the relative 
risk of developing prolapse was 8.4 for a woman who had delivered two children and 
10.9 for someone with four or more children.10 Every additional delivery up to five 
births increased the risk of worsening prolapse by 10-20%.2 Furthermore, women 
with a body-mass index of more than 26 kg/m2 are more likely (OR 3.0,1.6-5.7) to 
undergo surgery for prolapse than those with a lower value.11 
Potential other risk factors are forceps delivery, prolonged second stage of 
labour, macrosomia, family history of POP, race, occupations entailing heavy lifting, 
constipation, connective tissue disorders and previous hysterectomy.1 Maternal 
history of POP and symptoms of prolapse during pregnancy are proven risk factors 
for the development of POP as well.8
pelVic Organ suppOrt and pathOphysiOlOgy
Anatomical support of pelvic viscera is mainly provided by the levator ani muscle 
complex and connective tissue attachments of the pelvic organs (endopelvic fascia).1 
Disruption or dysfunction of one or both of these components can lead to loss of 
support and, eventually, pelvic organ prolapse. The muscles of the levator ani complex 
are tonically contracted at rest and act to close the genital hiatus and provide a 
platform for the pelvic viscera. Defects in the pubovisceral and iliococcygeal areas of 
the levator ani muscle complex have been noted on Magnetic Resonance Imaging in 
20% of primiparous women, which are not seen in nulliparous individuals, suggesting 
that vaginal delivery contributes to the development of pelvic organ prolapse through 
levator ani muscle injury.12, 13 Levator ani defects can also be detected by translabial 
ultrasound imaging techniques.14-16 
The endopelvic fascia is the connective tissue network that envelops all organs of 
the pelvis and connects them loosely to the supportive musculature and bones of the 
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pelvis. DeLancey has documented three levels of fascial suspension of pelvic organs 
(figure 3). The upper third of the vagina (level I) is suspended from the pelvic walls by 
vertical fibers of the paracolpium, which is a continuation of the cardinal ligament. 
In the middle third of the vagina the paracolpium attaches the vagina laterally to the 
arcus tendineus and fascia of the levator ani muscles (level II). The vagina’s lower 
third fuses with the perineal membrane, levator ani muscles, and perineal body 
(level  III).17 It’s increasingly realized today that restoration of level I support is of 
utmost importance in securing a successful outcome in prolapse surgery.18 
Historically, cystoceles have been divided into so-called ‘displacement’ and 
‘distension’ cystoceles. Displacement cystoceles result from detachments of the 
endopelvic fascia from the arcus tendineus fascia pelvis, which are also known as 
paravaginal defects and were first described by White in 1909.19 In 1976 Richardson 
described, next to what he called the fascia-lateral (or paravaginal), transverse and 
midline defects. The latter defects were considered to cause a ‘distension’ cystocele 
and are also known as so-called central defects.20 The overall prevalence of a 
paravaginal defect in patients with anterior vaginal wall prolapse though is low and 
clinical detection poor.21 
clinical presentatiOn 
Women who develop pelvic organ prolapse can present either with only one 
symptom, such as vaginal bulging or pelvic pressure, or with several complaints, 
including many bladder, bowel, and pelvic symptoms.1 With the exception of vaginal 
bulge symptoms however, none is specific to prolapse. Considerable overlap exists 
with other pelvic-floor disorders, and clinicians should be aware of other potential 
figure 3.   The ‘levels of Pelvic Organ Support’ (with permission of John O. DeLancey)
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sources for a patient’s complaints. It is stressed here once more: the only symptom 
that is acknowledged consistently by patients with severe pelvic organ prolapse is the 
presence of a vaginal bulge that can be seen and/or felt.4, 5, 22 
Lower urinary-tract complaints are frequent in women with pelvic organ prolapse. 
Stress urinary incontinence, particularly when prolapse is not severe, is often present.23 
Overactive bladder symptoms are clearly related to higher degrees of pelvic organ 
prolapse, and reports of urinary retention are frequent as well.4, 24, 25
Women with pelvic organ prolapse frequently complain of symptoms related to 
bowel dysfunction, including a feeling of incomplete emptying, straining, the need 
to apply digital pressure to the vagina or perineum (‘splint’) to start or complete 
defecation, urgency and incontinence. In studies on the relation between bowel 
dysfunction and presence and severity of prolapse, researchers have reported either 
a weak correlation between posterior vaginal wall support and specific ano-rectal 
symptoms or no link at all.5, 22, 26 The defecatory symptom that arises most consistently 
with respect to posterior vaginal wall prolapse though, is the need to splint the vagina 
or perineum to defecate.1, 5, 22 
Women with pelvic organ prolapse have comparable rates of sexual activity to 
similarly aged individuals without this disorder.27 A third of sexually active women 
with pelvic organ prolapse complain that their prolapse interferes with sexual 
function.28, 29 However, in a comparison of sexual function of individuals with and 
without prolapse, using a validated sexual-function questionnaire, no difference was 
noted in frequency of intercourse, libido, vaginal dryness, dyspareunia, orgasmic 
function, or overall sexual function between the two groups.27 
management
Management options for women with symptomatic pelvic organ prolapse include 
observation, pelvic physiotherapy, the use of a pessary or surgery.
Not every woman with pelvic organ prolapse presents with symptoms or bother. 
This is especially true for women with prolapse that does not extend beyond the 
hymen. Explanation and reassurance and a ‘watchful waiting’ strategy in such cases is 
appropriate. However, signs of obstructed urination or defecation, vaginal erosions or 
hydronephrosis due to ureteral kinking are indications for treatment, even in women 
with few symptoms of their prolapse.1 
Evidence for the efficacy of pelvic floor muscle training in the management of 
pelvic organ prolapse is so far minimal.30 There is only one study suggesting that daily 
pelvic floor muscle strengthening can slow the progression of anterior vaginal wall 
prolapse in elderly women.31 
The use of a pessary (figure 4) can be an effective treatment for symptom relief in 
women with pelvic organ prolapse, particularly for those who do not opt for surgical 
treatment. Ancient pessary treatments with halve pomegranates soaked in sour wine 
and corks covered with wax, have today been replaced by modern elastic silicone 
objects of various shapes and sizes which can be used by women of all ages. Most 
frequently used devices are rings, rings with support, Gelhorn and donut pessaries. 
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The use of a pessary is able to adequately relieve many symptoms of POP and may 
contribute to improvement of quality of life scores in women suffering from POP.32 
A vast group of women however seems to prefer surgical correction of the 
aberrant vaginal anatomy. In 2003, more than 300.000 women underwent prolapse 
surgery in the United States, indicating that POP is among common indications for 
surgery.33 Precise data for the Netherlands are difficult to distract, for since 2005, 
20 of 97 Dutch hospitals no longer supplied data on their operative procedures to 
the LMR (Landelijke Medische Registratie). However, it is been calculated that the 
number of hospital admissions for POP per year between 2001 and 2009 in the 
Netherlands has increased with 50% to a roughly estimated 13.000 per year (Source: 
Kiwa Prismant, and personal communication R.J.Detollenaere).
The surgical treatment of POP can be broadly categorized into reconstructive and 
obliterate techniques. One example of the latter is the colpocleisis according Le Fort 
(France) or Neugebauer (Germany), that corrects pelvic organ prolapse by moving 
pelvic viscera back into the pelvis and closing off the vaginal canal either partially 
or totally.34, 35 Reconstructive surgeries for prolapse aim to correct the prolapsed 
vagina while maintaining (or improving) vaginal sexual function and relieving any 
associated pelvic symptoms. Although either an abdominal or vaginal route can 
be undertaken for surgery of pelvic organ prolapse, the majority of procedures is 
performed vaginaly.36, 37 
With the increasing life expectancy and the changing lifestyle of elderly women, 
one may anticipate on a further increase in the demand of POP surgery in the nearby 
future (source: CBS and Sociaal & Cultureel Planbureau). This is already expressed 
in recent data on the lifetime risk for a woman to undergo a single operation for POP 
or UI, which has been adjusted upwards from 11% in 1997 to 19-20% at present.37-39 
why this thesis?
Fifteen years ago an important scientific paper on the epidemiology of surgically 
managed pelvic organ prolapse (POP) and urinary incontinence (UI) was published.37 
figure 4.   Examples of frequently used pessaries (from Lamers et al)
1GENERAL INTRODUCTION 17
At that time the authors were probably not fully aware of the revolutionary swing 
they had caused in urogynecological research and consequently the development of 
new POP repair techniques. 
Two conclusions in this paper were considered a challenge and thus became the 
inspirational source of this thesis. 
‘Pelvic floor dysfunction is a major health issue for older women, as shown by the 
11,1% lifetime risk of undergoing a single operation for pelvic organ prolapse and 
urinary incontinence, as well as the large proportion of reoperations (29.2%), and the 
time intervals between repeat procedures that decreased with each successive repair.’
1st challenge; is it possible to reduce recurrence rates and increase durability of POP 
repairs?
‘The long-term efficacy of pelvic floor surgery should be determined. Valid outcome 
assessment will require the development and application of a comprehensive and 
standardized assessment of patient symptomatology, pelvic organ support and pelvic 
floor function, before and after surgical intervention.’
2nd challenge; is it possible to optimize assessment of symptomatology and the 
anatomical and functional outcomes of prolapse repairs?
This thesis is an attempt to honour and respond to these two challenges.
first challenge. the evolution of vaginal surgical repair techniques
In the nineteen eighties, the years in which the author started his residency in 
Obstetrics & Gynecology, the common surgical treatment for a patient with POP, 
was an anterior and posterior colporrhaphy, combined with either trachelectomy or 
a vaginal hysterectomy.40 This ‘confection-like’ approach to the POP phenomenon 
gradually changed in the nineteen nineties of the former century to a more ‘tailored’ 
repair of POP.41-43 
Another development was the use of supportive mesh, biological or non-
-absorbable synthetic, with the principal aim to reinforce traditional native tissue 
repairs, whereby the mesh was used as an overlay to augment the durability of 
traditional colporrhaphies.44-49 
Parallel to that development, and inspired by the success of the ‘transobturator 
route’ of the tension-free vaginal tape to treat stress urinary incontinence as well as the 
superior results of non-absorbable synthetic mesh to native tissue repairs in inguinal 
hernia surgery, a collaborative group of French gynecologists invented the Tension Free 
Vaginal Mesh (TVM) technique, which was a whole new approach to the surgical repair 
of POP.50-52 This resulted in a technique that was ‘blind’ and ‘trocar- guided’, and that 
avoided traditional colporrhaphy and at the same time solved the academic dilemma 
of how to treat a ‘central’ or ‘paravaginal’ anterior wall defect.53 In 2005 the first 
commercially available ‘mesh kit’ (figure 5) was launched on the market and the first 
results of this trocar-guided tension-free vaginal mesh insertion (Gynecare Prolift Pelvic 
Floor Repair SystemTM, Ethicon, Somerville, NJ, USA) were published in 2007.54 
In 2008 the next attempt was undertaken to improve mesh surgical outcomes 
and improve biocompatibility with the introduction of a new lighter-weight, partially 
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absorbable mesh, which aimed to reduce some of the adverse effects of the previous 
heavier-weight meshes, which were particularly related to mesh contraction.55, 56 
The first one-year outcomes of an observational cohort study on the trocar-guided 
insertion of this new light-weight and partially absorbable mesh were published in 
2011 and are part of this thesis.57 
second challenge. tools to standardize and quantify treatment outcomes
I. Pelvic Organ Prolapse-Quantification (POP-Q)
One year in advance of the publication of the Olsen paper, Bump et al published a 
scientific paper on the consensus on the standardization of terminology of female 
pelvic organ prolapse and pelvic floor dysfunction.6 This article presented a standard 
system of terminology, which had, at that time, been recently approved by the 
International Continence Society, the American Urogynecologic Society, and the 
Society of Gynecologic Surgeons, and was meant for the description of female pelvic 
organ prolapse and pelvic floor dysfunction (figure 6). An objective site-specific 
system for describing, quantization, and staging of pelvic support in women was 
included, which was named the P(elvic) o(rgan) P(rolapse)-Quantification system. It 
had been developed to enhance both clinical and academic communication regarding 
individual patients and populations of patients. Clinicians and researchers caring for 
women with pelvic organ prolapse and pelvic floor dysfunction were encouraged to 
learn and use the system.6 Though it took time for clinicians in everyday practice in 
particular, but for researchers as well, to learn and use the system, it has recently been 
published that between the years 2004 and 2007 the use of POP-Q had increased 
from 64.9% to 82.1% while other grading systems, such as the ‘Baden Walker half 
way system’, decreased. POP-Q was used more frequently in the US than in other 
countries. Urologists used POP-Q less and Baden-Walker more frequently than other 
specialists. The authors concluded that POP-Q had been adopted as the universal 
language of prolapse quantification in the published literature.58 
figure 5.   Total Tension-Free Vaginal Mesh schematically inserted (ProliftTM Kit) (with permission of 
Ethicon Women’s Health & Urology, Amersfoort, the Netherlands) 
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II. Health-related quality of life questionnaires
In 1994 Shumaker et al introduced two condition-specific instruments specifically 
designed to assess the Health-related quality of life of Urinary Incontinence (UI) 
in women: the ‘Urogenital Distress Inventory’ (UDI) and the Incontinence Impact 
Questionnaire (IIQ). Used in conjunction with one another, these two measures 
provided detailed information on how UI affects the lives of women.59 One year 
thereafter the results of the use of the short forms of these questionnaires (UDI-6 and 
IIQ-7) were published.60 
However, pelvic floor disorders not only comprehend urinary incontinence, but 
also prolapse and defecatory disorders. Therefore Barber et al presented the long 
forms and the respective short versions of the Pelvic Floor Distress Inventory (PFDI/
PFDI-20) and the Pelvic Floor Impact Questionnaire (PFIQ/PFIQ-7), two condition-
-specific quality of life instruments for women with pelvic floor disorders, that were 
based on the UDI, but had additional questions regarding pelvic organ prolapse 
and colorectal dysfunction, in 2001 and 2005 respectively.61, 62 In 2003 the Dutch 
version of the UDI was validated by van der Vaart et al.63 This resulted in the first 
Dutch standard urogynecological questionnaire approved by the Dutch Pelvic Floor 
Society of Gynecologists (Werkgroep Bekkenbodem-NVOG), released for use by 
‘urogynecologists’ in 2006. This standard questionnaire is a comprehensive summary 
of in total 47 questions, among which 42 concern urinary incontinence (UDI derived), 
genital prolapse and defecatory disorders (Defecatory Distress Inventory), and the 
impact of these disorders on several quality of life domains (Incontinence Impact 
Questionnaire). The questionnaire has five additional questions on sexual function 
and also contains an internationally recognized measure of general Health Status, 
Euroquol-5D (EQ5-D) and in the ‘follow-up version’ a Patient Global Impression of 
Improvement scale (PGI-I).64-66 This widely used Dutch questionnaire is divided in 
3 subcategories (UDI, DDI and IIQ), of which each is subdivided in domains (5 for the 
UDI, 4 for the DDI and 5 for the IIQ), with a score ranging from 0 to 100, whereby 
figure 6.   Example of a POP-Q registry 
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low scores indicate little bother and good quality of life and high scores the reverse: 
lots of symptom bother and worst quality of life. 
III. Sexual Function questionnaire 
Although the Standard Dutch Urogynecological Questionnaire contains a few 
questions on sexual function, these are not exclusively informative. On the other hand, 
two international widely used sexual function questionnaires are available. The Female 
Sexual Function Index (FSFI), developed by Rosen et al in 2000 is one of these.67 This 
questionnaire however is a generic one and was not developed to be condition specific 
for women with pelvic floor disorders. In 2001 therefore Rogers et al developed a 
condition-specific, validated, and self administered questionnaire to evaluate sexual 
function in women with POP and/or UI (PISQ-31), of which the validated version of 
the short form, the ‘Pelvic organ prolapse/urinary Incontinence Sexual Questionnaire’ 
short form (PISQ-12), is the other and was published in 2003.68, 69 
The PISQ-12 has been translated into Dutch. Forward and backward translation by 
native speakers and a panel discussion with experts in the field has been performed. 
From that time onwards the Dutch translated version of the PISQ-12 has been 
supplemented to the Standard Urogynecological Questionnaire of the ‘Werkgroep 
Bekkenbodem-NVOG’. 
sOurce 
In 2005 the Reinier de Graaf Group Delft/Voorburg and the Radboud University Medical 
Center decided to start a collaborative database, in which the data of all consecutive prolapse 
patients from these two urogynecological centers were stored and saved for the sake of 
scientific research. This still growing database is the principal and basic source of the studies 
presented in this thesis. The outcomes of these studies however, serve more goals than mere 
academic research. They are an excellent means of clinical evaluation of the various surgical 
prolapse procedures performed in these two cooperating urogynecological centers.
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Outline Of this thesis
This thesis studies the anatomic and functional outcomes of vaginal prolapse repair 
techniques, with and without the use of a synthetic mesh. 
The main research questions were the following:
•	 What are the anatomical and functional outcomes of midline fascial plication 
under continuous digital transrectal control for the repair of posterior vaginal wall 
prolapse? (Chapter 2)
•	 Can we identify factors that are responsible for anatomic failure of this midline 
fascial plication? (Chapter 2)
•	 Is the use of titanium coated ultra light-weight synthetic mesh safe, when used for 
augmentation of traditional colporrhaphies in patients with a recurrent prolapse 
stage ≥ II or a primary prolapse stage ≥ III, and what are the anatomical and 
functional outcomes? (Chapter 3)
•	 Is a total trocar-guided tension free vaginal mesh repair with one continuous 
piece of synthetic polypropylene mesh safe, and what are the anatomical and 
functional outcomes of such a repair in patients with a post-hysterectomy vaginal 
wall prolapse? (Chapter 4)
•	 What are the anatomical outcomes of a partially absorbable lightweight 
polypropylene mesh and are these comparable to the original non-absorbable 
mesh in patients with a pelvic organ prolapse stage ≥ III? (Chapter 5)
•	 How is sexual function affected in patients who are surgically treated with a partially 
absorbable synthetic mesh for pelvic organ prolapse stage ≥ III? (Chapter 5)
•	 Is sexual function affected differently in patients with recurrent prolapse who are 
treated surgically either with trocar-guided mesh insertion or by a native tissue 
repair? (Chapter 6)
•	 Can we identify factors that are associated with deterioration in sexual function? 
(Chapter 6)
•	 What are the anatomic results of trocar-guided tension free vaginal mesh insertion 
according different outcome definitions? (Chapter 7) 
•	 Can we identify predictors of failure in trocar-guided tension free vaginal mesh 
surgery? (Chapter 7) 
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abstract
Introduction and hypothesis 
The aim of the study was to report anatomic and functional outcome of midline 
fascial plication under continuous digital transrectal control and to identify predictors 
of anatomic failure. 
Methods 
Prospective observational cohort study. Anatomic success defined as POP-Q stage 
≤ I of the posterior compartment. Validated questionnaires to measure bother and 
impact on quality of life. Logistic regression was used to identify risk factors for 
anatomic failure. 
results
Two hundred thirty-three patients with posterior POP stage ≥ II underwent midline 
fascial plication under continuous digital transrectal control. Median follow-up: 
14 months (12-35), and anatomic success was 80.3% (95% CI 75-86). Independent 
predictors of failure were posterior compartment POP stage ≥ III [OR 8.7 (95% CI 2.7-
-28.1)] and prior colposuspension [OR 5.6 (95% CI 1.1 – 27.8)]. Sixty-three percent of 
patients bothered by obstructed defaecation experienced relief after surgery. 
Conclusions
Anatomic and functional outcomes were good. Risk factors for anatomic failure were 
initial size of posterior POP (stage ≥ III) and prior colposuspension.
2MIDLINE FASCIAL PLICATION
intrOductiOn
Posterior colporrhaphy is reported to be one of the most common gynaecological 
procedures performed in over 40% of women undergoing surgical correction of 
prolapse.1
Restoration of the posterior compartment, which includes perineum, rectum 
and the peritoneum of the cul-de-sac, knows many approaches. The transvaginal, 
transanal and laparoscopic approaches have been described to correct defects in this 
compartment.2 
In a randomized controlled trial that compared the transanal with the transvaginal 
approach, the latter approach proved to be anatomically more successful.3 Maher 
et al. have demonstrated excellent anatomic and functional outcomes after midline 
rectovaginal fascial plication.4 In a retrospective survey by Abramov et al. a significant 
higher anatomic recurrence rate of rectoceles was noted after discrete site-specific 
repair as compared to the midline fascial plication.5 Therefore at present the midline 
plication of rectovaginal connective tissue is considered to be the most suitable 
surgical approach for the repair of symptomatic posterior vaginal wall prolapse.
We have added an, in our opinion, important element of the discrete fascial defect 
repair to our surgical protocol of midline fascial plication, namely the continuous 
digital transrectal control with the index finger of the non dominant hand.6 
In the majority of women pelvic organ support defects rarely exist in only one 
vaginal compartment; in a population based sample of women with POP, the 
most frequent single compartment affected was the posterior wall, where isolated 
prolapse was seen in 20% of women, but the most common prolapse combination 
was anterior and posterior wall in 40%.7 Therefore combined surgical procedures will 
often have to be performed to correct these defects. The influence of concomitant 
POP surgery on the anatomic outcome in the posterior compartment has not received 
much attention in the literature.8 
The aim of this article is twofold: to report the anatomical and functional outcome 
of midline fascial plication under continuous digital transrectal control and to identify 
independent risk factors for anatomic failure in the posterior compartment.
material and methOds
In 2003 we started a prospective data registry of all patients undergoing POP surgery 
in two major urogynecological centres in the Netherlands, the Reinier de Graaf 
Hospital in Delft and the Radboud University Medical Centre in Nijmegen. After 
obtaining informed consent consecutive patients were enrolled in this prospective 
observational cohort registry. 
Preoperatively genital prolapse was quantified in the dorsal lithotomy position using 
the POP-Q measurement system, as recommended by the ICS.9 Patients were asked to 
complete the standard urogynecological questionnaire of the Dutch Pelvic Floor Society. 
This questionnaire contains the validated Dutch versions of the Urinary Distress 
Inventory (UDI), the Incontinence Impact Questionnaire (IIQ) and the Defaecatory 
Distress Inventory (DDI).10-12 The questionnaire contains some questions on sexual 
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functioning as well. Patients rate the amount of bother in various domains on a 
5-point Likert scale, ranging from 0 (no bother at all) to 4 (a lot of bother). Domain 
scores for UDI, DDI and IIQ are calculated and range from 0 (no bother at all or best 
quality of life) to100 (most bother or worst quality of life). Patients were considered 
to be significantly bothered in any of the DDI domains if the average answer to the 
questions of that particular domain was at least a little bother (to a lot), which was 
equivalent to a domain score of ≥ 33 (range 0-100).
surgical procedure
Peroperative antibiotic prophylaxis was given with a single dose of Cefalozine-
-Natrium (Kefzol® Lilly, the Netherlands) and Metronidazol (Flagyl® Aventis Pharma 
BV Hoevelaken, the Netherlands). Patients were positioned in the dorsal lithotomy 
position with their hips flexed between 90o and 110o. After hydrodissection (Lidocaine 
hydrochloride monohydrate 200mg with epinephrine hydrogen tartrate100μ g in 
20 ml - Astra Zeneca BV Zoetermeer the Netherlands- diluted in 100 ml of 0.9% 
saline solution) a midline incision was made in the posterior vaginal wall from an area 
at least 1cm above the superior aspect of the vaginal defect close to the posterior 
fornix all the way to the level of the posterior fourchette. The incision was not as deep 
as is used in mesh surgery, but at a more superficial level to allow identification of 
the so called rectovaginal ‘fascia’, achieved by cleaving the vaginal wall at the level of 
its fibromuscular and adventitial layer. Allis clamps were placed on the vaginal walls 
and usually gentle sideward traction produced a nice cleavage area. A gloved finger 
covered with an unwound gauze helped further blunt dissection when considered 
necessary. The gloved index finger of the non-dominant hand was then introduced 
into the rectum and with the finger and thumb of this hand connective tissue could 
be grasped on both lateral sides to allow placement of several interrupted Vicryl 2-0 
sutures. More cranially the connective tissue layer is less apparent and at these points 
a thin layer of the adventitia and fibromuscular vaginal wall was grasped bilaterally 
to be incorporated in the sutures.13 Plication of the fascia was performed in a cranial-
-caudal direction with an average number of 6- 8 sutures. Knots of the sutures were 
tied by the assistant under continuous control by the non-dominant finger of the 
surgeon. On removal of the finger from the rectum, gloves were changed and modest 
vaginal trimming was performed bilaterally. A running Vicryl 2-0 suture was used to 
close the vaginal wall from cranial to caudal direction (fig 1 a-h). A gauze pack was 
left overnight in the vagina as well as an indwelling urinary catheter. Patients were 
all operated by or under supervision of the first or last author. The other authors 
performed surgery after being trained by the former.
study endpoints
Primary endpoints of this study were anatomic outcome of the posterior compartment 
after a follow up period of at least 12 months and the identification of independent 
predictors of anatomic failure. Secondary endpoints were functional efficacy in terms 
of significant change in experienced bother in the various domains of UDI, DDI and 
IIQ, as well as effect of surgery on dyspareunia. 
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Anatomic success was defined as ICS POP stage 0 or I of the posterior compartment. 
Anatomic failure as a POP stage ≥ II of the posterior compartment.9 Follow-up 
investigations were performed, by the second, third and fourth author. 
data collection
To obtain data on anatomical efficacy POP-Q measurements at baseline were 
compared with those obtained at follow up. Data on the functional efficacy, quality 
of life and effect on sexual function were derived from the standard urogynecological 
questionnaires at baseline and follow-up. Data were analysed using a Statistical 
Package for the Social Sciences 17.0 database. 
Baseline and surgical data are presented as median (range) or numbers with 
corresponding percentages and where appropriate with 95% Confidence Intervals. 
Pearson’s Chi square was used where appropriate. Domain scores of UDI, DDI and 
IIQ are presented as means with standard deviations. Differences in means between 
baseline and follow-up were tested with the paired-samples t-test. A p-value ≤0.05 
was considered significant. To quantify clinically relevant effects, effect sizes were 
calculated in the various domains of UDI, DDI and IIQ by using Cohen’s d, which 
Domains IIQ
Physical functioning 27.6 (28.3) 16.2 (27.2) < 0.001 0.8
Mobility 33.0 (25.7) 22.3 (24.8) < 0.001 0.8
Emotional health 27.1 (26.3) 17.9 (24.5) < 0.001 0.7
Social functioning 16.1 (18.3) 12.0 (19.3) < 0.001 0.4
Embarrassment 15.0 (20.4) 12.2 (21.6) 0.005 0.3
UDI: Urinary Distress Inventory
DDI: Defaecatory Distress Inventory
IIQ: Incontinence Impact Questionnaire
Scores presented as mean (± standard deviation)
Scores range between 0 (least bother and best quality of life) to 100 (maximum bother and worst quality of life)
P* Paired samples t-test.
†Effect size (Cohen’s d): Small: 0.2, Medium 0.5, Large ≥ 0.8 (in bold)
Fig. 1   Midline fascial plication under continuous transrectal control of a stage II posterior vaginal wall 
prolapse. a. Incision after hydrodissection. b. Sideward traction and cleavage of vaginal wall. c. Blunt dissection 
of fascia. d. Suturing at cranial side of rectocele. e. Tie of a knot by the assistant of the surgeon. f. Transrectal 
control of firmness. g. Trimming of vaginal wall. h. End result and running suture of vaginal wall.
Acknowledgements Mr. Ruud van de Voorde for the medical photography.
figure 1.   Midline fascial plication under continuous transrectal control of a stage II posterior vaginal 
wall prolapse. a. Incision after hydrodissection. b. Sid ward traction and cleavage of vaginal wall. 
c. Blunt dissection of fascia. d. Suturing at cranial side of rectocele. e. Tie of a knot by the assistant of 
the surgeon. f. Transrectal control of firmness. g. Trimming of vaginal wall. h. End result and running 
suture of vaginal wall.
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represents the difference between two means divided by the pooled standard 
deviations of these means. The effect size is defined as small if Cohen’s d = 0.2, 
medium if d = 0.5 and large if d ≥ 0.8.14 
Univariable logistic analysis was performed to select potential risk factors for 
anatomic failure. Covariariables that showed a p value <0.1 at univariable analysis 
were entered in a stepwise forward multivariable logistic regression model to identify 
independent predictors of anatomic failure. P-values < 0.05 were considered significant 
and data are presented as adjusted odds ratio with 95% confidence intervals.
results
Two hundred and thirty-three patients with a posterior vaginal wall prolapse stage 
II or more were operated and available for follow-up analysis. Median follow-up 
was 14 (12-35) months. Not all patients responded to our invitation for follow-up 
examination, but on 208 (89%) patients a POP-Q examination could be performed. 
At baseline one hundred and eighty-seven (80%) and at follow-up two hundred and 
fourteen patients (92%) responded to our request to complete the urogynecological 
questionnaire. 
Baseline and surgical characteristics are presented in table 1. Seventy-three 
patients (31%) underwent an isolated posterior wall repair procedure; all others 
(69%) underwent concomitant repairs in the other vaginal compartments as well. 
Anatomical results
Data on POP-Q measurements and POP stage at baseline and follow-up are shown 
in table 2. Overall anatomic success in the posterior compartment was 80% (95% CI 
75-86). Sub analysis revealed a success rate of 85 % (95% CI 79-91) for combined 
posterior repairs and 70% (95% CI 59-81) for isolated repairs. 
Predictors of failure
Table 3 shows the results of univariable and multivariable analysis of covariates 
potentially related to anatomic failure. Five covariates were entered in a stepwise 
forward multivariate logistic analysis model. Posterior POP stage ≥ III and a history of 
prior colposuspension were the only factors that could be identified as independent 
significant predictors of anatomic failure in the posterior compartment.
functional results
Functional data on the various domains of UDI, DDI and IIQ with their respective 
calculated effect sizes are summarized in table 4. Except for fecal incontinence all 
domains of UDI, DDI and IIQ showed statistically significant improvements. The domains 
of genital prolapse and pain in the UDI revealed a large treatment effect size (Cohen’s 
d ≥ 0.8). For all DDI domains, effect sizes appeared to be of medium size only (0.3-0.7).
At baseline 150 patients completed all questions in the domain of obstructed 
defaecation. Thirty-eight (25%) were considered to be significantly bothered (domain 
score ≥ 33). Mean domain score before surgery of these patients was 48.5 (SD16.9). 
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Mean postoperative score was 22.5 (SD17.2) (p<0.001, effect size: 1.5). Twenty-four 
patients (63%) reported to be cured or improved at follow-up. 
At baseline 170 of the 187 patients who completed the urogynecological 
questionnaire answered questions on sexual functioning. Hundred and ten patients 
(65%) reported to be sexually active. At follow-up this percentage remained unchanged: 
64%. At baseline 42% of patients reported to have some degree of dyspareunia. At 
follow-up this rate had dropped to 34%. Nineteen percent of patients who did not 
complain of dyspareunia before surgery reported this complaint at follow-up, so this 
was considered to be de novo dyspareunia. Fifty-eight percent of patients however, 
who initially complained of dyspareunia, reported to be cured at follow-up.
table 1. Baseline and surgical characteristics.
n: 233
Age (years) 59 (29-85)
BMI (kg/m2) 25 (16-42)
Parity 2 (1-10)
Postmenopausal 180 (77%)
Prior related surgery
Vaginal hysterectomy 77 (33%)
Abdominal hysterectomy 39 (17%)
Anterior colporrhaphy 51 (22%)
Posterior colporrhaphy 44 (19%)
Sacrocolpopexy 12 (5%)
2 prior prolapse repairs 21 (9%)
≥3 prior prolapse repairs 24 (10%)
Prior incontinence surgery
Colposuspension 34 (15%)
TVT 8 (3%)
surgical procedures
Isolated posterior repair 73 (31%)
Combined repairs
 Anterior colporrhaphy
 Perineoplasty
 Manchester procedure
 Vaginal hysterectomy
 McCall & enteroceleplasty
160 (69%)
143 (89%)
38 (24%)
28 (17%)
43 (27%)
22 (14%)
surgical characteristics
Duration of surgery (min) 75 (10-205)
Bloodloss (ml) 100 (40-600)
Spinal analgesia 104 (45%)
General anesthesia 129 (55%)
Hospital stay (days) 4 (2-13)
Data presented as median (range) or number (percentages).
33
CHAPTER 2
table 2. POP-stage and POP-Q variables at baseline and follow-up.
PoP-Q variable Baseline (233) follow-up (208) Change from baseline
Ba 0.2 (2.2) -1.5 (1.5) 1.7 (2.2)
C -4.2 (3.4) -6.7 (2.3) 2.5 (4.1)
D -5.2 (3.3) -7.8 (2.2) 1.4 (4.0)
Bp 0.5 (1.2) -2.2 (1.2) 2.7 (1.3)
TVL 9.4 (1.5) 9.1 (0.9) 0.3 (1.6)
GH 4.6 (1.1) 3.7 (0.9) 0.8 (1.2)
PB 3.4 (1.2) 3.8 (1.0) 0.4 (1.4)
PoP stage success rate 
Anterior 0 26 (11.1%) 63 (30.3%)
61.5% (54.4-67.7)
I 40 (17.2%) 65 (31.2%)
II 98 (42.1%) 75 (36.1%)
III 69 (29.6%) 5 (2.4%)
IV - -
Apical 0 55 (23.6%) 87 (41.8%)
97.6% (95.5-99.7)
I 142 (60.9%) 116 (55.8%)
II 17 (7.3%) 1 (0.5%)
III 19 (8.2%) 4 (1.9%)
IV - -
Posterior Isolated Combined Isolated Combined
80.3% (74.9-85.7)†
0 - - 27 (40.3%) 80 (56.7%)
I - - 20 (29.8%) 40 (28.4%)
II 43 (58.9%) 136 (85%) 17 (25.4%) 21 (14.9%)
III 30 (41.1%)‡ 24 (15%)‡ 3 (4.5%) -
IV - - - -
Data are presented as mean (± standard deviation) cm for POP-Q variable and as number of patients 
(percentage) for POP stage.
Ba: most descendant point at anterior vaginal wall. C: vaginal apex. Bp: most descendant point at 
posterior vaginal wall (all in cm distance from the hymenal remnants).
 TVL: Total Vaginal Length, GH: Genital Hiatus, PB: Perineal Body length in cm (± standard deviation).
† 95% Confidence Interval. ‡ Pearson’s Chi square: p < 0.001.
discussiOn
The surgical technique used by us actually is a combination of the classical midline 
fascial plication and a site defect specific repair. The addition of continuous transrectal 
digital control during the procedure helps identify any interruptions in the connective 
tissue layers and one ensures that the repair is sufficiently solid, has no weak spots 
and that no sutures accidentally enter the rectal lumen. A relative disadvantage of 
our technique though, is the fact that the surgeon cannot tie the sutures himself but 
has to rely on the assistant for this. Whether this protocol assignment significantly 
contributes to the anatomical efficacy is not shown by our study but can only be 
determined in a controlled study that compares the ‘classical’ midline plication with 
a procedure that adds this ‘continuous transrectal control’. 
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Anatomical results and risk factors for failure 
The overall anatomic cure rate of 80% (95% CI 75-86) is comparable with previous 
reports on midline fascial plication by other authors, though our study group was 
considerably larger.4, 5, 15, 16 
Only two factors, POP-Q stage > II in the posterior compartment and a history of 
prior colposuspension, were identified as independent risk factors. Two other authors 
demonstrated already earlier that women with POP stage ≥ III are at increased risk 
of developing a recurrence or failure after surgical repair without grafts.17, 18 Prior 
colposuspension is known to provoke posterior compartment prolapse, but has never 
been identified as a risk factor for recurrence after posterior compartment surgery.19 
An interesting finding was the fact that at first glance the anatomical outcome 
of patients with combined repairs appeared significantly better than the outcome 
after isolated repairs only. In the isolated repair group though a significantly higher 
percentage of patients with a posterior POP stage III were present as compared to 
the combined repairs (table 2). In the group that underwent concomitant repairs, 
DeLancey’s level I support was taken care of, as by the modified Manchester 
procedure or high McCall procedure, in 50 of 160 patients (31%; Table1).20, 21 It 
has been reported that apical support might explain half of the variation in anterior 
compartment support.22 To a somewhat lesser extent this could be demonstrated 
for the posterior compartment as well; in a group of patients with POP stage ≥ II 
Lowder et al demonstrated that point Bp changed to stage 0 and I after simulated 
apical support in at least 30% of cases.8 In our study though, we could not detect 
table 3. Univariable and multivariable logistic regression analysis of factors that might influence 
anatomic outcome.
Covariables
univariable analysis Multivariable analysis
p or (95% CI) p or (95% CI)
Age 0.089 1.026 (0.996 – 1.058) 0.409
Prior posterior wall repair 0.243 0.292 (0.037 – 2.302)
Prior sacrocolpopexy 0.602 0.563 (0.065 – 4.877)
Prior POP surgery 0.068 1.917 (0.954 – 3.851) 0.529
Prior colposuspension 0.062 3.893 (0.934 – 16.226) 0.037 5.558  
(1.112 – 27.779)
Isolated posterior repairs 0.013 2.432 (1.209 – 4.892) 0.124
Concomitant anterior colporrhaphy 0.439 0.711 (0.934 – 16.226)
Concomitant apical support surgery 0.774 0.882 (0.375 – 2.076)
Concomitant perineoplasty 0.198 0.497 (0.171 – 1.440)
Concomitant vaginal hysterectomy 0.300 0.586 (0.213 – 1.611)
Posterior compartment stage ≥ III <0.001 7.613 (3.585 – 16.170) <0.001 8.767  
(2.739 – 28.060)
Data presented with p-values and odds ratio’s (OR) with 95% CI. 
Covariables with p < 0.1 in univariable analysis (n: 5) were entered in a multivariable logistic analysis 
model, method stepwise forward (LR). 
Significant p values are shown in bold. 
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table 4. UDI, DDI and IIQ domain scores at baseline and follow-up with calculated effect sizes.
domains udI Baseline (187) follow-up (214) P* effect size†
Prolapse 45.1 (33.0) 7.7 (18.5) < 0.001 2.9
Incontinence 26.5 (26.1) 20.9 (23.7) < 0.001 0.5
Overactive bladder 31.7 (24.9) 22.9 (23.2) < 0.001 0.7
Obstructive micturition 25.8 (26.9) 17.7 (23.0) < 0.001 0.6
Pain 33.7 (29.3) 18.1 (23.0) < 0.001 1.2
domains ddI
Constipation 16.8 (20.4) 12.2 (19.3) 0.002 0.4
Obstructed defaecation 17.5 (20.6) 11.2 (15.1) < 0.001 0.7
Pain 14.6 (23.0) 10.1 (20.0) 0.014 0.4
Incontinence 7.1 (16.0) 5.8 (14.2) 0.065 0.3
domains IIQ
Physical functioning 27.6 (28.3) 16.2 (27.2) < 0.001 0.8
Mobility 33.0 (25.7) 22.3 (24.8) < 0.001 0.8
Emotional health 27.1 (26.3) 17.9 (24.5) < 0.001 0.7
Social functioning 16.1 (18.3) 12.0 (19.3) < 0.001 0.4
Embarrassment 15.0 (20.4) 12.2 (21.6) 0.005 0.3
UDI: Urinary Distress Inventory, DDI: Defaecatory Distress Inventory, IIQ: Incontinence Impact 
Questionnaire.
Scores presented as mean (± standard deviation). Scores range between 0 (least bother and best 
quality of life) to 100 (maximum bother and worst quality of life).
P* Paired samples t-test. †Effect size (Cohen’s d): Small: 0.2; Medium 0.5; Large ≥ 0.8 (in bold).
any significant protective effect of the above mentioned apical support surgery on 
the anatomic outcome in the posterior compartment. 
The vast majority of patients that underwent concomitant surgery underwent an 
anterior colporrhaphy as well (89%). The success rate of the group as a whole in the 
anterior compartment was 61.5% (54.4-67.7) (table 2). Although the outcome in 
the anterior compartment was not an endpoint in this study, results are half as good 
as compared to the posterior compartment, but comparable with recent reports by 
other authors.23, 24 Concomitant anterior repairs did not influence outcome of the 
posterior compartment.
Although in our study prior prolapse repair surgery as a whole appeared close 
to significance at univariable analysis, neither this factor nor a prior posterior wall 
repair could be identified as significant risk factor for anatomic failure of the posterior 
compartment.
functional results
All mean domain scores of the UDI show statistically significant improvements, of which 
two domains even with a large effect size, of which the domain of genital prolapse 
shows the largest calculated effect size at follow up. Except for the domain of faecal 
incontinence, all domains of the DDI show statistically significant improvements as well, 
however with a smaller effect size. Although only weak correlations between bowel 
symptoms and posterior vaginal wall prolapse have been reported, the defaecatory 
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symptom that most consistently arose with respect to posterior vaginal prolapse, was 
the need to splint the vagina or perineum to defaecate.25 Thus we were especially 
interested in the domain of obstructed defaecation. Seventy-five percent of patients 
were not considered to be significantly bothered by obstructed defaecation. That 
means that mean domain scores of the group as a whole were dampened by those 
who are not bothered at all, which is demonstrated by the low initial score. However, 
if patients were significantly bothered by obstructed defaecation, the improvement in 
this domain score appeared not only statistically significant, but also demonstrated a 
large effect size. In our study patients that were significantly bothered by obstructed 
defaecation had a 63% chance that these symptoms improved or disappeared after 
surgery. 
The positive effects of surgery on the quality of life of patients are particularly 
demonstrated for the domains of physical functioning and patients’ mobility.
The percentage of patients that reported dyspareunia had decreased at follow-up. 
Though19% of patients reported de novo dyspareunia, in 58% this complaint was 
no longer present after surgery. We realize that this section of the urogynecological 
questionnaire is rather intimate for most (older) patients and therefore the least well 
answered part. However, the data are comparable with data published by other 
authors and earlier work by us.4, 15, 16, 26, 27
strengths and weaknesses 
Strengths of this study are the large sample size with a high follow-up rate and the use 
of validated instruments as recommended by the ICS, such as POP-Q and validated 
urogynecological questionnaires. Another strength is the systematic surgical protocol 
followed by all surgeons.
Drawbacks however are, that at the start of our registry we missed some 
questionnaires, so that the number of questionnaires at follow-up was somewhat 
higher than at baseline. The tendency of our, mostly older, patients to be somewhat 
reluctant with the response to questions on sexual functioning is another concern 
that deserves an appropriate solution for the benefit of future research.
cOnclusiOn
Midline ‘fascial’ plication under continuous digital transrectal control for the repair of 
symptomatic posterior vaginal wall prolapse is anatomically and functionally effective.
Two independent risk factors for anatomic failure could be identified: 
POP stage ≥ III of the posterior compartment and a history of prior colposuspension. 
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abstract
objectives 
To determine the safety and efficacy of ultra lightweight titanium coated polypropylene 
mesh to augment conventional vaginal prolapse repair in women with recurrent 
symptomatic prolapse stage II or more or primary prolapse stage III or more.
study design
A prospective observational cohort study was performed at two urogynecological 
centres in the Netherlands. Women with recurrent symptomatic prolapse at least 
stage II or primary vaginal prolapse ICS POP stage III or more participated in the 
study. POP-Q and validated urogynecological questionnaires were used pre- and 
postoperatively. Outcome measures were mesh-related morbidity and prolapse 
recurrence, defined as ICS POP stage II, as well as changes in domain scores on 
Urogenital Distress- and Defaecatory Distress Inventory (UDI and DDI), Incontinence 
Impact Questionnaire (IIQ) as well as sexual functioning. Wilcoxon’s signed ranks test 
for paired variables and 95% confidence intervals, respectively were used to analyse 
these data.
results 
The study group comprised 71 patients with a median follow-up of 9 months (6-14). 
Mesh erosions were detected in four patients (5.6%), all on the posterior vaginal 
wall. After Ti-mesh® augmentation in 14 patients (36%) the anterior vaginal wall 
and in 7 patients (18%) the posterior vaginal wall, was categorised as ICS POP 
stage II and were thus considered failures. UDI and DDI domain scores all improved 
significantly, except for the domains of incontinence and pain, respectively. Three out 
of five domains of the IIQ showed significant improvement. Surgery did not have any 
significant negative impact on sexual functioning. 
Conclusion 
Ultra lightweight titanized polypropylene mesh to augment conventional vaginal 
prolapse repair surgery showed minimal morbidity, but no additional value compared 
to conventional surgery at short-term follow-up. 
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intrOductiOn
Pelvic Organ Prolapse (POP) is a highly prevalent condition among the ageing 
female population.1 Olsen et al. calculated that by the age of 80 years 11.1% will 
have undergone a single operation for prolapse or incontinence (lifetime risk). 
Reoperation was found to be common (29.2%) and the interval between repeat 
procedures decreased with each successive repair.2 Between 2000 and 2003, the 
number of operations performed annually for POP in the Netherlands increased 
by almost 16%.3 Prolapse recurrence after vaginal prolapse repair surgery occurs 
frequently: in 26% to 34% of anterior wall repairs and in about 12% of posterior 
wall repairs.4, 5 Recurrences after surgical repair were more common in women who 
prolapsed at a younger age and in women with more advanced stages of POP.6 
The reason for the growing interest in biocompatible synthetic meshes to augment 
prolapse repair surgery lies within the need to reduce the high recurrence rates of 
vaginal prolapse. In inguinal and femoral hernia surgery, there is distinct evidence 
that the use of synthetic mesh to augment repair surgery considerably reduces the 
risk of recurrence.7 Unfortunately, the use of such mesh in vaginal prolapse repair 
surgery is relatively contraindicated, because various complications can arise, such as 
rejection, tissue erosion and shrinkage. The ideal synthetic mesh is type I, macroporous 
monofilament polypropylene.8 Several studies showed advantages of the addition 
of polypropylene mesh in vaginal prolapse repair surgery.9-11 However only in two 
studies polypropylene mesh was used to augment traditional colporrhaphy.12,13 In one 
of these publications, the authors advised against the use of Prolene mesh in vaginal 
prolapse repair surgery, because of the high rates of postoperative dyspareunia 
and erosions.13 In an animal (rat) experiment it could be shown that lightweight 
polypropylene mesh had more favourable biocompatible characteristics than the 
conventional heavyweight polypropylene mesh, without losing any critical tensile 
strength.14 In another animal (pig) study different types of polypropylene mesh and 
their handling properties were compared and was found that coating the mesh with 
titanium caused less severe inflammatory reactions than non-coated polypropylene. 
This titanium coated mesh (Ti-Mesh®) combined the advantages of material reduced 
polypropylene with a superior biocompatibility of a titanium coating, at least in terms 
of chronic inflammatory reactions.15 
Ti-Mesh® (GfE Medizintechnik GmbH, Höfener Strasse 45, 90431, Nürnberg, 
Germany) is commercially available in two variants: a lightweight (35 gr/m2) and an 
ultra lightweight variant (16 gr/m2). The layer of titanium coating is only 30 nm. 
Preliminary results after its use in human inguinal hernia surgery were good.16 
We performed a prospective observational pilot study on this new ultra lightweight 
titanium coated mesh in human vaginal prolapse repair surgery. The aim of the study 
was to establish material safety, in terms of mesh related morbidity, and its efficacy, in 
terms of prolapse recurrence, bother and health related quality of life. The mesh was 
used in conventional vaginal prolapse repair for patients with recurrent symptomatic 
prolapse ICS stage II or more, or primary vaginal prolapse stage III or more. 
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materials and methOds
The sample size was calculated for bother as measured by the domain genital 
prolapse in the UDI. A difference of 20 units per scale was considered as a clinical 
relevant treatment related change. With standard deviation of 40 units, a type I 
error of 0,05 and 90% power, 44 patients were needed using a two-sided paired 
t-test. We estimated, prior to the start of this prospective observational study, that 
a recruitment period of 18 months would be needed to include these patients in 
two centres. 
Between June 2004 and November 2005, 78 women with recurrent symptomatic 
prolapse or primary vaginal prolapse ICS stage III or more were operated on and 
asked to participate. All the participants gave written informed consent. The study 
was performed at two centres: the Reinier de Graaf Hospital, Delft-Voorburg and 
the St. Radboud University Medical Centre, Nijmegen.
 Genital prolapse was quantified pre- and postoperatively in the dorsal lithotomy 
position according to the POP-Q system, as recommended by the ICS.17 In this 
system the most distal part of the prolapsed upper anterior vaginal wall is called 
point Ba and that of the posterior vaginal wall point Bp. Their distance is measured 
in centimetres to the hymenal remnants. A negative value indicates that the most 
dependant part of prolapse is located within the hymenal remnants, whereas a 
positive value means prolapse beyond the hymen. 
The standard urogynecological questionnaire (proposed by the Pelvic Floor 
Committee of the Dutch Gynaecological Society) was completed before and 
after surgery. This questionnaire includes questions that address the general 
quality of life and health, derived from the Dutch version of the Euroqol 5D.18 
Disease-specific questions on quality of life and bother were incorporated from 
the validated Dutch translation of the Incontinence Impact Questionnaire and 
Urogenital Distress Inventory respectively.19 Questions were also added from the 
recently validated Defaecatory Distress Inventory (DDI).20 The more extensive Dutch 
language standardized version of the questionnaire has been validated as a whole.21 
Several questions addressed sexual functioning.22 The answers to the questions 
were transformed into bother scores in the following domains: overactive bladder, 
obstructed micturition, urinary incontinence, pain and genital prolapse on the UDI 
and constipation, obstructed defaecation, pain and faecal incontinence on the DDI. 
Disease-specific quality of life questions covered the following five domains: physical 
functioning, mobility, emotional and social functioning and embarrassment. Scores 
could range from 0 (no bother at all or perfect quality of life) to 100 (maximum 
bother or worst quality of life in a particular domain). 
All the operations were performed by the first or last author, or under the direct 
supervision of one of these. Patients underwent standardized vaginal dissection 
and subsequent plication of the vesico- or rectovaginal fascia before application of 
the mesh. 
In the case of anterior colporrhaphy (n=41), hydrodissection was performed 
and 2-3cm distal to the external urethral meatus a midline incision was made 
to the cervix or vaginal apex. Next, the vaginal mucosa was separated from the 
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remnants of the vesicovaginal fascia that covers the bladder. These fascial remnants 
were then plicated with Vicryl 2.0 sutures. In the case of posterior colporrhaphy, 
a similar hydrodissection and midline incision technique was used, starting from 
the posterior commisura to the cervix or apex of the vagina. After the rectovaginal 
fascia was freed, it was plicated in the midline with Vicryl 2.0 sutures under digital 
control in the rectum by the index finger of the surgeon.23 To cover the anterior side 
of the vagina, the mesh was cut into the shape of a long sleeved T shirt. Total width 
of this graft, including the arms, was approximately 8-9cm. The two arms were 
brought into the space of Retzius (in the first 20 patients) or introduced through 
the obturator foramen with the help of a large Deschamps needle. The body of the 
graft was positioned in such a way that it covered the plicated cystocele. No sutures 
were used to fix the mesh. To cover the posterior side of the vagina (n=36), the 
mesh was cut into the shape of a broad V, with two 4-5cm arms at the top. The two 
arms were inserted into the pararectal space, in the direction of the sacrospinous 
ligaments. No additional sutures were used to fix the mesh arms. Afterwards the 
vaginal wall was classically trimmed and closed with a running Vicryl 2.0 suture. All 
the patients received peroperative antibiotic prophylaxis with Cefazoline- Natrium 
(Kefzol® Lilly, the Netherlands) and Metronidazol (Flagyl® Aventis Pharma BV 
Hoevelaken, the Netherlands). 
The first outpatient check-up took place six weeks after surgery and was 
performed by the surgeon. Special attention was paid to the presence of mesh 
exposure or other vaginal abnormalities. At follow-up, which was at the earliest 
six months postoperatively, the above described standard urogynecological 
questionnaire was readministered to the patients and they were asked to express 
their satisfaction about the result of the operation on a Visual Analogue Scale 
(0 = extremely dissatisfied, 10 = extremely satisfied) and invited for anatomical 
assessment. These examinations were performed by an independent ‘non-surgical’ 
resident. Anatomical failure was defined as postoperative POP stage II or more. In 
five patients, postoperative follow-up was shorter than six months, one patient was 
unable to comply with our request due to transportation problems and one patient 
was lost to follow-up. In the remaining 71 patients POP quantification in the dorsal 
lithotomy position was repeated. The vagina was examined carefully for signs of 
erosion or mesh-related shrinkage. 
All the data were entered into an SPSS database. Mean domain scores were 
calculated on the UDI, DDI and IIQ. Differences between the preoperative and 
postoperative scores were tested with Wilcoxon’s signed ranks test for paired 
variables, using SPSS version 12.0.1. Percentages of answers per category and 95% 
confidence intervals were used to analyse the questions on sexual functioning.
results
Table 1 shows the baseline patient characteristics and performed surgical procedures. 
One or more previous prolapse repairs in the same or another compartment had been 
conducted in the majority (78%) of these patients. 
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Mesh- related morbidity
In four patients (5.6%) slight ‘erosion’ of the posterior vaginal wall (size: 2 to 3mm) 
was detected. All the affected areas were located in the midline at the level of the 
original vaginal incision. Only one patient had noticed this erosion herself during 
sexual intercourse. The erosions were treated by simple removal of the piece of 
exposed mesh and closure of the vaginal defect at the outpatient clinic. None of the 
patients showed any signs of abnormal consistency, pain on palpation, or changes in 
the size or shape of the vagina that suggested mesh retraction.
Complications
One patient developed a pararectal haematoma, which was treated conservatively. 
In one patient, a small part of mesh hung out of the external urethral meatus six 
weeks after the operation. This bizarre complication had probably been caused by 
perforation of the bladder peroperatively when the arms of the mesh were introduced 
into the retropubic space. The piece of mesh could be removed easily by cystoscopy 
during a day care procedure. 
Anatomical results
Changes in mean scores of POP-Q at points Ba and Bp pre- and postoperatively 
are illustrated in figures 1 and 2. Table 2 (a and b) shows the POP stages before 
and after surgery with Ti-mesh® augmentation on the anterior wall and posterior 
wall, respectively. Fourteen patients (36%) who underwent anterior wall repair with 
Ti-mesh® and seven (18%) who underwent posterior wall repair with Ti-mesh® were 
postoperatively categorised as POP stage II.
table 1. Baseline and surgical characteristics
Follow-up in months 9 (6-14)
Age in years 56 (33-78) a
BMI in kg/m2 25 (18-41)
Parity 2 (0-7)
Number of previous prolapse surgeries 1 (0-5)
Hospital stay in days 3 (2-7)
Bloodloss in ml 100 (50-600)
Duration of catheterisation in days 3 (1-20)
Number of patients with anterior repair with Ti-mesh 23 (33%) b
Posterior repair with Ti-mesh 26 (37%)
Anterior & posterior repair with Ti-mesh 10 (14%)
Anterior repair with Ti-mesh & posterior without 7 (10%)
Anterior repair with Ti-mesh & posterior without & VHc 1 (1%)
Posterior repair with Ti-mesh & anterior repair without 3 (5%)
a data presented as median (range), b data presented as number (percentage), c VH= vaginal 
hysterectomy.
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functional results
Table 3 shows the mean domain scores on general quality of life, UDI, DDI and IIQ 
before and after surgery. Scores were significantly lower after prolapse repair, which 
reflects significant improvements in the various domains, except for general quality of 
life, urinary incontinence and the domains of social functioning and embarrassment. 
figure 1.   POP-Q point Ba before and after Ti-mesh®.
figure 2.   POP-Q point Bp before and after Ti-mesh®.
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Table 4 compares the frequency of sexual intercourse and dyspareunia pre- and 
postoperatively. We could not detect any significant difference in the answers given 
to these questions before and after prolapse surgery with Ti-mesh® augmentation.
The mean Visual Analogue Scale score for satisfaction with the results of the 
procedure was 8.13 (± 1.45). 
table 2a. Anterior vaginal wall pre- and post-operative ICS POP stages
Anterior vaginal wall Pre-operative (%) Post-operative (%)
Stage 0 - 14 (36)
Stage I - 11 (28)
Stage II 22 (56) 14 (36)
Stage III 17 (44) -
Stage IV - -
table 2b. Posterior vaginal wall pre- and post-operative ICS POP stages
Posterior vaginal wall Pre-operative (%) Post-operative (%)
Stage 0 - 15 (39)
Stage I - 16 (42)
Stage II 21(60) 7 (18)
Stage III 14 (40) -
Stage IV - -
table 3. Mean general QoL scores, domain scores on UDI, DDI and IIQ before and after surgery
Before After difference 
General quality of lifea 6.7 (1.8) 6.9 (1.7) N.S
UDI Genital Prolapseb 56.1 (36.3) 5.2 (10.8) <0.0001
UDI Incontinence 23.3 (24.6) 25.5 (27.9) N.S
UDI Overactive Bladder 39.6 (30.0) 31.7 (28.8) 0.003
UDI Obstructive Micturition 34.2 (31.4) 20.3 (23.5) 0.001
UDI Pain 36.7 (31.9) 21.7 (23.4) <0.0001
DDI Constipationb 17.8 (21.0) 10.9 (18.7) 0.002
DDI Obstructed Defecation 22.2 (23.0) 12.5 (14.8) <0.0001
DDI Incontinence 10.6 (20.3) 5.8 (14.8) 0.038
DDI Pain 14.0 (22.2) 8.3 (18.3) N.S
IIQ Physical functioning 30.4 (28.5) 21.5 (26.8) 0.049
IIQ mobility 33.7 (26.5) 27.7 (24.2) 0.043
IIQ emotional health 25.0 (26.3) 20.2 (22.5) 0.011
IIQ social functioning 17.0 (20.4) 13.4 (17.4) N.S
IIQ embarrassment 11.8 (26.3) 14.4 (23.7) N.S
a General QoL scores range 0-10 (SD),
b UDI and DDI domains. Scores range 0-100 (SD). 0 reflects no bother at all, 100 maximum bother.
c Impact on quality of life domains. Scores range 0-100 (SD). 0= Good quality, 100= worst quality of 
life.
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discussiOn
The anatomical results of Ti-mesh augmentation after this short term follow-up are 
no better then results from previous reports on conventional colporrhaphy alone.4
In conformity with others, we defined anatomical failure as POP stage II or more.24 
For the anterior compartment 14 patients (36%) met this criterion. In 4 of them (10%) 
point Ba had the same value after the operation as before. In all remaining 10 patients 
point Ba improved (from 1 to 5cm). The mean bother score on genital prolapse in these 
14 patients dropped significantly from 50 before to 7 after surgery (p 0.01). 
In seven patients (18%) postoperatively the posterior compartment was classified 
as stage II. Postoperative points Bp were all -1 and had improved from 1 to 4 cm. 
In our opinion it is debatable whether one should classify patients with a stage II 
prolapse (that is leading edge is >-1<+1) without prolapse symptoms as surgical 
failure. In addition one has to realize that in the normal population ICS stage II 
table 4. Influence of surgery on sexual intercourse and dyspareunia
“how often do you have sexual 
intercourse?”
Before surgery After surgery
P% 95% CI % 95% CI
Answer:
Never 33 21-45 31 19-42 N.S
< 1 a month 8 1-15 15 7-24 N.S
1-2 times a month 22 11-32 15 7-24 N.S
1 time a week 23 13-34 23 13-33 N.S
Several times a week 13 5-22 15 7-24 N.S
Total (n) 60 65
“do you experience pain during 
sexual intercourse?”
Before surgery After surgery P
Answer:
No, or not at all bothersome 41 29-54 33 22-44 N.S
Yes, a little 12 4-20 16 8-25 N.S
Yes, rather much 19 9-29 15 6-23 N.S
Yes, very much 5 -1-11 9 2-16 N.S
No intercourse 22 12-33 27 16-37 N.S
Total (n) 58 67
“Is the vagina too narrow to have 
sexual intercourse?”
Before surgery After surgery P
Answer:
No, or not at all bothersome 73 61-84 65 54-77 N.S
Yes, a little 2 -2-5 0 0-0 N.S
Yes, rather much 2 -2-5 6 0-12 N.S
Yes, very much 2 -2-5 4 0-10 N.S
No intercourse 22 11-33 24 14-35 N.S
Total (n) 59 66
Data presented as percentages of given answers and 95% confidence intervals.
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prolapse is commonly seen. Swift et al. reported 48 % and found that prolapse 
complaints increased significantly when the leading edge of the prolapse reached 
beyond the hymenal remnants, which finding led to their statement that this helps 
defining symptomatic pelvic organ prolapse.25 
The functional results of the operations, in terms of diminished bother scores in 
the various domains were good. With the exception of incontinence on the UDI and 
pain on the DDI all bother scores on UDI and DDI decreased significantly. It should 
be emphasized that urinary incontinence was not the indication for surgery in these 
patients. In another Dutch study of sacrospinous hysteropexy with classical anterior 
repair the same questionnaire was used but unfortunately only postoperatively.26 
Postoperative bother scores on the domains of overactive bladder and obstructive 
micturition in our study are higher than in that study, but the technique used in that 
study (hysteropexy) was essentially different from ours (no apex fixations). Since pre-
-operative values of the two mentioned domains are missing in that study an actual 
comparison is not possible. The scores on the domain of genital prolapse in our study 
decreased sharply, which reflects the high efficacy of repair surgery on the symptoms 
of vaginal prolapse.
erosion and shrinkage
Erosions and potential ‘shrinkage’ induced by synthetic mesh might cause deformation 
of the vagina. Shrinkage is provoked by chronic inflammatory reactions to the mesh.27 
These reactions may lead to fibrosis, with scarring and retraction of the surrounding 
tissues, which subsequently ‘compresses’ the underlying mesh. The lack of any 
clinically detectable shrinkage in our patient group was comparable with findings 
in the quoted animal study.15 However, this issue requires further attention during 
longer-term follow-up.
In the retrospective series evaluated by the 2 other mentioned research groups, 
Dwyer et al. observed erosions after a mean follow-up of 29 months (range 6-52) 
in 9% of patients. They considered that the risk of erosion was not only related to 
the type of graft material, but also to the experience of the surgeon.12 Milani et al. 
reported an overall erosion rate of 10% after a median follow-up of 17 months (range 
3-48) and a high rate of postoperative dyspareunia. Therefore, they put forward 
arguments to abandon the use of synthetic mesh in vaginal prolapse surgery.13 The 
erosion percentage of 5,6% in our study is low compared to other studies with non-
-coated heavier polypropylene mesh. The median follow-up in our study however 
was relatively short. We could not confirm the high rate of postoperative dyspareunia 
as found by the research group of Milani et al.13 We found no statistically significant 
differences in the answers given to the questions as shown in table 4 before and after 
surgery. All 4 cases of erosion were detected in the posterior compartment, in the 
vaginal scar. None were seen in the apex of the vagina or posterior commisura, or in 
the anterior compartment. In these vaginal wall repairs, the mesh was placed beneath 
the vaginal epithelium so that it covered the plicated fascial layers of the bladder and 
rectum, respectively. It is a matter of debate as well whether positioning the mesh 
under the fascial layer of the rectum could have decreased the risk of erosion, as 
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was questioned by one of the other research groups.13 After using collagen coated 
low-weight polypropylene mesh in tension-free vaginal repair surgery, De Tayrac 
et al. reported erosion rates of 6% on the anterior wall and 1,3% on the posterior 
wall.24 These lower percentages provide further evidence of the advantages of using 
low-weight mesh and/or coating to reduce erosion rates. 
Despite the prospective nature and the use of validated questionnaires and 
standardized POPQ, a limitation of our study is the relatively short follow-up period. 
Continued prospective follow-up will show whether the mesh related morbidity 
stays at the level of the presented data. To answer the question of the anatomical 
efficacy of augmentation of conventional colporrhaphy with Ti-mesh®, a well-
-powered randomized controlled study, comparing Ti-mesh versus non-mesh surgery, 
is necessary. We did not detect any erosion in the anterior vaginal compartment, but 
the risk of prolapse recurrence seems highest in that anatomical region.4 Therefore, 
to our opinion, future research should mainly focus on this compartment and we 
strongly agree with the conclusion drawn in a recent evidence-based review on the 
surgical management of anterior vaginal wall prolapse that particularly controlled 
studies are necessary.28
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abstract
Introduction and hypothesis
The objective of this study was to report on one-year anatomical and functional 
outcomes of trocar-guided total Tension free Vaginal Mesh (ProliftTM) repair for post 
hysterectomy vaginal vault prolapse with one continuous piece of polypropylene 
mesh. 
Methods 
We conducted a prospective observational cohort study on 46 patients. A minimum 
sample size of 35 patients was needed to detect a recurrence rate of less than 20% 
at 12 months. Instruments of measurement: POP-Q and validated questionnaires. 
results 
Overall anatomical success was 91% (95% CI 83-99), with significant improvements in 
experienced bother- and quality of life. Mesh exposure occurred in seven patients (15%). 
Adverse effects on sexual functioning could not be detected. 
Conclusion 
Trocar-guided total Tension free Vaginal Mesh (ProliftTM) repair with one continuous 
mesh for post hysterectomy vaginal vault prolapse is well tolerated and anatomically 
and functionally highly effective. Results of controlled trials will determine its position 
in the operative armamentarium. 
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intrOductiOn
Pelvic organ prolapse in women is common, affecting 50% of parous women over 
50 years of age, with a lifetime prevalence risk of 30-50%.1 A challenging aspect of pelvic 
organ prolapse is the treatment of the prolapsed vaginal vault. The incidence of post 
hysterectomy vaginal wall prolapse that requires surgery has been estimated at 1.3 per 
1000 women-years.
The risk of prolapse surgery was 4.7 times higher in women whose initial 
hysterectomy was indicated by prolapse and 8.0 times higher if preoperative prolapse 
stage II or more was present.2 
The surgical treatment of vaginal vault prolapse can either be performed by vaginal 
or abdominal route. A prospective randomized clinical trial on vault prolapse, which 
compared the abdominal sacral colpopexy with the vaginal sacrospinous colpopexy, 
showed similar results in both groups with regards to subjective and objective postoperative 
anatomical assessment and impact on quality of life, but found that the abdominal route 
was associated with a longer operating time, slower return to activities of daily living, 
and greater cost than the vaginal sacrospinous colpopexy.3 Both techniques have some 
drawbacks. Prolapse of the anterior compartment following sacrospinous colpopexy and 
of the posterior compartment following abdominal sacral colpopexy are well reported.4, 5 
Vice versa, treatment of the anterior and / or posterior compartment alone will invariably 
affect the vaginal vault.6 The ideal solution therefore would be a surgical approach with 
minimal morbidity that simultaneously treats all three compartments equally successful. 
A number of synthetic implant materials with surgical instrument kits is currently 
commercially available. The rationale for using these are to decrease surgical failures. 
One of these surgical kits is designed for the total vaginal repair of vault prolapse with 
one continuous mesh interposition on the anterior, middle and posterior compartment 
and aims to be a bilateral sacrospinous ligament suspension as well (ProliftTM, Ethicon, 
Somerville, NJ, USA). The first data on the efficacy and safety of this novel trans vaginal 
mesh technique are reported from retrospective case series and do not explicitly focus 
on this total vaginal mesh treatment with one continuous mesh for vault prolapse.7, 8 
Prospective data on this tension free vaginal mesh technique were scarce and with 
short term follow-up.9 Only one paper on trocar-guided vaginal mesh repair shows a 
prospective follow-up of one year, but the authors do not discriminate between the 
combined anterior and posterior repair with preservation of the uterus and a true 
total repair with one continuous mesh for vaginal vault prolapse.10
The aim of this paper is to exclusively report on the efficacy and safety of the total 
Tension free Vaginal Mesh (ProliftTM) repair with one continuous piece of mesh for 
the anterior, middle and posterior compartment in case of post hysterectomy vaginal 
wall prolapse.
material and methOds
In September 2005 an ongoing prospective observational cohort study with the 
ProliftTM pelvic floor repair system was started in two urogynecological centres in 
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the Netherlands, the Reinier de Graaf Hospital in Delft and the Radboud University 
Nijmegen Medical Centre. 
After obtaining informed consent consecutive patients with recurrent vaginal wall 
prolapse stage II or more or with a primary vaginal wall prolapse stage III or more 
were enrolled in this study. At the beginning of 2009 297 patients were included. One 
hundred ninety-six patients (66%) had completed their one-year follow-up. Of those 
46 patients (24%) underwent the total continuous vaginal mesh procedure for vault 
prolapse. Four surgeons who were trained prior to the start of the study performed 
surgical procedures. Most postmenopausal patients were treated with topical estrogen 
6-8 weeks prior to surgery and continued this treatment postoperatively when 
considered necessary. Concomitant anti-incontinence surgery was not performed in 
this patient series, in order to prevent increased risk on complications as reported 
earlier by us.11 All patients were counselled about this strategy prior to surgery. 
Preoperatively genital prolapse was quantified in the dorsal lithotomy position 
using the POP-Q measurement system.12 Postoperatively POP-Q measurements were 
performed at both 6 and 12 months. 
surgical procedure
Peroperative antibiotic prophylaxis was given with a single shot of Cefalozine-
Natrium (Kefzol® Lilly, the Netherlands) and Metronidazol (Flagyl® Aventis Pharma 
BV Hoevelaken, the Netherlands). Patients were positioned in the dorsal lithotomy 
position with their hips flexed to about 110o. The anus was covered with Tegaderm®. 
After liberal use of hydrodissection (Lidocaine hydrochloride monohydrate 200mg 
with epinephrine hydrogen tartrate100μ g in 20 ml - Astra Zeneca BV Zoetermeer the 
Netherlands- diluted in 100 ml of 0.9% saline solution) an anterior midline incision was 
made which included full thickness of the fibromuscular wall of the vagina from about 
2.5 cm distal from the external urethral meatus to about 2 cm distal of the vaginal 
apex. Bilateral mostly blunt and incidentally sharp dissection was used to open the 
vesicovaginal fascia on each side in order to reach distally the cranial side of the ischial 
spine, the arcus tendineus fascia pelvis and the retropubic space. The transobturator 
insertion of the cannula equipped guides and retrieval devices has extensively been 
described elsewhere and was not altered in our hands.7 Then, after hydrodissection of 
the posterior vaginal wall, a full thickness vaginal wall incision was made to the vaginal 
apex leaving an apical bridge of vaginal tissue of about 3cm to the anterior incision. 
The pararectal space was bilaterally bluntly dissected until the caudal side of the ischial 
spines were reached and the sacrospinous ligaments were properly identified. The 
cannula equipped guides were used to perforate and pass the sacrospinous ligaments 
about two cm medial from the ischial spines as described in the paper by Fatton et al.7 
Then a canal was carefully dissected under the apical bridge of the vaginal vault in order 
to allow passage of the posterior part of the total ProliftTM mesh. After gloves were 
changed to minimize colonisation of bacteria and decrease infection risk, a slender 
forceps was used to gently pull the posterior part of the mesh through the previously 
dissected canal at the level of the vault in such a manner that the middle part of the 
mesh exactly fitted under this bridge of vaginal tissue (figure 1). After fixation of the 
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mesh with two Vicryl 00 sutures at the level of the bladder neck and two Vicryl 00 
sutures close to the posterior vaginal commisura the four anterior and two posterior 
mesh arms were gently pulled through the cannulas by the respective retrieval devices. 
The mesh was carefully spread out to avoid unnecessary mesh folding after which the 
full thickness of the anterior and posterior vaginal walls were closed with a running 
Vicryl 00, without any prior vaginal wall dissection. After repositioning the vagina 
with two Breisky specula to its physiological anatomical position the cannulas were 
gently withdrawn and finally a finger in the rectum gently uplifted the posterior mesh 
with the intention to prevent future tension on the rectum, after possible shrinkage 
of the mesh. The cutaneous remnants of the mesh arms were cut and the small skin 
incisions closed with rapidly dissolving Vicryl 000. An iodized gauze pack was left in 
the vagina for at least 24 hours. The indwelling catheter was removed on the second 
postoperative day. 
study endpoints
We defined the primary endpoint of this study to be prolapse recurrence at 
12  months. Anatomical failure was defined if at least one of the compartments 
at 12 months was classified as POP ≥ stage II. Anatomical success was defined as 
overall POP stage 0 or I. 
figure 1.   Total mesh in position under the vaginal apical bridge (Medical photography: Mr. Ruud 
van de Voorde, Image manipulation Mr. George Bazan).
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Secondary endpoints were anatomic success per compartment, per- and 
postoperative morbidity, and change in experienced bother, quality of life and global 
impression of change at 6 and 12 months, as well as effects on sexual functioning. 
sample size
We defined study success as an upper 95% Confidence Interval for recurrence <20% 
at 12 months. We assumed that an estimated success of 90% at 12 months in the 
mesh treated compartments would be realistic.8 With this estimated 90% success 
rate, a two-sided 95% Confidence Interval of 10% was allowed, which meant that 
we needed a minimum sample size of 35 patients for this study. 
data collection
To obtain data on the functional efficacy and impact on patients quality of life the 
standard urogynecological questionnaire of the Dutch Pelvic Floor Society was used 
at baseline and at 6 and 12 months postoperatively. This questionnaire contains the 
validated Dutch versions of the Pelvic floor Distress Inventory (UDI and DDI), the Pelvic 
Floor Impact questionnaire (IIQ), Patients Global Impression of Improvement (PGI-I) 
and questions on sexual functioning.13, 14 All data were entered into a SPSS 16.0 
database. Baseline and surgical data are presented as median (range), complications 
as numbers with corresponding percentages. Differences in numbers were tested 
using Pearson’s Chi-square test. Mean domain scores and standard deviations were 
calculated on the domains of UDI, DDI and IIQ. Differences in means between baseline 
and postoperative scores at 6 and 12 months were tested with the paired-samples 
t- test. A p-value ≤ 0.05 was considered significant.
results
Forty-six consecutive patients who were operated according the total vaginal mesh 
procedure (ProliftTM) for post hysterectomy vaginal wall prolapse were analysed. 
For various reasons we missed 7 patients at the 6 months visit. At the 12 months 
visit one patient refused to come for POP-Q examination, since she stated to have 
no complaints. We could not convince her of the usefulness of this check-up. She 
was willing though to send us her completed questionnaire. One other patient was 
not able to complete her 12 months questionnaire because of progressive cerebral 
dementia, but she was willing to be examined for POP-Q measurements. Median age 
was 66 (38-86) years. All but one patient (98%) had undergone previous prolapse 
surgery, of whom 4 (9%) more than once. Baseline and other surgical characteristics 
are presented in table 1. 
Anatomical results
Baseline, 6 and 12-month data per POP-Q variable, overall POP stage and POP stage 
per compartment are shown in table 2. At baseline 40 patients (87%) were classified 
having a vaginal prolapse with the leading edge at POP stage III or IV and 6 (13%) 
at stage II. 
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Twelve months after surgery 41 out of 45 patients (91%: 95% CI 83-99) fulfilled 
the criteria of an overall anatomical successful repair. Four (9%) were thus classified as 
anatomical failures. One of these was classified as stage III (C+4). She later underwent 
an abdominal sacrocolpopexy. Mean changes from baseline per POP-Q variable at 
6 and 12 months are shown in table 2 as well. All changes are considerable and 
significant. The size of the genital hiatus decreased significantly with more than 1 cm, 
although surgery on the vaginal introitus was performed in none. The mean total 
vaginal length decreased statistically significant with 0.3 cm, but seemed not to be 
clinically significant.
table 1. Baseline, surgical characteristics & complications.
Baseline characteristics (n: 46)
Age (years) 66 (38-86)
BMI (kg/m2) 25 (21-32)
Parity (n) 2 (0-5)
Postmenopausal 43 (93%)
Abdominal hysterectomy 13 (28%)
Prior prolapse related surgery 45 (98%)
Vaginal hysterectomy 33 (72%)
Anterior repair 25 (54%)
Posterior repair 21 (46%)
More than one prolapse repair 4 (9%)
Prior surgery for incontinence 3 (7%)
surgical characteristics
Duration of surgery (minutes) 80 (54-109)
Bloodloss (ml) 100 (50-1300)
Spinal analgesia 21 (46%)
General anesthesia 25 (54%)
Duration of stay indwelling catheter (days) 2 (1-6)
Hospital stay (days) 4 (3-8)
Complications
> 500ml Bloodloss 2 (4%)
Bladder lesion 0
Rectal lesion 0
Postoperative hematoma 2 (4%)
Urinary retention after removal catheter 8 (17%)
Accumulated mesh exposure (12 months) 7 (15%)
Exposure in anterior compartment 3 
Apical exposure 2
Exposure in posterior compartment 2
Data are presented as median (range) or number (percentage).
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Morbidity
In table 1 is shown that there were no bladder- or rectal perforations in this patient 
series. In two patients a hematoma presented postoperatively in the buttock region, 
which resolved spontaneously within 10 days. A total number of seven patients (15%) 
were found to have a small mesh exposure; four at the 6 months follow-up and 
another three at the 12 months visit. Three of these mesh exposures were located on 
the anterior scar, two close to the level of the vault, and two in the posterior scar. All 
of these were asymptomatic and measured between 5 and 20 mm in size. All seven 
table 2. Anatomical data per POP-Q variable and POP stage at baseline, 6 and 12 months
PoP-Q variable
Baseline 
(n: 46)
6 months
 (n: 39)
Change from 
baseline
12 months 
(n: 45)
Change from 
baseline
Ba 3.0 (2.6) -2.7 (0.5) 5.3 (2.2)* -2.5 (1.1) 5.4 (2.4)*
C -0.2 (4.7) -7.4 (1.5) 6.5 (4.2)* -7.1 (2.3) 6.7 (4.6)*
Bp 1.9 (2.9) -2.6 (0.7) 3.9 (2.3)* -2.4 (1.2) 4.2 (2.6)*
TVL 8.8 (1.2) 8.5 (1.1) 0.2 (1.2) 8.5 (1.2) 0.3 (0.9)†
GH 4.8 (1.3) 3.5 (1.0) 1.3 (1.3)* 3.5 (1.0) 1.2 (1.4)*
PB 3.5 (1.2) 3.5 (0.9) 0.0 (1.0) 3.5 (0.9) 0.0 (1.0)
PoP stage Baseline success at 6 months success at 12 months
Anterior 0 - 26 (66.7%) 100% 31 (68.9%) 95.6%
I 2 (4.3%) 13 (33.3%) 12 (26.7)
II 12 (26.1%) - 1 (2.2%)
III 30 (65.2%) - 1 (2.2%)
IV 2 (4.4%) - -
Apical 0 1 (2.2%) 33 (84.6%) 97.4% 36 (80%) 95.6%
I 25 (54.3%) 5 (12.8%) 7 (15.6%)
II 3 (6.5%) 1 (2.6%) 1 (2.2%)
III 14 (30.4%) - 1 (2.2%)
IV 3 (6.6%) - -
Posterior 0 1 (2.2%) 26 (66.7%) 94.9% 30 (66.7%) 91.1%
I 3 (6.5%) 11 (28.2%) 11 (24.4%)
II 20 (43.5%) 2 (5.1%) 3 (6.7%)
III 20 (43.5%) - 1 (2.2%)
IV 2 (4.3%) - -
overall 0 - 15 (38.5%) 94.9% 15 (33.3%) 91.1%
(82.8-99.4)‡I - 22 (56.4%) 26 (57.8%)
II 6 (13%) 2 (5.1%) 3 (6.7%)
III 37 (80.5%) - 1 (2.2%)
IV 3 (6.5%) - -
Data are presented as mean (± standard deviation) for POP-Q variable and as number (percentage) 
for POPstage. Ba: most descendant point at anterior vaginal wall, C: vaginal apex, Bp: most 
descendant point at posterior vaginal wall (all in cm distance from the hymenal remnants). TVL: 
Total Vaginal Length, GH: Genital Hiatus, PB: Perineal Body length in cm (± standard deviation). 
* P level <0.001 (paired samples t-test), † P level 0.018 (paired samples t-test), ‡ 95% confidence 
interval.
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patients were initially treated with topical estrogens and for reasons of insufficient 
healing the tiny mesh exposure was excised in five patients in a day-care procedure. 
The two other patients preferred an expectant management.
functional results
In table 3 data on sexual functioning at baseline and 12 months are shown.
The percentages of patients reporting dyspareunia before and after operation 
were equal (37%). De novo dyspareunia occurred in two patients (18%). In another 
two (28%) however dyspareunia disappeared after surgery. 
Table 4 shows functional data in the domains of UDI, DDI and IIQ as well as 
PGI-I.13, 14 Scores ranged between 0 (least bother and best quality of life) to 100 
(maximum bother and worst quality of life). Six and 12 months after surgery 94 and 
93% of patients respectively stated to be much to very much better compared to 
their baseline situation. 
discussiOn 
To our knowledge this study is the first of considerable size that prospectively and 
specifically evaluates the efficacy and safety of the Total Tension free Vaginal Mesh 
repair with one continuous piece of polypropylene mesh for all three compartments 
of the prolapsed vaginal vault. The ProliftTM total prolapse repair system is unique in 
this respect and at present the only available kit that offers the possibility of such a 
complete repair. It aims at support of the weakened vaginal walls of the anterior and 
posterior compartments and at suspension of the middle compartment by means of a 
bilateral sacrospinous ligament fixation and thus restoring Delancey level I support.15 
Other mesh kits are designed to treat the anterior and posterior compartments, either 
alone or simultaneously, with a separate (split) mesh. Suspension of the vault in these 
procedures is not achieved by a bilateral sacrospinous ligament fixation, but by means 
of bilateral infracoccygeal sacropexy as described by Petros.16 Most data on these 
table 3. Data on sexual function at baseline and 12 months
 Baseline  12 months P*
Regular intercourse 19 of 42 (45%) 19 of 43 (44%) N.S
Dyspareunia 7 of 19  (37%)
A little 
Rather much
Very much 
2
3
2
7 of 19 
(37%)
A little 
Rather much
Very much
2
2
3
N.S
De novo dyspareunia 2 of 11 (18%) 
A little 
Rather much
1
1
Resolved dyspareunia 2 of 7 (28%) 
De novo intercourse 3 of 23 (13%)
Abstained intercourse 4 of 19 (21%)
Data presented as number of patients (percentages). *Pearson Chi-square test.
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procedures are derived from congress abstracts, retrospective reports or studies with 
short follow-up.7, 9, 17 Only few data are published with a medium long term follow-
-up, but none of these focuses exclusively on the total repair with one continuous 
piece of mesh.8, 10 
Anatomical effect
Considering the high percentage of patients with recurrent prolapse (98%) and high 
stage POP (III and IV) in this study group at baseline (87%) and the follow-up period 
of one year, the overall anatomical success of 91% is respectable. This is also reflected 
in the mean changes of the three most relevant POP-Q variables (Ba, C, Bp) between 
baseline and 12 months, which even exceed those reported by other authors.8 
Anatomical success rates per compartment, are comparable with that report. 
table 4. Functional data on domains of UDI, DDI, and IIQ at baseline, 6 and 12 months & PGI-I
Baseline 6 months
(n: 39) P *
12 months
(n: 45) P **
domains UDI
 Prolapse 69.1 (33.6) 0.4 (2.7) <0.001 2.3 (11.3) <0.001
 Incontinence 24.2 (29.5) 16.2 (18.5) 0.250 14.2 (17.1) 0.122
 Overactive bladder 31.6 (30.6) 10.5 (17.6) 0.002 11.1 (18.3) 0.001
 Obstructive micturition 29.4 (29.9) 7.4 (17.6) 0.002 5.4 (11.3) <0.001
 Pain 26.7 (28.4) 12.6 (20.6) 0.005 10.2 (17.7) 0.001
domains DDI
 Constipation 8.3 (14.6) 3.8 (9.1) 0.205 2.4 (6.9) 0.291
 Obstructed defaecation 12.1 (17.2) 4.3 (8.9) 0.009 3.5 (7.7) 0.003
 Pain 7.7 (19.0) 4.2 (12.8) 0.366 2.4 (10.8) 0.146
 Incontinence 7.3 (13.5) 3.2 (7.8) 0.090 2.1 (6.7) 0.103
domains IIQ
 Physical functioning 32.5 (34.0) 8.1 (2.1) 0.002 9.3 (23.3) 0.001
 Mobility 34.5 (25.8) 9.1 (12.7) 0.062 11.9 (20.2) <0.001
 Emotional Health 23.1 (27.9) 5.2 (8.9) 0.002 9.9 (18.7) 0.001
 Social Functioning 18.1 (18.9) 3.5 (7.8) 0.002 6.9 (13.7) <0.001
 Embarrassment 16.7 (23.6) 2.8 (6.3) 0.016 7.8 (16.5) 0.062
Patients Global Improvement (PGI-I) at 6 months at 12 months
 Very much better 50% 48%
 Much better 44% 45%
 Little better 6% 5%
 No change - -
 Little worse - 2%
UDI: Urinary Distress Inventory, DDI: Defaecatory Distress Inventory, IIQ: Incontinence Impact  
Questionnaire. Scores range between 0 (least bother and best quality of life) to 100 (maximum 
bother and worst quality of life).  
Values presented as means ± standard deviation. * P value between baseline and 6 months (paired 
samples t-test). ** P value between baseline and 12 months (paired samples t-test). 
PGI-I: Patients Global Impression of Improvement (percentage of patients with answer).
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Anatomical results in this study seem somewhat better than those reported 
by the Scandinavian group, who reported 79-82% for the anterior compartment 
and 81-86% for the posterior compartment.10 Neither of these authors however 
makes a distinction between the combined anterior and posterior mesh treatment 
and the total treatment with one continuous piece of mesh. A clear comparison is 
therefore not possible. The Scandinavian group reported the combined results of 
26 participating centres, while we report on only two major centres. Therefore the 
number of procedures performed per surgeon and possibly the experience related 
to this might be different. Only one small other study reported on 21 ProliftTM total 
repairs with one continuous piece of mesh and showed an anatomical success of 
87% at 12 months.18 The fairly small number of patients that could be evaluated 
in that study makes 95% Confidence Intervals rather wide (14%) and results less 
comparable.
The success rate of 95% for restoration of level I support of the apex is comparable 
with the 74-100% success rate of apical support in abdominal sacrocolpopexy and 
the 89-97% success rate for restoration of apical support by sacrospinous ligament 
fixation.19-21 The advantage of this total vaginal mesh procedure however is that it 
adds support to both other vaginal compartments as well, and compared to the 
abdominal sacrocolpopexy, has a shorter operation time and can be considered as a 
relatively minimally invasive treatment.
At 12 months the measured total vaginal length was a mean 0.3 cm shorter than 
at baseline. This slight shortening probably is due to some shrinkage of the mesh, 
which actually is not a shrinkage of the material itself, but rather a retraction due 
to fibrotic reactions to the polypropylene mesh.22 Although this slight shortening is 
statistically significant we, as other authors, could not detect any clinical significance 
of this finding.10 If shrinkage continues however, this could become relevant in the 
future, so longer follow-up is mandatory.
surgical and peri-operative morbidity
In this series of patients with a total ProliftTM repair we experienced no bladder or 
rectal injuries, which in the large retrospective French series are well reported in 
percentages of 0.7 and 0.15 respectively.23 The rate of postoperative hematomas in 
our series is comparable with those of the Scandinavian and French reports.10, 23
Mesh exposure
One important adverse effect of mesh surgery is the fairly high number of mesh 
exposures. We found seven (15%) after 12 months. Interestingly we found none at 
the first postoperative visit at six weeks, but four at 6 months and another three at the 
12-month visit. Neither of these patients was symptomatic. Therefore a very careful 
follow-up even beyond 12 months seems mandatory. The number of exposures in 
the remaining 150 patients of our database who completed their 12 month follow-
-up (at present data are being processed for submission) is 10% and not statistically 
significant different from the percentage in this series (Pearson’s Chi-square 1.067; p 
0.301). The Scandinavian group reported similar findings; the erosion percentage rose 
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from 7% at two months to 11% at twelve months.10 A similar percentage (11.3%) 
is also reported in the large retrospective French series.23 Since we are not aware of 
the natural development of these most asymptomatic mesh erosions, we felt the urge 
to treat them. Initially with topical estrogens, but as this was not sufficient in most 
of them, we performed a minor mesh excision in five (11%) patients. The remaining 
two patients who preferred an expectant management are still without symptoms. 
Of these seven patients with a tiny mesh exposure, four didn’t have intercourse 
at baseline, but one of these had resumed intercourse at 6 months. One other 
patient continued to have intercourse. Neither of both complained of dyspareunia. 
Of three patients in whom a mesh exposure was detected at the 12-month visit, 
two had intercourse at baseline. At 12 months one of these continued to have 
intercourse without symptomatic dyspareunia and the other patient had abstained 
from intercourse for other reasons than pain. Apparently sexual intercourse by these 
patients was not hindered by the presence of these minor mesh exposures. 
We found that the mean duration of surgery in the group of patients who 
developed a mesh exposure (92 ± 13) was 14 minutes longer than in those who 
did not (78 ± 15). Whether this is a significant item in this relatively small group 
of patients remains unclear. This study group however represents a fairly complex 
group of patients with recurrent prolapse in all but one. The special technique, which 
leaves a small bridge of vaginal vault intact, might jeopardize the vascularisation of 
the vaginal tissue and could be responsible for poor wound healing and thus mesh 
exposure. In our opinion though the rate of mesh exposures is still too high and 
determinants other than those already published need to be discovered to lower this 
incidence.23-25
functional effects
Some earlier studies warned for the use of synthetic mesh in prolapse surgery 
because of high risk of dyspareunia.26 Other authors, who used modern kits with low 
weight polypropylene designed by other companies, such as coated polypropylene 
(Ugytex, Sofradim, France) or the Perigee Transobturator Prolapse Repair System 
(American Medical Systems, Minnetonka, MN) reported de novo dyspareunia 
after one year in 13% and 9% of patients respectively.27, 28 We detected de novo 
dyspareunia in two out of eleven patients (18%), but these are small numbers. On 
the other hand the percentages of patients having intercourse or dyspareunia at 
baseline and 12 months were practically identical. In two out of seven patients (28%) 
who suffered from dyspareunia at baseline this complaint was no longer present at 
12 months. Furthermore three out of twenty three patients (13%) who were not 
having intercourse at baseline had resumed this at 12 months. These data show 
that prolapse itself is a cause of dyspareunia and prolapse repair, in this case with a 
fairly large synthetic mesh, is able to resolve this problem in some. These results are 
comparable with observations done by the Scandinavian group, who used the short 
form of the PISQ questionnaire.29 They observed an overall deterioration of sexual 
function scores in women one year after trocar-guided transvaginal mesh surgery. 
However, the worsening was attributed to decreased scores on behavioural-emotive 
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and partner-related items, such as partner inability to have an erection. Dyspareunia 
neither improved, nor worsened, as is our observation.30 Although the rate of de 
novo dyspareunia seems low with the present light weight meshes we should remain 
cautious and await longer-term follow-up for realistic interpretations.
From a patients point of view probably more important than the objective 
anatomical success is the subjective improvement in experienced bother and quality of 
life. This is clearly shown by the stable percentage of patients (93%) that experienced 
their situation to be much to very much better 12 months after surgery compared to 
baseline.
The improvements in the various domains of UDI, DDI and IIQ remain stable 
between 6 and 12 months and are highly significant compared to baseline, except 
for the domains of incontinence of the UDI and constipation, pain and incontinence 
of the DDI and embarrassment of the IIQ. As mentioned before, so far it has been 
our strategy not to treat patients simultaneously for their prolapse and potentially 
manifest or masked stress urinary incontinence. All patients were counselled about 
this strategy before surgery. Only one patient needed and underwent a midurethral 
sling procedure between her 6 and 12 months visit because of unmasked stress 
urinary incontinence. 
In our opinion the strengths of this study are its prospective nature and the use of 
internationally accepted instruments of measurement such as validated questionnaires 
and POP-Q, the follow-up period of one year, as well as the high follow-up rate and 
data acquisition in all patients. A limitation of this study on the other hand is that not 
all POP-Q measurements were performed by an independent examiner. 
Conclusion
The trocar-guided total tension free vaginal mesh repair for post hysterectomy vaginal 
vault prolapse with one continuous piece of polypropylene mesh is very well tolerated 
and anatomically and functionally highly effective at 6 and 12 months follow-up. 
Whether this procedure is more effective and safe than other forms of prolapse 
surgery remains to be determined in randomized controlled trials. 
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abstract
objective
To evaluate anatomical and functional outcomes at 1-year following trocar-guided 
transvaginalprolapse repair using a partially absorbable mesh.
study design
Prospective multi-centre cohort study at 11 international sites.One hundred twenty-
-seven patients with pelvic organ prolapse stage ≥ III were operated and evaluated at 
3 months and 1year post-surgery compared to baseline. Instruments of measurements: 
POP-Q, PFDI-20, PFIQ-7, PISQ-12and PGI-C. 
results
Anatomic success, defined as prolapse stage ≤ I in the treated vaginal compartments, 
was 77.4% (95% CI 69.0%-84.4%). Significant improvements in bother, quality of 
life and sexual function were detected at 3 months and 1 year compared to baseline. 
At one year following surgery, 86.2% of patients indicated their prolapse situation 
to be ‘much better’.
Mesh exposure rate was 10.2% and rate of de novo dyspareunia 2% at 1 year. 
Conclusion
These results demonstrate improved anatomic support, associated with excellent 
functional improvements, without apparent safety concerns. 
5PARTIALLY ABSORBABLE MESH
intrOductiOn
Pelvicorganprolapse (POP) is a common problem and may occur in up to 50% of parous 
women.1 A Dutch cross-sectional study demonstrated a prevalence of symptomatic 
POP as high as 11,4%.2 In 2003 over 300,000 women underwent prolapse surgery 
in the United States, indicating that POP is among common indications for surgery.3
There is increasing evidence that the tension-free vaginal insertion of prosthetic 
mesh in patients with symptomatic POP reduces the chance of anatomic failure.4-8 
The introduction of these new materials in pelvic reconstructive surgery has 
introduced new kinds of morbidity. Among the most prevalent complications are 
mesh exposure and shrinkage of tissue around the mesh. These may result in pelvic 
pain and dyspareunia.9, 10 De novo dyspareunia following traditional POP repair 
ranges between 14.5-36.1% and a recent retrospective study reported a similar rate 
(16.7%) following repair with a mesh kit system.1, 11, 12 Prospective studies and a large 
retrospective study using such mesh, have reported mesh exposure rates that ranged 
between 10 and 15%.13-16
The superiority of the light-weight large pore mesh compared to conventional 
heavier-weight mesh with regard to reduced numbers of long-term complications 
and increased comfort, has been clearly demonstrated in a review on inguinal 
hernia repair.17 A trocar-guided mesh system with a non-absorbable, mono-filament 
polyprolyene mesh was introduced in 2005.12, 14-16, 18-20 One of the key rationales for 
adopting a new, lighter-weight mesh with improved directional elastic properties 
was to minimize tissue shrinkage, which may lead to dyspareunia. This new mesh is 
composed of a fifty-fifty blend of monofilament non-absorbable polypropylene and 
absorbablepolyglecaprone 25.21, 22 Before absorption, this mesh weighs 57 g/m2. Full 
absorption after 90-120 days results in a final weight of 31 g/m², as opposed to the 
45 g/m² of the original polypropylene mesh. Due to warp knitting, this mesh provides 
increased elasticity in the longitudinal direction and has larger pores compared to the 
original mesh to allow more tissue in-growth. 
The primary objective of this study was to assess anatomic and functional 
outcomes with this new mesh one year post-surgery. The secondary objective was to 
assess adverse events, particularly pain and dyspareunia. 
materials and methOds
The study protocol and informed consent documentation received ethics committee / 
institutional review board approval at all participating sites. The trial was registered 
at ClinicalTrials.gov; NCT00833001. Eleven urogynecological centres from Belgium, 
France, Germany, the Netherlands and the US enrolled patients between April and 
October 2008; one year follow-up visits were completed by November 2009. All 
patients gave written informed consent prior to participation in the study. Inclusion 
criteria were POP stage III or IV, according to the Pelvic Organ Prolapse Quantification 
(POP-Q) classification system.23 Concurrent hysterectomies and / or perineal repairs 
were allowed, but exclusion criteria were: other additional surgical repair of prolapse, 
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including paravaginal repair, sacrocolpopexy and colporrhaphy in a non-mesh treated 
compartment; previous prolapse repair using mesh; systemic diseases known to 
affect bladder or bowel function and any medical or psychiatric condition that could 
potentially affect the patient’s ability to complete study visits.
All patients underwent the standardized trans-vaginal mesh placement technique 
(GYNECARE PROLIFT+M Pelvic Floor Repair System, ETHICON, Somerville, NJ; 
referred to as Prolift+M). All surgeons were experienced with the procedure prior 
to participation.18 Depending on the site of prolapse, the mesh repair could be 
anterior, posterior or total; in patients with an intact uterus, the total mesh was 
cut. Concurrent hysterectomies, perineal repairs and/or mid urethral sling procedures 
were performed at each surgeon’s discretion. Cystoscopy was required for repairs 
involving the anterior compartment. All procedures were performed under antibiotic 
coverage, according to the standard of each participating site. 
Pelvic examination, including the POP-Quantification system was performed at 
baseline, 3 months and 1 year post-surgery.23 Subsequent follow-up evaluations will 
be obtained at 2 and 3 years post-surgery.
The primary outcome was defined as anatomic success in the treated compartment 
at one year, being a POP-Q Stage ≤ I, without further surgical re-intervention for POP 
in that compartment. A priori, an alternate outcome measure was defined: leading 
edge of prolapse proximal to the hymen (i.e. <0 cm) in the treated compartment at 
one year, without further re-operation. To address the untreated compartment, a 
secondary outcome was the incidence of de novoprolapse, defined as occurrence of 
post-operative prolapse (ICS Stage ≥ II) in the untreated compartment, provided there 
was no pre-operative defect in that compartment (i.e. ICS Stage ≤ 1).
Other secondary outcomes were self-completed patient-reported outcome (PRO) 
measures, administered at 3 months and 1 year. POP-specific symptom bother and 
quality of life (QoL) were measured by the short form versions of the Pelvic Floor Distress 
Inventory (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7), respectively.24 
The validated American English versions of these questionnaires were used at US 
sites. For use in German, Dutch, Flemish and French languages, the American version 
underwent translation and cultural adaptation in accordance with the International 
Society of Pharmacoeconomics and Outcomes (ISPOR) guidance.25 To gauge patients’ 
subjective impression of improvement specific to the POP-intervention, the Patients 
Global Impression of Change (PGI-C), was used.26
An internationally recognised measure of general health status, EQ-5D, was used 
thatenables comparisons of impact across different diseases.27
 For sexually active women, the short-form of Pelvic Organ Prolapse/Urinary 
Incontinence Sexual Function (PISQ-12) questionnaire was administered to evaluate 
sexual function at baseline, 3 months and 1 year.28 The validated English version was 
used at the English speaking sites, while the other language versions underwent the 
same translation and cross-cultural adaptation as described above. Dyspareunia was 
assessed at baseline, 3 months and 1 year in sexually active patients by asking “If the 
subject has been sexually active in the last 6 months / since the study surgery, have 
they experienced dyspareunia?” 
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Pelvic pain was evaluated during routine life and/or during pelvic examination 
at baseline and follow-up visits. The incidence of mesh contraction and vaginal wall 
stiffness was determined if pain was elicited on gentle palpation of mesh and its 
attachment points during pelvic examination. A pre-determined safety outcome was 
the incidence of any exposures / erosions including location. 
Sample size estimation:assuming that anatomic results of this new mesh were 
similar to the original polypropylene mesh, an anatomic success rate in the treated 
compartment of 80% stage ≤ I was realistic. With a two-sided 95% confidence 
interval of 7% at least 125 subjects were needed to be enrolled. Anticipating on 
a drop out rate over the first year of 5%, this would ensure 118 subjects to be 
evaluable at 1 year.
Results are summarized as follows; mean, standard deviation, minimum, median, 
maximum and 95% CI for continuous data and number, percent for discrete data. 
Student t-test was used to calculate p-values where appropriate for change from 
baseline to 3 months and 1 year. The 95% CI for success rates were constructed 
using the exact binomial method (Clopper-Pearson). Analyses were performed 
using statistical software (SAS EG 4.1 with SAS version 9.1.3). A p value <0.05 was 
considered statistically significant.
results
One hundred and twenty-eight women consented to the study. Surgery was completed 
in 127. Ten major protocol deviations were recorded in 9 patients: 4 patients with 
POP stage II were inappropriately included and in 6 patients additional prolapse 
procedures were performed. For analysis of the 3 months results, 9 more patients 
from a single centre were excluded due to data collection problems, which were 
resolved prior to collection of the 12-month data (figure 1). Baseline and surgical 
characteristics are presented in table 1.
Forty-one patients (32.3%) underwent an anterior mesh repair; 16 (12.6%) 
a posterior repair and 70 women (55.1%) a total pelvic floor repair (total uncut 
mesh in absence of uterus: 28; total cut mesh in presence of uterus: 42). Anatomic 
success (POP Stage ≤ I) in the treated compartments at 1 year was 77.4% (95% CI 
69.0% - 84.4%). The protocol-defined primary endpoint, based on the per-protocol 
analysis set, which excluded the 9 patients with a major protocol deviation, yielded 
a success rate of 78.3% (95% CI 69.6% - 85.4%). When anatomic success was 
defined as leading edge < 0 cm, the success rate was 89.5% (95% CI 82.7% - 
94.3%). Four re-interventions were reported within 1 year following surgery, three 
in the treated compartment. One patient encountered an immediate recurrence of a 
stage IV prolapse after a coughing episode during extubation. She was immediately 
re-operated with a new Prolift +M mesh placement. Despite the fact that this 
patient demonstrated a successful anatomic result at one year, she was a surgical 
re-intervention and therefore considered a failure. One patient required a vaginal 
hysterectomy due to utero-vaginal prolapse following a total, cut mesh repair. Two 
patients underwent subsequent laparoscopic sacrocolpopexy: one for posterior 
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vaginal wall prolapse after total, uncut mesh repair; one for apical failure after an 
anterior repair. Of 57 patients who had only a single compartment treated, 13 had an 
untreated stage II prolapse that was not deemed necessary to surgically address. Of 
44 patients without prolapse in the other compartment, 9 (20.5%) had developed a 
de novo stage II prolapse in the untreated compartment by one year. Anatomic results 
and success rates according to both definitions at 3 months and 1 year are presented 
in tables 2 and 3. 
Significant improvements were observed in all subscales of disease-specific 
symptoms and QoL scores from baseline compared to 3 months and 1 year 
(table 4). The mean changes from baseline to 3 months were statistically significant 
and sustained at 1 year. At baseline 91.2% of patients reported bulge symptoms, 
compared to 8.9% by one year. Based on the PGI-C, 86.0% of patients indicated 
their prolapse situation at one year to be “much better.” 
Consented to study (n=128)
= SafetyAnalysis Set
Completed Mesh Surgery (n=127)
Clinical Follow-up available at 3 months (n=118)
Clinical Follow-up available at 1 year (n=124)
3 monthsfunctional/QOL Follow-Up (n=116)
12 monthsfunctional/QOL Follow-Up (n=123)
Per Protocol Set at 1 year:
Excluding all major protocol deviations (n=118)
1 cystotomy, mesh procedure 
abandoned
figure 1.   Patients study disposition.
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table 1. Baseline and surgical characteristics.
Patients n: 127
Mean Age (years) 63.9 (10.1)
Mean BMI kg/m2 27.5 (3.8)
Median Vaginal deliveries (range) 2 (0-6)
Post-menopausal (n) 117 (92.1%)
surgical history
 Hysterectomy 52 (40.9%)
 Previous POP repair 27 (21.3%)
 Previous incontinence surgery 9 (7.1%)
Concomitant procedures
 Hysterectomy 21 (16.5%)
 TVT or TVT-O 36 (28.3%)
 Perineal repair 14 (11%)
 Additional intervention for prolapse  6 (4.7%)
Anesthesia type
 General 80 (63%)
 Spinal 47 (37%)
Data presented as means (± standard deviation), median (range) or number (percentage).
table 2. Anatomical results for the treated compartment at 3 and 12 months.
PoP stage Baseline (n=127) 3 Months (n=118) 12 Months (n=124)
Stage 0 0 68 (57.6%) 51 (41.1%)
Stage I 0 42 (35.6%) 45 (36.3%)
Stage II 4 (3.1%) 7 (5.9%) 24 (19.4%)
Stage III 104 (81.9%) 0 1 (0.8%)
Stage IV 10 (15.0%) 0 0
Re-intervention - 1 (0.8%) 3 (2.4%)
success rate % (95% CI) 93.2 % (87.0 - 97.0) 77.4% (69.0 - 84.4)
Leading edge Baseline (n=127) 3 Months (n=118) 12 Months (n=124)
-3 cm 0 70 (59.3%) 54 (43.5%)
-2.5 to -1.5 cm 0 40 (33.9%) 42 (33.9%)
-1 to -0.5 cm 0 1 (0.8%) 15 (12.1%)
0 0 5 (4.2%) 4 (3.2%)
+0.5 to +1 cm 4 (3%) 1 (0.8%) 5 (4.0%)
+1.5 to +2 cm 57 (45%) 0 0
+2.5 to +3 cm 28 (22%) 0 0
>+3 cm 38 (30%) 0 1 (0.8%)
Re-intervention - 1 (0.8%) 3 (2.4%) 
success rate % (95% CI) 94.1% (88.2 - 97.6) 89.5% (82.7 - 94.3)
Data presented as numbers (%), CI; confidence interval.
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table 3. Anatomical results in POP-Q measurements.
All (n=127) Anterior repair (n=41) Posterior repair (n=16) total repair (n=70)
Baseline 12 months Baseline 12 months Baseline 12 months Baseline 12 months
Ba 2.4 (2.3) -2.3 (0.9)** 2.3 (0.7) -2.3 (0.9)** -2.0 (0.7) -2.3 (1.0) 3.4 (1.9) -2.3 (0.9)**
C -1.7 (4.5) -6.5 (2.1)** -4.9 (2.2) -7.0 (1.8)** -3.1 (3.5) -6.5 (2.1)* 0.4 (4.6) -6.3 (2.3)**
Bp 0.6 (2.8) -2.5 (0.8)** -2.0 (0.7) -2.1 (1.0) 3.4 (1.5) -2.4 (1.0)** 1.5 (2.7) -2.8 (0.4)**
Gh 4.3 (1.0) 3.4 (0.8)** 3.9 (0.9) 3.2 (0.8)** 4.1 (1.0) 3.2 (0.9)* 4.6 (1.0) 3.6 (0.8)**
Pb 2.9 (0.9) 3.2 (0.7)** 3.0 (0.7) 3.2 (0.8) 2.6 (1.0) 2.9 (0.6) 2.9 (1.0) 3.3 (0.7)**
TVL 8.7 (1.3) 8.3 (1.2)** 8.7 (1.4) 8.4 (1.1) 7.6 (1.0) 8.3 (1.2) 8.9 (1.2) 8.2 (1.3)**
POP-Q data presented as mean (± SD). * for p<0.05 and ** for p<0.001. Ba = most dependent point on 
anterior wall; C = most dependent point of cervix or cuff; Bp = most dependent point of posterior vaginal 
wall; Gh = genital hiatus; Pb = perineal body; TVL = total vaginal length.
table 4. Functional results.
All patients n: 127 Baseline 3 months 12 months
PFDI-20 98.9 (52.0) 31.2 (26.4)* 25.9 (28.1)*
POPDI-6 41.4 (21.9) 5.9 (8.2)* 6.3 (9.8)*
CRADI-8 21.6 (17.0) 11.5 (12.3)* 10.4 (13.0)*
UDI-6 35.7 (25.0) 13.8 (17.1)* 9.3 (14.3)*
PFIQ-7 74.5 (70.5) 17.6 (36.5)* 9.3 (23.1)*
POPIQ 24.8 (27.7) 3.8 (12.0)* 1.8 (9.3)*
CRAIQ 18.4 (24.6) 4.7 (13.5)* 3.1 (9.8)*
UIQ 31.3 (27.6) 9.1 (16.6)* 5.6 (13.8)*
PISQ-12 (n=58) 33.4 (7.8) 38.9 (4.9)* 39.0 (4.4)*
PGI-C
Much better - 96 (85.0%) 106 (86.2%)
A little better - 11 (9.7%) 12 (9.8%)
About the same - 3 (2.7%) 3 (2.4%)
A little worse - 3 (2.7%) 1 (0.8%)
Much worse - - 1 (0.8%)
eQ-5d
Utility 0.837 (0.161) 0.926 (0.130)* 0.940 (0.114)*
Health state 78.8 (15.7) 86.1 (10.9)* 85.2 (12.5)*
Data presented as mean (± SD) and n (%). PFDI-20 and PFIQ-7 scores range from 0 (best score) to 
300 (worst score); POPDI, CRADI, UID, POPIQ, CRAIQ, UIQ scores range from 0 (best score) to 100 
(worst score). PISQ-12 scores range from 0 (worst score) to 48 (best score). EQ-5D Utility ranges from 
0 (worst score) to 1 (best score) and Health State ranges from 0 (worst score) to 100 (best score). 
* for p<0.001.
There were large and statistically significant improvements in the EQ-5D Utility 
and Health State scores from baseline to 3 months and 1 year (table 4). 
Sixty-one patients were sexually active at baseline, 58 of whom completed a 
PISQ-12 questionnaire. At 3 months and 1 year, 48 and 57 patients completed the 
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questionnaire, respectively. There was a statistically significant improvement in sexual 
function score in these patients at 3 months, which was sustained at one year, with 
a mean change in PISQ-12 of 5.2 (SD 6.9; p<0.001) (table 4).
At baseline, dyspareunia was reported in 18/61 (29.5%) sexually active patients. 
At 1 year, 13 of 17 sexually active patients (76,4%) reported resolution of dyspareunia; 
4 had ongoing dyspareunia and 1 patient had not returned to sexual activity for 
unrelated reasons. There was one report of de novo dyspareunia out of 49 (2.0%) 
patients who reported to be sexually active at 1 year. This patient underwent a total, 
cut mesh repair and TVT-O sling. There was no mesh exposure. Pain occurred during 
penetration and was attributed to vaginal dryness. Nine (13.6%) of 66 patients who 
were not sexually active at baseline, resumed sexual intercourse without reporting de 
novo dyspareunia following surgery (fig 2). 
Seven patients (5.5%) reported pelvic pain at baseline during routine activities. 
By 1 year, there was resolution of this pre-existing pelvic pain in all 7. At 1 year, in 5 
(3.9%) patients pelvic pain was reported: 2 during routine daily life, and in 3 patients, 
pain was only elicited during pelvic examination. These, however, were not present 
at time of the 3-month assessment. In 2 (1.6%) of the patients reporting pain during 
pelvic examination, the investigator considered that there was evidence of vaginal 
wall stiffness. One had an anterior repair and the other total repair; a concomitant 
retropubic TVT sling was performed in both cases.
A summary of key adverse events is summarized in table 5. Bladder perforation 
occurred in 3 (2.3%) patients: 1 during dissection, which resulted in the mesh repair 
being abandoned; another 1 during dissection and 1 as a result of the trocar passage. 
After repair of the perforation, mesh was placed in the latter two patients. Recovery 
in these patients was uneventful. Hemoglobin levels dropped 2.2 +/- 1.3 g/dL for 
total, 1.7 +/- 1.1 g/dL for anterior and 1.0 +/- 0.7 g/dL for posterior repair. One 
patient who underwent a total repair, required transfusion of 4 units of packed 
red blood cells. She recovered uneventfully. Thirteen patients had mesh exposure 
reported over a period of 1 year (10.2%). Eleven of these 13 patients (85%) with 
mesh exposure underwent a total mesh repair (4 cut, 7 uncut total meshes), the 
other two were anterior mesh repairs. Seven of these 13 patients had concomitant 
surgeries: 3 vaginal hysterectomies, 2 mid-urethral slings and 1 perineal repair. The 
majority of exposures were located at the apex of the vagina (n=6) or on the anterior 
vaginal wall (n=6); there was one exposure in the posterior wall. Seven patients 
(54%) underwent partial mesh excision to treat mesh exposure. The remaining six 
(46%) have been treated successfully with the use of topical estrogen. 
cOmment
This prospective observational multicentre cohort study provides evidence that this 
partially absorbable mesh used in trans-vaginal mesh surgery results in improved 
anatomic and functional outcomes at one year in patients with stage III and IV POP. 
The major drawback of this study is the lack of a control group, for example 
with conventional POP surgery. Cohort studies are exposed to selection bias and 
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confounding. In this study, no attempt was undertaken to avoid the surgeons’ 
potential bias during follow-up visits or to capture the patients’ characteristics that 
were screened before entry into the trial. Ideally an investigator blinded to the 
procedure should have performed these. Future preferably randomized, controlled 
studies are necessary to generate evidence on a risk/benefit analysis of different 
mesh versus conventional repairs. The strengths of this study on the other hand 
figure 2.   Disposition of sexual function.
table 5. Complications
event n=128
Bladder perforation  3 (2.3%)
Bowel perforation  0
Requirement for transfusions 1 (0.8%)
Pulmonary embolus 2 (1.6%)
Wound infection 2 (1.6%)
Infected hematoma 1 (0.8%)
Temporary urinary retention 1 (0.8%)
Voiding dysfunction 7 (5.5%)
Mesh exposure: 13 (10.2%)
 Excised 7 (5.5%)
 Conservative treatment 6 (4.7%)
SUI (worsening / de novo): 17 (13.3%)
 Treated with slings (11); bulking agents (2) 13 (10.2%)
Urge (de novo): 1 (0.8%)
 Requiring anti-cholinergic treatment 1 (0.8%)
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are its prospective and international multicentre nature, with the use of validated 
instruments of measurement, such as POP-Q, PGI-C, PFDI-20, PFIQ-7 and EQ-5D as 
well as its adequate sample size.
According to strict anatomic outcome criteria the overall anatomic success (POP ≤ 
stage I) in the treated compartments at 1 year was 77.4% (69.0 - 84.4). The population 
and results are consistent with similar prospective, multicentre studies reporting 
1 year anatomic outcomes, ranging from 79-91%, following POP repair with the 
original polypropylene mesh in the Prolift system.14, 16A decrease in the success rate 
was observed between the 3 and 12 months follow-up. Other authors have reported 
similar changes over time. Van Raalte et al reported 94.2% anatomic success at 
6  months and 86.6% at 1 year or more after treatment of POP with the Prolift 
system.20 A Scandinavian prospective multicentre study on Prolift reported 87-91% 
success at 2 months, but the same investigators reported 80.6% (74.3-85.7) after 
1 year.14, 29 Furthermore, it might be argued that the absorbable polyglecaprone-25 
component, which is added to facilitate handling during surgery, might initially 
contribute to the graft’s strength which could be reflected in the anatomic success 
rate at 3 months. However, this is unlikely since the material retains only 20-30% 
of its burst strength after two weeks in vivo, whilst absorption is only complete 
between 91 and 119 days.30 In a hernia porcine model light-weight polypropylene 
mesh with an absorbable monofilament was shown to maintain mean burst strength 
comparable to medium weight polypropylene, while becoming less stiff than heavier 
weight meshes after 5 months of tissue incorporation.31 Another explanation of the 
difference in anatomic outcome at 3 months and 1 year might be the increased 
longitudinal elasticity of this lightweight mesh compared to the original Prolift mesh.
Improvements in the leading edge definition of success (leading edge < 0 cm) 
(89.5%) were consistent with the patient’s report of “much better” on the PGI-C global 
scale (86.2%). The discrepancy between the PGI-C result and the primary definition of 
success highlights the ongoing debate on the appropriateness of POP stage ≤ I as the 
ultimate anatomic goal to be achieved in POP repairs. Swift et al demonstrated that 
POP symptoms clearly correlate with the leading edge of prolapse beyond the hymenal 
remnants.32 We therefore agree with Barber et al, who suggested that in future studies 
on POP surgery, next to anatomic criteria and the absence of reinterventions, the 
absence of bulge symptoms should be included to determine success.33
It is important to note that the differences from baseline in all three subscales in 
symptoms and QoL, using PFDI-20 and PFIQ-7 questionnaires were significant and 
sustained over time. 
The results from the EQ-5D questionnaire demonstrated that there were 
significant improvements in utility and health status at 3 months, which continued to 
1 year. These values not only indicate good health status and utility improvement of 
the POP intervention to the patient, but enables comparison to other disease states 
and future cost-effectiveness analysis of mesh kits. It is worthwhile noting that the 
improvements seen on the EQ-5D were congruent with the improvements seen on 
disease-specific questionnaires. 
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In this study, the rate of de novo dyspareunia was 2.0%, which was encouragingly 
low compared to previous reports following traditional prolapse repair (14.5-36.1%) 
and a recent retrospective study reported quoting a similar rate (16.7%) following 
repair with the original polypropylene mesh.1, 11, 12The data of our study suggest a true 
impact of the new mesh’s characteristics on the development of dyspareunia. This might 
be explained by the increased unidirectional elasticity and reduced fibrotic reaction, 
allowing adequate vaginal distension, which has been shown to be essential to allow 
normal sexual intercourse.34 Accordingly, a significant improvement of 5.2 points in 
the mean scores of the PISQ-12 was found in this study. Contrariwise, a previous study 
on sexual function one year after Proliftrepair reported adecline in mean PISQ-12 
score of 3-4 points.35 The improved sexual function observed in this study therefore 
is encouraging and warrants further evaluation in well designed comparative studies, 
with sexual function and de novo dyspareunia as primary outcomes. 
The rate of vaginal wall stiffness at one year was 1.6%. This study prospectively 
evaluated vaginal wall stiffness, which currently still is a subjective measurement based 
on clinician judgment. Identifying a reliable and reproducible objective measure of 
vaginal wall stiffness will be of importance in future studies to evaluate the effects of 
mesh, as well as conventional POP repairs on the physical characteristics of the vaginal 
wall and any associated adverse effects. The low rate of de novo pelvic pain and vaginal 
wall stiffness was reassuring. This observation could be related to a reduced surface 
area of this mesh, which would have lead to a reduction in fibrotic reaction around the 
individual mesh fibres, resulting in the formation of a scar net rather than a scar plate.31
This observational series with this partially-absorbable light-weight mesh did not 
demonstrate a difference in mesh exposure rate compared to procedures using the 
original mesh, which could have been expected based on preclinical data of animal 
studies.17, 31 The safety profile was comparable to the original mesh repairs.13, 14, 16
The results of this study are suggestive that this lightweight mesh provides 
anatomic support consistent with the original polypropylene mesh, and demonstrate 
high functional improvements. No apparent safety concerns appeared from the 
change in mesh. The low rate of de novo dyspareunia together with the absence of 
clinically relevant mesh shrinkage is particularly encouraging. Longer-term evaluation 
of this lightweight mesh continues. 
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abstract
Introduction
Surgical treatment of pelvic organ prolapse (POP) affects sexual function. Generally 
this results in improved sexual function, but deterioration is reported also.
Aim
The purpose of this study was to evaluate and compare sexual function in patients 
with recurrent POP undergoing either a vaginal surgical repair with native tissue or a 
trocar-guided mesh insertion.
Main outcome Measures
Primary outcome was sexual function at 12 months following surgery, measured by 
the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire 
(PISQ-12). Secondary outcomes were the identification of factors independently 
associated with change in PISQ-12 scores and changes in individual PISQ-12 question 
scores.
Methods
Sexually active patients randomly assigned to either native tissue repair or trocar-
guided mesh insertion, which had completed the PISQ-12 both at baseline and 
at 12 months, were included. Total, subscale and individual question analysis was 
performed. Logistic regression was used to identify factors that were independently 
associated with improvement/deterioration in total PISQ-12 scores.
results
Sixty patients were included; 32 in the mesh arm and 28 in the native tissue arm. At 
12 months PISQ-12 scores were not different in both treatment arms (34.3, S.D 6.7 vs. 
34.7, S.D 5.7), but improvement was detected in the native tissue arm, whereas PISQ-12 
total score remained unchanged in the mesh arm. Deteriorations were observed in 
the behavioral/emotive subscale and partner related items in the mesh arm. In the 
native tissue arm significant improvements in the physical and partner related subscales 
were observed. The presence of mesh exposure was independently associated with 
deterioration in total PISQ-12 score.
Conclusion
At 12 months PISQ-12 scores were not different in either treatment arm, but were 
affected differently by trocar-guided mesh insertion or by native tissue repair. Mesh 
exposure was independently associated with deterioration in sexual function.
SEXUAL FUNCTION
intrOductiOn
Pelvic Organ Prolapse (POP) is a common problem and may occur in up to 50% 
of parous women.1 A large Dutch cross-sectional study demonstrated a prevalence 
of symptomatic POP as high as 11.4%.2 The frequently cited study by Olsen et al, in 
which a lifetime risk of undergoing a prolapse or urinary incontinence operation in the 
U.S of 11.1% was reported, has been replicated, whereby the initial estimate could 
be confirmed with a lifetime risk of 11.8%.3, 4 Recently, Australian authors calculated 
that the risk of surgery for POP in the general female population of Western Australia 
was as high as 19%.5 The high likelihood of undergoing surgery for POP combined 
with known anatomic failure rates for native tissue repairs that range between 
30-70% for the anterior vaginal wall and around 20% for the posterior vaginal wall, 
have led to increased use of prosthetic mesh in vaginal POP surgery with the aim to 
reduce failure rates and increase durability.6-9
The use of these materials has introduced new kinds of morbidity, such as mesh 
exposure and contraction of tissue around the mesh.10 These may result in pelvic pain 
and dyspareunia.11 Sexual function may be adversely affected by these problems, 
but the presence of POP has adverse effects on sexual function as well, although 
data on this association are somewhat conflicting.12-15 Rogers et al have developed a 
condition specific, validated and self-administered questionnaire to evaluate sexual 
function in women with POP and/or urinary incontinence, of which the short form 
is the PISQ-12.16 This instrument has been used in studies evaluating sexual function 
after surgery for pelvic floor dysfunction, with increased postoperative PISQ scores in 
around 70%.14 Recently, deterioration in sexual function has been reported following 
the use of synthetic mesh kits for the repair of POP.17, 18
Aims
The purpose of this study was to evaluate and compare sexual function measured by 
the PISQ-12 in women undergoing surgery for recurrent POP one year after either a 
vaginal native tissue repair or surgery with a commercially available mesh kit.
methOds
This study is a secondary analysis of data from patients of a multicenter randomized 
controlled trial that primarily aimed to compare anatomic outcomes of the treated 
vaginal compartments in patients with recurrent POP, who were randomly assigned 
to either a conventional vaginal native tissue repair or to a tension free vaginal mesh 
insertion with a commercially available mesh kit (Prolift, Ethicon, Somerville, NJ, 
USA).19 Native tissue repair surgery was performed according guidelines described in 
that trial. The mesh procedure was performed as described by Fatton et al.20 
Patients were included in the present study if they were sexually active and had 
completed the PISQ-12, both at baseline and at 12 months following surgery.16 
Patients were considered to be ‘sexually active’ if they answered ‘yes’ to the question; 
‘Are you having sexual contact with your partner?’ PISQ-12 individual question scores 
range from 0 (never) to 4 (always) according a five point Likert scale. Total PISQ-12 
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scores range from 0, which represents poorest sexual function, to 48, best sexual 
function. A questionnaire was considered valid if there were no more than 2 missing 
items.16 Patients, who completed only one questionnaire, either at baseline or at 
12 months, were excluded, but included in a missing data analysis. 
Baseline evaluation included medical history, physical and gynecological 
examination and a Pelvic Organ Prolapse Quantification (POP-Q), as well as the 
completion of the self-administered standard Dutch urogynecological questionnaire, 
that contains the validated Dutch versions of the Urogenital Distress Inventory (UDI), 
the Defecatory Distress Inventory (DDI) and the Incontinence Impact Questionnaire 
(IIQ) and PISQ-12.16, 21-23 The validated American English version of the PISQ-12 
was translated into Dutch, underwent cultural adaption in accordance with the 
International Society of Pharmacoeconomics and Outcomes (ISPOR) and was back 
translated.24 At 12 months POP-Q examinations were repeated and patients were 
requested to complete these questionnaires once more. 
Main outcome measures
Primary outcome of this study was sexual function at 12 months following POP 
surgery and changes (improvement/deterioration) in sexual function scores measured 
by the PISQ-12. Secondary outcomes were the identification of factors that were 
independently associated with these changes and changes in individual PISQ-12 
question scores. 
Sample size calculation was based on an estimated difference of 10 points in 
PISQ-12 scores between the two treatment groups at 12 months, assuming an 
average decline of 5 points for the mesh group and an estimated equal rise for the 
native tissue repair group. To detect this difference with a power of 80% 30 patients 
were needed in each group.17, 18, 25 To objectify the clinical relevance of statistically 
significant changes in PISQ-12 scores we calculated effect sizes, using Cohen’s d. 
Effect sizes (E.S) are defined as small if Cohen’s d=0.2, medium if d=0.5 and large if 
d≥0.8.26 
To compare mean continuous data within groups paired samples t-tests were 
used and for comparison between groups independent samples t-tests. For numbers 
smaller than 30 and comparison within groups Wilcoxon signed rank test was used 
and for comparison between groups Mann-Whitney U test. To compare categorical 
variables Pearson’s Chi-square was used, and for numbers smaller than 5 Fisher exact 
test. Improvement in PISQ-12 score was defined as a postoperative score at least 
one point higher than the pre-operative score, deterioration as a postoperative score 
at least one point lower than the pre-operative score. Logistic regression was used 
to identify factors that were associated with either improvement or deterioration in 
total PISQ-12 scores. Covariariables with a p<0.3 were entered in a multivariable 
logistic analysis model using Method Forward Wald. P-values <0.05 were considered 
statistically significant. Statistical analysis was performed using Statistical Package for 
the Social Sciences, version 18.0 (SPSS Inc.,Chicago,III.,USA).
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results
One hundred and ninety-four patients with recurrent POP were enrolled and randomly 
assigned to either a Prolift or a conventional vaginal POP repair. Ninety-three patients 
underwent Proliftrepair and 97 a native tissue repair between June 2006 and July 
2008. Fifty-four of 78 (69%) and 50 of 76 (66%) patients in the mesh arm and native 
tissue arm respectively were considered ‘sexually active’. Sixty patients completed a 
PISQ-12 both at baseline and 12 months. Of those 32 underwent Proliftrepair and 
28 a native tissue repair. Thirty-one and 27 patients, in the mesh and native tissue 
arm respectively, completed only one PISQ-12, either at baseline or at 12 months. 
They were considered ‘incomplete responders’. 
Table 1 shows some baseline, clinical, surgical and anatomic outcome characteristics 
of the 60 study patients. Patients did not differ in age, perceived general health 
(mean VAS-score), BMI, parity, amount of co morbidity, or prior (POP) surgery. In both 
treatment arms one hematoma was recorded and treated conservatively. In the mesh 
arm two patients had a bladder perforation that occurred during dissection. In both 
cases the perforation was repaired and mesh inserted. In the mesh arm 11 of 32 
patients (34%) were diagnosed with a mesh exposure detected between six weeks 
and 12 months postoperatively. Overall POP stages for both groups at baseline and 
12 months are shown. Anatomic improvements, in terms of stage of leading edge 
of prolapse were significant, but not different between groups. Anatomic successes, 
defined as overall POP stage ≤I were equal: 15 of 32 (47%) patients in the mesh arm 
and 13 of 28 (46%) in the native tissue repair arm. Highly significant improvements 
in UDI domain score of prolapse were observed in both arms. No differences between 
groups were observed in UDI, DDI and IIQ domain scores at baseline (not shown), 
except for the UDI domain of pain, that scored significantly higher (worse) in the 
native tissue arm; 29.9 (27.3) vs. 16.7 (22.4) respectively (p 0.048).
In table 2 mean total and subscale PISQ-12 scores are shown at baseline and 
12 months. No significant differences in total PISQ-12 scores were observed at 
12  months between groups, but there were differences in total PISQ-12 score at 
baseline. A significant improvement in PISQ-12 score was observed in the native 
tissue repair group that could be particularly attributed to significant improvements 
in the physical (E.S 0.68, p 0.002) and partner-related (E.S 0.62, p 0.018) subscales. 
In contrast with this improvement, a significant and clinically relevant deterioration in 
the behavioral/emotive subscale (E.S 0.34, p 0.012) was observed in the mesh arm. 
Table 3 shows the results of individual PISQ-12 question scores. Significant declines 
in the frequency of orgasm (E.S 0.42, p 0.018) and being sexually excited were 
observed in patients of the mesh group (E.S 0.47, p 0.006). An increase in problems 
related to erectile function of the male partners was observed in this group as well 
(E.S 0.38, p 0.032). Avoidance of sexual intercourse because of bulge symptoms 
decreased in both arms, but with a larger effect size in the conventional arm (E.S 0.91, 
p 0.002 vs. 0.43, p 0.028). The intensity of orgasms increased significantly in the 
native tissue repair group (E.S 0.46, p 0.017). Neither in the mesh, nor in the native 
tissue repair arm significant changes post- to preoperatively were recorded in pain 
during sexual intercourse.
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Table 4 shows results of univariable and multivariariable logistic regression analysis 
for factors expected to be associated with change in total PISQ-12 scores.27, 28 A native 
tissue repair as compared to a mesh repair appeared to be independently associated 
with improvement in PISQ-12 scores with an odds ratio (OR) of 4.6 (95%CI 1.4-15.2, 
p 0.012). On the other hand the presence of a mesh exposure was independently 
associated with deterioration of PISQ-12 scores (OR 7.8; 95%CI 1.5-41.0, p 0.015). 
Table 5 shows the results of the missing data analysis. No significant differences 
could be detected between full and incomplete responders, except for two items. At 
baseline a statistically significant higher score in the IIQ domain embarrassment was 
observed in the incomplete responders group. The presence of mesh exposures on 
the other hand was overrepresented in the full responders group (11 of 32, 34% vs. 2 
of 31, 6%; p 0.005). 
discussiOn 
In this study we observed no significant differences in total PISQ-12 scores at 
12 months between patients who had been treated with trocar-guided mesh insertion 
or by vaginal native tissue repair of POP. However, in contrast with the mesh arm, we 
observed improvements of sexual function in patients treated by native tissue repair, 
which could be entirely attributed to improvements in the physical and partner related 
domains, while the behavioral/emotive subscale remained unchanged. Likewise, 
Rogers et al previously had reported higher PISQ scores in 70% of women 3  to 
6 months following conventional surgery for POP and/or urinary incontinence (UI), 
as a result of improvements of the physical and partner-related domains, while the 
behavior/emotive domain showed no change.28 Other authors reported comparable 
results after treatment for stress UI and abdominal sacrocolpopexy.29, 30 
In contrast with these reports we noticed that subtle improvements in the physical 
subscale of patients in the mesh arm were nullified by a significant deterioration 
of the behavioral/emotive subscale. More recent studies on mesh and its effect on 
sexual function do show a differentiated picture. Sentilhes et al reported no change 
in PISQ-12 scores at one year following transvaginal POP repairs with a variety of 
non-absorbable meshes in a group of 37 sexually active women.31 However, Altman 
et al reported significant deteriorations of PISQ-12 scores, with a mean of almost 
4 points, at one year following trocar-guided transvaginal mesh repairs, which 
were entirely attributed to worsening in the behavioral/emotive and partner-related 
items.17 Su et al reported an even greater average decline of 10 points in PISQ-12 
scores, caused by deteriorations in all three subscales, of 33 patients, 6 months after 
a Prolift procedure.18 
Searching for the rationale of the lack of improvement in total PISQ-12 scores in the 
mesh arm and more in particular the deterioration of the behavior/emotive subscale 
we propose the following possible explanation. This type of non-absorbable mesh is 
known for its inherent fibrosis and potentially considerable contraction of tissue around 
the mesh.10, 32 Insertion of this type of mesh possibly impairs vaginal compliance and 
thereby the physiological response to sexual stimuli. Sexual arousal normally results in 
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congestion and vaginal wall thickening, tenting and lubrication.33, 34 A recent study on 
a partially absorbable and more flexible mesh, in an otherwise identical trocar-guided 
mesh kit, demonstrated significant increases in overall PISQ-12 scores.35 To our opinion, 
these findings do support the hypothesis that a mesh that causes less fibrosis and tissue 
contraction facilitates a more physiological sexual response of the vaginal wall. 
Another explanation for the unequal changes in PISQ-12 scores between the 
two treatment arms could be the difference in altered body image after the two 
surgical procedures. Lowenstein et al recently reported that PISQ-12 scores were not 
related to stage or compartment of POP, but to a woman’s self-perceived body image 
and degree of bother from POP.36 Lowder et al reported improved body image and 
sexual function following a variety vaginal and abdominal POP repairs.37 The authors 
however did not report on a sub analysis of vaginal mesh and non-mesh repairs. 
table 5. Comparison of full and incomplete responders.
Baseline data
Full Responders 
N: 60
Incomplete Responders 
N: 58 P
Age (years) 60.7 (8.4) 59.3 (9.8) 0.411
VAS general Health 74.6 (14.8) 76.5 (16.2) 0.553
BMI 26.6 (4.2) 27.6 (6.7) 0.405
Overall POP      Stage II 31 (52%) 32 (55%) 0.702*
                        Stage III 27 (45%) 22 (38%) 0.533*
                        Stage IV 2 (3%) 4 (7%) 0.378**
Prolift repair 32 (53%) 31 (53%) 0.990
Mesh exposure 11 (34.4%) 2 (6.4%) 0.005**
Native tissue repair 28 (47%) 27 (47%) 0.990
UDI OAB 29.6 (28.6) 32.1 (25.8) 0.512
UDI Incontinence 19.0 (21.7) 21.9 (21.5) 0.492
UDI Obstructive micturition 25.1 (28.4) 22.5 (27.7) 0.628
UDI Pain 22.6 (25.1) 28.5 (24.1) 0.235
UDI Genital prolapse 47.4 (32.8) 55.9 (32.0) 0.208
DDI Constipation 13.7 (17.4) 10.1 (18.4) 0.324
DDI Obstructed defecation 16.2 (19.5) 11.7 (13.3) 0.169
DDI Pain 10.4 (19.3) 7.6 (16.1) 0.413
DDI Incontinence 7.3 (13.9) 10.5 (22.0) 0.391
IIQ Physical functioning 20.5 (24.0) 27.9 (29.7) 0.170
IIQ Mobility 23.2 (24.0) 29.0 (26.2) 0.236
IIQ Social functioning 14.9 (18.7) 20.8 (18.5) 0.108
IIQ Embarrassment 9.5 (14.5) 18.1 (22.7) 0.030
IIQ Emotional Health 18.5 (20.5) 22.9 (24.0) 0.319
PISQ-12 score baseline 33.4 (6.6) 30.6 (6.4) (n: 15) 0.147
PISQ-12 score 12 months 34.5 (6.2) 33.1 (6.6) (n: 43) 0.478
Data presented as mean (SD), VAS score: 0-100.p-value: independent samples t test, * Pearson’s Chi 
square test, ** Fisher exact test. Bold p-value is statistically significant.
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Last but not least, the role of the male sexual partner is unclear and rather 
underexposed in the literature on sexual function and POP surgery. Improved female 
sexual function, measured with the Female Sexual Function Index, has been reported 
in patients following a vaginal native tissue POP repair with simultaneously increased 
interest, sexual drive and overall satisfaction by their male partners.38 It is imaginable 
that the awareness of a mesh-reinforced vaginal repair by the male partner makes 
him to be more reluctant and thoughtful in sexual engagement with his wife, which 
could possibly affect his sexual interest, which in return could be perceived by her as 
an increase in problems with erectile function of her partner. Furthermore we found 
the presence of a mesh exposure to be independently associated with deterioration 
in PISQ-12 score. The awareness of such a mesh exposure could at least be another 
reason for diminished sexual interest, arousal and consequently erectile function 
of the male partner. Seven of the 11 mesh exposure patients and their partners 
were aware of these before completing the 12-months questionnaires. This could 
be a cause of sexual distress. The psychological awareness of such a mesh exposure 
could therefore have had impact on the way these patients answered the PISQ-12 
questions.15 
Remarkably, increase of pain during sexual intercourse following trocar-guided 
mesh surgery, as has been reported by others, was neither observed in this nor in 
previous work by us and is comparable with results of Altman et al.17, 39, 40 
Strengths of this study are its randomized controlled design and the use of 
validated instruments of measurement. Computation of effect sizes contributed to 
the unraveling of the clinical relevance of statistical significant findings.26 
On the other hand this study is subject to several limitations as well. To start, 
patients in the native tissue arm demonstrated lower PISQ-12 scores at baseline 
compared with patients in the mesh arm. Recently normative values for the PISQ-12 
have been established in a general female, sexually active population. A normative 
score of 40 was suggested for sexually active women without bothersome POP or 
UI. Women, bothered by POP or UI, showed a mean score of 36 (±5.6), women with 
depressive symptoms and POP had lower mean scores (33.1±5.7) and women who 
scored high on a pelvic Pain and Urgency/Frequency scale scored significantly lower 
than women without these symptoms (30.9±6.5).25 The latter seems plausible as 
explanation for the lower PISQ-12 scores at baseline for patients in the native tissue 
arm, since they scored significantly higher on the UDI domain of pain at baseline than 
patients in the mesh arm (table 2). Despite clear entry criteria of the original study 
the randomization procedure, which was generated by a central computer, could 
not prevent that this difference in baseline characteristic occurred.19 Secondly, the 
group of incomplete responders was rather large. A missing data analysis however, 
revealed no significant differences between complete and incomplete responders, 
except for inequality in the percentage of mesh exposure and the domain score of 
embarrassment of the IIQ. This could explain some of the reluctance of these patients 
to complete an intimate sexual function questionnaire. 
Explanations for the lack of difference in total PISQ-12 scores between groups at 
12 months could be the equality of overall anatomic outcome for either treatment 
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arm, the relative high number of patients with a mesh exposure in the mesh arm or 
the lack of power of the study to detect a difference. We would be able to detect a 
difference of 10 points (assuming an average decline of 5 for the mesh arm (33→28) 
and a similar rise of 5 (33→38) for the conventional arm) with a power of 80%, given 
the a priori sample size of 30 for each arm (α 0.05, β 0.20).17, 18, 25 For differences 
smaller than 10 points, the chance of a type II error increases. Furthermore, the 
PISQ-12 might not be sensitive enough to capture all delicate changes in sexual 
function following POP repair with or without mesh.41
In conclusion we found no difference in PISQ-12 scores at 12 months between 
the two types of vaginal surgery. Overall sexual function did not improve following 
trocar-guided mesh insertion, in contrast with native tissue repair and was affected 
differently. Mesh exposure appeared to be independently associated with deterioration 
in PISQ-12 scores. Future research on POP and sexual function should also incorporate 
body image and male aspects of sexual function.
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abstract
objectives
To compare one-year conventional and composite outcomes of trocar-guided vaginal 
mesh surgery and identification of predictors of failure. 
study design
Prospective observational Cohort study. Failure outcome definitions were: I; prolapse 
stage > II in mesh treated compartments, II; overall prolapse stage > II, III; composite 
outcome of overall prolapse > hymen and presence of bulge symptoms or re-surgery. 
Logistic regression to identify predictors of failure.
results
One-year follow-up of 433 patients. Treated compartment failure (I): 15% (95% CI 
12-19). Overall prolapse failure(II): 41% (95% CI 36-45). Composite failure (III): 9% 
(95% CI 7-13). Predictor of failure in all outcomes: combined anterior/posterior mesh 
with the uterus in situ. 
Conclusion 
Outcome of prolapse surgery depends on outcome definition. The mesh treated 
compartment failure outcome (I) and the composite failure outcome (III) appeared 
not to be statistically different. Consistent factor for failure in all outcomes was the 
combined anterior/posterior mesh insertion with the uterus in situ.
OUTCOMES & PREDICTORS OF FAILURE
intrOductiOn
Pelvic Organ Prolapse (POP) may occur in up to 50% of parous women.1 The lifetime 
risk of undergoing surgery for POP in the general female population to the age 
of 85 has recently been reported to be as high as 19-20%.2, 3 This high likelihood 
of undergoing surgery for POP combined with the knowledge of anatomic failure 
rates for native tissue repairs that range between 30-70% for the anterior vaginal 
wall and around 20% for the posterior vaginal wall, have led to the increased 
use of prosthetic mesh in vaginal prolapse surgery with the main aim to reduce 
anatomic failure rates and increase the durability of repairs.4-9 Most studies have 
used strict anatomic outcome criteria as proposed by the National Institutes of Health 
(NIH) Workshop on Standardization of Terminology for Researchers in Pelvic Floor 
Disorders in 2001, and only used patient reported outcomes as a secondary outcome 
measure.10, 11 But recently Barber et al have demonstrated that the postoperative 
absence of vaginal bulge symptoms had a significant relationship with a patient’s 
assessment of  overall improvement, while anatomic success alone did not.12 The 
authors therefore suggested that any future definition of success of POP surgery 
should include the absence of bulge symptoms in addition to anatomic criteria and 
the absence of re-treatment. The authors agreed with Swift et al that the hymen 
should thereby be regarded as the threshold for anatomic success.12, 13
The primary objective of this study was to compare one-year outcomes of a large 
cohort of patients that underwent trocar-guided tension-free vaginal mesh surgery 
(ProliftTM, Ethicon, Somerville, NJ, USA) according to the conventional NIH Workshop 
criteria with the newly suggested composite outcome of Barber et al.12 The second 
objective was to identify possible predictors of failure for these outcomes. 
materials and methOds
This prospective observational cohort study is part of an ongoing outcome quality 
registration project of Radboud University Medical Centre the Netherlands, which 
has been approved by CMO Arnhem-Nijmegen, April 2006. The present analysis 
includes 12-month follow-up data of consecutively performed trocar-guided tension-
-free vaginal mesh procedures (Prolift, Ethicon) between September 2005 and April 
2010. Details of 150 patients in this cohort have previously been reported in a study 
focusing on de novo prolapse in untreated vaginal compartments, and 93 were 
part of a randomized controlled trial, comparing mesh with native tissue repair in 
recurrent prolapse.8, 14
Inclusion criteria were increased risk of recurrence, which was considered recurrent 
pelvic organ prolapse stage II or higher or primary pelvic organ prolapse stage III or 
higher.8, 15, 16 Exclusion criteria were (contemplating) pregnancy or a compromised 
immune system.
Surgery was performed by17 gynecologists in 13 collaborating centers. The range 
of procedures varied from 1 to 209 (mean: 25, median: 3). Four performed more 
than 25 procedures. All gynecologists were trained for the tension-free vaginal mesh 
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procedure as described by Fatton et al.17 Depending on the prolapsed compartment, 
mesh insertion could be anterior, posterior, anterior and posterior (in case of uterus 
or cervix in situ), or total (in case of a prolapsed vaginal vault). 
Concomitant native tissue repairs were allowed for other less prolapsed 
compartments or compartments that were not at increased risk of recurrence. To 
reduce the risk of mesh exposure, simultaneous hysterectomy or T-incisions were 
avoided.18 For most of the participating centers it was policy not to simultaneously 
insert a mid urethral sling because of anticipated increased risk on postoperative 
urinary retention.19 Patients were counseled on this strategy and the possibility 
of a second procedure. In case the presence of stress urinary incontinence post-
surgery necessitated the insertion of a mid urethral sling, this was not considered 
a re-intervention for POP and thus not registered as failure; on the other hand the 
symptomatic recurrence of POP that necessitated re-surgery was a re-intervention for 
POP and thus counted as a failure.
All procedures were performed under peri-operative antibiotic prophylaxis. Patients 
received an indwelling catheter for 1to 2 days and a vaginal gauze pack for 24 hours.
Postoperative urinary retention was defined as repeated post-void residual volume 
> 100 mls measured with a bladder scanner. De novo stress urinary incontinence was 
considered significant if a patient responded yes; ‘moderately to quite a bit’ to the 
question: ‘do you experience urinary leakage during physical activity, coughing or 
sneezing?’ 
The mesh used in the original trocar-guided Mesh procedure is monofilament 
polypropylene mesh, weighing 45 gr/m2. In 2009 some centers started using a partially 
absorbable mesh, consisting of a fifty-fifty blend of monofilament non-absorbable 
polypropylene and absorbable polyglecaprone 25 (Prolift+M, Ethicon). The technique 
is identical, but the mesh weighs 57 gr/m2 before absorption and after full absorption 
after 90-120 days only 31 gr/m2.20 
Baseline evaluation included medical history and assessment of POP by using the 
Pelvic organ Prolapse Quantification (POP-Q) System.11 Data on symptoms and bother 
were obtained by the standard Dutch urogynecological questionnaire, which among 
others contains the Dutch validated version of the Urogenital Distress Inventory (UDI).21 
Follow-up visits were scheduled at 6 weeks, 6 and 12 months. At 12 months a 
POP-Q examination was performed and patients were again requested to complete the 
standard urogynecological questionnaire.
Failure outcomes were defined as follows: 
•	 NIH failure mesh treated compartment; POP stage > II of mesh treated vaginal 
compartment(s) or re-surgery for POP in mesh treated compartments within 
12 months.
•	 NIH failure overall POP; leading edge of prolapse in any compartment stage > II 
or re-surgery for POP in any compartment within 12 months.
•	 Composite outcome failure; leading edge of any compartment > hymen and 
presence of bulge symptoms or re-surgery for POP within 12 months.12
‘Presence of bulge symptoms’ was defined clinically significant if a patient 
responded yes; ‘moderately to quite a bit’ to either of two questions: ‘do you see or 
do you feel a vaginal bulge?’21 
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To determine the minimum sample size we anticipated on a 90% success rate 
for the mesh treated compartments.8, 22, 23 We considered treatment successful if the 
one-sided 95% confidence interval (CI) did not fall below 85%. This resulted in a 
minimum number of 282 patients that were necessary for inclusion in this study. 
Results are summarized as numbers with corresponding percentages or as medians 
with range. Primary outcomes were failure percentages with 95% confidence 
intervals per pre-defined outcome definition. Univariable logistic regression was used 
to identify possible risk factors of failure in each of the outcomes. Considered risk 
factors were patient’s age, menopause, previous POP repair(s), parity, pre-operative 
POP stage, Body Mass Index, location of mesh insertion, the use of the new partially 
absorbable mesh, mesh combined with native tissue repairs, mesh combined with 
sacrospinous fixation, the presence of the uterus, operating time, blood loss, 
complications and mesh exposure. 
Crude Odds ratios (OR) for the possible risk factors of failure for each outcome 
were calculated with corresponding 90% confidence intervals (CI). To optimize 
the validity of the logistic model, restriction of the number of test variables was 
necessary.24 To ensure that the number of events per variable (EPV) did not drop 
below 10, only the allowed number of the most significant variables was selected 
for entry in the multivariable model. Multivariable logistic regression with forward 
selection was used to identify those variables that were independently related to 
failure in each of the outcomes. Variables reaching statistical significance at the 
P<0.10 level in the univariable analysis were considered valid for entry in the forward 
selection model. The adjusted OR with 95% CI are presented. A P value of <0.05 was 
considered statistically significant. Statistical analysis was performed using SPSS 18.0 
for Windows.
results 
Four hundred and thirty-three women met the inclusion criteria for trocar-guided 
mesh surgery and were included. Four hundred and nineteen (97%) completed 
the 12-month follow up. Baseline characteristics and preoperative POP stage are 
presented in table 1. Median age of patients was 64 (range 16-93). Seventy-two 
percent of patients had a recurrent POP and 67% a POP stage ≥ Stage III.
Table 2 shows peri- and postoperative data. Eighteen percent of patients (77) 
underwent surgery with a partially absorbable mesh. According to the 12-month 
follow-up questionnaire 38 of 280 (13.6%) patients were classified having de novo 
stress urinary incontinence.
Table 3 shows failure rates per location of mesh insertion for all pre-defined 
outcomes. NIH failure of the mesh treated compartments POP stage ≥ II was 15% 
(95% CI 12-19). NIH failure overall POP stage ≥ II was 41% (95% CI 36-45) and 
composite failure was 9% (95% CI 7-13). Re-surgery was performed in 18 of 433 
(4%) patients, of which sixteen (89%) in the untreated vaginal compartments. 
Highest failure rates were observed for combined anterior/posterior mesh 
insertions.
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table 1. Baseline characteristics.
total n (%) or median (range)
Age, years 433 64 (16-93)
BMI, kg/m2 320 25.6 (18.9-41.8)
Menopause 396 348 (88)
Parity (number) 367 2 (0-7)
Previous POP repair 425 307 (72)
Pelvic organ prolapse
 Stage 0 429 0 (0)
 Stage I 429 0 (0)
 Stage II 429 141 (33)
 Stage III 429 266 (62)
 Stage IV 429 22 (5)
POP = pelvic organ prolapse.
table 2. Peri- and post-operative data.
total n (%) or median (range)
Location tension-free vaginal mesh
 Anterior 433 116 (27)
 Posterior 433 152 (35)
 Anterior and posterior 433 64 (15)
 Total 433 100 (23)
Partially absorbable mesh 433 77 (18)
Mesh procedure combined with native tissue POP 
repair (‘Mesh combined’)
432 83 (19)
 Sacrospinous ligament fixation 432 26 (6)
 Modified Manchester procedure 432 3 (1)
 Anterior colporrhaphy 432 17 (4)
 Posterior colporrhaphy 432 18 (4)
 Perineal repair 432 9 (2)
 Enterocele repair 432 10 (2)
 Mid-urethral sling 432 5 (1)
Operating time (min) 417 60 (20-150)
Blood loss (ml) 412 100 (0-1300)
Complications*
 Rectal serosa lesion 423 2 (0)
 Bladder injury 423 10 (2)
 Urinary retention 423 34 (8)
 Blood loss > 500 ml 412 4 (1)
 Postoperative hematoma 432 22 (5)
 Any complication 432 66 (15)
Mesh exposure within 12 months 425 54 (13)
POP = pelvic organ prolapse. * Multiple diagnoses possible.
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Table 4 shows crude Odds ratios with 90% confidence intervals per outcome 
definition for each of the tested variables. Variables that reached statistical 
significance at the P<0.10 level (shown in bold) were considered valid for entry in the 
multivariable logistic regression model. Since outcome I resulted in just 64 failures, 
we only selected 7 of the 9 most significant variables for entry in the multivariable 
regression model.24
Table 5 shows adjusted Odds ratios after multivariable logistic regression analysis. 
For NIH outcome II (overall POP ≥ stage II), stage of prolapse ≥ III and a solitary 
mesh, be it anterior or posterior, significantly increased the risk of failure. A combined 
anterior/posterior mesh with the uterus in situ appeared to be independently 
associated to failure in all outcomes. Of 35 patients that were diagnosed with a 
composite outcome failure, 9 had undergone a combined anterior/posterior mesh 
insertion. Seven of these 9 (78%) patients had a symptomatic descent of the cervix/
uterus at 12-months; 4 were operated before the 12-months and underwent vaginal 
hysterectomy with a McCall procedure, and one an abdominal sacrocolpopexy. One 
patient was operated beyond the one-year follow-up, but had point C diagnosed at 
+5 cm at 12-months. 
The use of the partially absorbable mesh appeared only to be independently 
related to NIH failure of the treated compartment.
table 3. Failure outcomes at 12 months.
total n Percentage 95% CI
I. NIH failure of mesh treated compartment POP stage > 
II or re-surgery 
415 64 15 (12-19)
 Anterior mesh only 112 20 18 (11-26)
 Posterior mesh only 146 9 6 (3-11)
 Anterior and posterior mesh 62 21 34 (22-47)
 Total mesh 94 14 15 (8-24)
II. NIH failure: overall POP stage > II or re-surgery 419 170 41 (36-45)
 Anterior mesh only 113 60 53 (43-63)
 Posterior mesh only 148 66 45 (36-53)
 Anterior and posterior mesh 62 30 48 (36-61)
 Total mesh 94 14 15 (8-24)
III. Composite failure: overall POP > hymen and bulge 
symptoms or re-surgery 
380 35 9 (7-13)
 Anterior mesh only 106 11 10 (5-18)
 Posterior mesh only 127 13 10 (6-17)
 Anterior and posterior mesh 58 9 16 (7-27)
 Total mesh 87 2 2 (0-8)
Re-surgery 433 18 4 (2-6)
 Mesh treated compartment 18 2 11 (1-35)
 Untreated compartment 18 16 89 (65-99)
Vaginal bulge symptoms 370 43 12 (9-15)
Data in bold are overall percentages with 95% CI per predefined outcome variable.
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cOmment 
Failure rates are highly dependent on outcome definition. The composite outcome 
showed the lowest failure rate, but appeared not to be significantly different from the 
NIH outcome of the mesh treated compartments (9%, 95% CI 7-13 vs. 15%, 95% CI 
12-19). With 41% (95% CI 36-45) the NIH outcome II (leading edge of any prolapsed 
compartment stage ≥ II) showed the highest failure rate. Stage of prolapse ≥ III was 
predictive for failure in NIH outcome II. Predictor of failure for all of the outcomes was 
the location of mesh insertion. Particularly a combined anterior/posterior mesh with 
the uterus or cervix in situ increased the risk of failure in all outcomes. 
One of the weaknesses of this study is that an examiner at the 12-month follow-
-up was not blinded. Use of unblinded POP-Q staging might underestimate overall 
recurrences.25 Another drawback is the relatively short follow-up period of 12 months. 
Strengths on the other hand were the use of validated tools of measurement, such 
as POP-Q and validated questionnaires to objectify symptoms and bother.11, 21 Further 
strengths are the study’s prospective data registry and large sample size. 
This study clearly demonstrates the importance of the outcome definition when 
reporting results of POP surgery. Although it seems logical to focus on the outcome 
in mesh treated vaginal compartment(s), this blurs overall anatomic outcomes as is 
demonstrated and by others.12, 26 Focusing on anatomic criteria only, easily verifiable 
to the physician, does ignore a patient’s perception of symptoms, for which she 
primarily had sought relief.  Chmielewski et al have reanalyzed data of a randomized 
trial of three techniques of anterior colporrhaphy and revealed considerably better 
success with the use of this clinically relevant composite outcome compared with 
strict anatomic criteria.26 These authors also stated that there is a considerable 
portion of women who receive routine gynecologic care that have a POP stage II on 
straining and would therefore not meet the NIH Workshop criteria of a ‘satisfactory’ 
treatment result.10, 27, 28 This is comparable with data from a large Dutch cross 
sectional study among community dwelling women, that revealed that of women 
aged between 45 and 85 years, 36,5% were diagnosed with a stage I and 33% with 
a stage II prolapse, of whom only 6,9% of women with stage I and 15,8% of those 
with stage II experienced vaginal bulge symptoms as opposed to 43,3% of women 
with stage III and 100% of those with stage IV prolapse.29 A large proportion of 
women with stage II prolapse is thus asymptomatic and should be considered to have 
‘physiological’ pelvic organ support. We therefore strongly agree with Barber et al 
that their suggested composite outcome of success, whereby the hymen is regarded 
as threshold for anatomic success and the absence of bulge symptoms as patients 
reported sign of symptom relief, is the most realistic outcome for prolapse surgery 
and should be the outcome of choice in future studies.12 In this analysis we have used 
a composite failure outcome. Since we were particularly interested in patients with 
prolapse beyond the hymen that was symptomatic, the inclusion of bulge symptoms 
in our definition of composite failure was obligatory. 
The large difference in outcome of the mesh treated compartments and overall 
POP, seems to be due to the effect that the treatment of only one vaginal compartment 
can have on the remaining non-treated compartments as was demonstrated in earlier 
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work of us and other studies.12, 14, 26 This finding is emphasized by the overall re-
-surgery rate of 4% (18 out of 433 patients), of which only 11% (2 out of 18 patients) 
were re-interventions in the mesh treated vaginal compartment, but the vast majority 
of 89% (16 out of 18 patients) in the non-treated vaginal compartments. These 
results are comparable with data of a recently published retrospective French study 
on 524 patients, of whom 3% underwent repeat surgery for prolapse recurrence, 
in particular of the untreated vaginal compartments.30 The odds ratios for overall 
failure stage ≥ II after solitary mesh insertions were high and significant (table 5). 
In an earlier study on 150 mesh treated patients we demonstrated that 46% of 
patients after solitary anterior mesh, and 25% after solitary posterior mesh insertion 
developed de novo prolapse stage II or more in the previously unaffected vaginal 
compartments.14 It was recently demonstrated that mesh insertion compared with a 
native tissue repair of only one vaginal compartment is responsible for a greater risk of 
de novo prolapse in other untreated vaginal compartments.31 This secondary analysis 
of a randomized controlled trial, that compared mesh with native tissue repair in 
patients with recurrent prolapse, revealed that 47% of women that underwent mesh 
insertion in only one vaginal compartment developed a de novo prolapse in untreated 
vaginal compartments, compared to only 17% of women after native tissue repair of 
only one vaginal compartment. These data indicate that we have to reconsider our 
surgical strategies when using mesh in only one vaginal compartment. 
In contrast with a solitary posterior mesh, a solitary anterior mesh was no risk 
factor for failure in the composite outcome. Apical suspension is considered crucial 
in prolapse surgery.32 A solitary posterior mesh has the advantage of additional apical 
support by its bilateral sacrospinous suspension. It is well known that sacrospinous 
ligament fixation facilitates anterior vaginal walls to descent.33 We hypothesize, 
that a solitary posterior mesh, by its strong reduction of prolapse enhances the 
effect that sacrospinous ligament fixations already have on the anterior vaginal 
wall. This may contribute to a greater and consequently symptomatic descent of 
the anterior vaginal wall. 
The combination of an anterior/posterior mesh with the uterus or cervix in situ 
appeared independently associated to failure in all outcomes. Multivariable regression 
analysis clearly showed that it was not the single fact of the uterus being in situ, 
but the combination of an anterior/posterior mesh with the presence of the uterus 
that appeared independently associated to failure. Alternative treatment for this 
simultaneous mesh insertion and fixation to the uterus could be a single anterior mesh 
combined with a sacrospinous hysteropexy. Concomitant midline fascial plication of 
the posterior vaginal will adequately treat any prolapsed posterior compartment, if 
necessary.9, 34 This strategy offers the advantage of reduced mesh usage, particularly 
since the evidence for the use of mesh in the posterior compartment is still limited.1 
Another approach to the combined anterior/posterior mesh insertion with pronounced 
uterine descent would be supracervical laparoscopic sacrocolpopexy.35 
The use of the partially absorbable mesh was only independently related to failure 
in the NIH treated compartment outcome, but to none of the others. The use of this 
lighter weight mesh has potential advantages over the heavier-weight original mesh 
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and might be responsible for lesser mesh contraction, less pelvic pain and de novo 
dyspareunia.20 However, the evidence that the use of this partially absorbable mesh 
is superior to native tissue repair surgery still has to be delivered by well-designed 
controlled clinical trials. 
Complication rates in this cohort were comparable with other large studies using 
this mesh.4, 36, 37 Mesh exposure rate in this series was 13%. It has recently been 
reported that most of these mesh exposures are asymptomatic and that two thirds of 
these resolve after minor surgery. It has also been demonstrated that the experience 
of the surgeon has a protective effect on the risk of mesh exposure.38
Recently a FDA Public Health Notification update informed the public in the 
United States on the potential serious complications of trans-vaginal mesh surgery 
and gave recommendations, among which, proper training of the surgeon was one.39 
We therefore believe that only experienced surgeons who are capable of treating an 
adequate volume of patients should be allowed to perform this vaginal mesh surgery. 
The finding that experience of the surgeon diminishes the risk of complications 
supports this statement.30, 38 Future research should focus on surgeons’ experience 
as a potential risk factor for failure; this might give insight into the learning curve 
aspects of vaginal mesh surgery.
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And future PersPeCtIVes

GENERAL DISCUSSION
general discussiOn
More than fifteen years have passed since the publication of the ‘Olsen’ paper.1 The 
challenges to science as stated in the introduction of this thesis have been honoured, 
but have we achieved our goals and optimized the outcomes of vaginal prolapse 
repair surgery? 
This section of the thesis is a reflection of the response to these challenges and to 
the research questions in the outline of this thesis.
The first challenge was to reduce recurrence rates and increase the durability of 
POP repairs. We believe that we certainly have contributed to this aspiration, but 
have not entirely been able to prove this in the work presented in this thesis. The 
first reason for this is that most of the studies that were performed and presented 
in this thesis were observational by nature, and since most of them lacked a control 
group, it is difficult, if not impossible, to determine their acclaimed superiority over 
other traditional type of POP repairs. The second reason is that follow up periods of 
one year are fairly short to claim increased durability of a repair. Longer follow-up 
periods are absolutely mandatory as are well-designed randomized controlled trials to 
definitely determine the position of new vaginal POP repair procedures. 
The second challenge was to optimize and standardize the assessment of 
patients’ symptomatology and anatomical and functional outcomes of POP repairs. 
We honestly believe that this goal has been achieved, as is demonstrated by the 
results presented in the studies of this thesis. The studies presented here, have been 
performed with pre- and postoperative anatomic and functional assessments by the 
systematic use of POP-Q and validated Health related Quality of Life Questionnaires 
and Sexual Function Questionnaires. These have enabled us to clearly and accurately 
objectify both anatomical and functional outcomes, that are indispensable for the 
comparison with other surgical treatments of POP that have used the same tools of 
measurement. Therefore it is absolutely necessary to internationally agree on which 
tools of measurement have to be used. The use of POP-Q has definitely shown its 
indispensable value in anatomical outcome assessment.2, 3 And for the criticasters 
of POP-Q, who state it is to difficult or time consuming to perform a POP-Q, Karp 
et al have recently shown that among examiners who routinely perform POP-Q 
examinations, there is no significant difference between “eyeball” estimated and 
measured POP-Q values and stage.4 
The systematic use of the standard Dutch Urogynecological questionnaire in all 
of the presented studies has greatly contributed to insight in the effect of surgery on 
patient symptomatology and its relation to pelvic floor disorders. This is particularly 
the achievement of van der Vaart et al who validated the Dutch version of the 
UDI, and a few enthusiastic ‘Wergroep Bekkenbodem’ members who selected and 
compiled all items that are present in the latest version of 2006 (see questionnaires 
in appendices).5-8 Although the Defecatory Distress Inventory (DDI) has been used 
in numerous Dutch studies and has proven its value, an official Dutch validation 
of the DDI has not yet been published.9, 10 For that reason and in order to join up 
internationally, we now feel it to be the right time to validate the Dutch versions of 
the PFDI-20 and PFIQ-7 for the purpose of international comparison of functional 
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outcomes of studies.11 This may also particularly facilitate the Dutch participation in 
international studies. 
The Dutch validated version of the PISQ-12 has shown its advantages in these 
respects already.12 However, the present PISQ-12 might not be sensitive or condition-
-specific enough to be able to discriminate in aspects of sexual function, and 
therefore it would also be of value to participate in the Dutch validation process of 
the translated revised PISQ, the ‘PISQ-R’. This process is under the supervision of the 
International Urogynecological Society.
Although the use of changes in the various domains scores of the UDI, DDI and IIQ 
have shown their value in the assessment of functional outcomes, we do believe that 
the addition of calculated effect sizes in particular domains might greatly contribute 
to the clinical relevance of statistically significant changes, and thus facilitates clinical 
interpretation of functional results.13
However, quantization of anatomy is important as is that of function and patients 
symptomatology, but data from the Dutch Brielle study have clearly demonstrated 
that prevalence of feeling and/or seeing a vaginal bulge in all women aged 45 to 
85 years was only 12.1%, while 38.5% of examined women were diagnosed with a 
POP stage II or more.14 This discrepancy clearly demonstrates that not all women with 
a POP stage II are bothered by vaginal bulge symptoms, and might be considered 
to have physiological pelvic organ support. This discrepancy also underlines the 
importance of choosing the right outcome measure in surgical POP studies. Most 
of the studies presented in this thesis have used the internationally accepted NIH 
outcome measures, which actually aim at what at present could be considered more 
or less ‘supra-physiological’ anatomic outcomes (stage 0 and I), and as a consequence 
are more a representation of so called ‘doctors’ goals’, in stead of being a reflection 
of the relieve of a patient’s bother and complaints caused by POP.15, 16 The NIH criteria 
are very strict and, with the present scientific knowledge, seem of limited value, 
since Barber et al have demonstrated that the postoperative absence of vaginal bulge 
symptoms had the most significant relationship with a patient’s assessment of overall 
improvement, while strict anatomic success alone did not.17 These authors therefore 
suggested to use a composite outcome that includes the absence of bulge symptoms 
in addition to anatomic criteria and the absence of re-treatment. They agreed with 
Swift et al to use the hymen as the threshold for anatomic success.18 We strongly 
agree with these authors that this newly proposed composite outcome, which is a 
combination of more realistic anatomic outcome criteria (leading edge of prolapse < 
hymen) with the most specific prolapse symptom of seeing and/or feeling of a vaginal 
bulge, to be the best and most realistic outcome measure. We therefore suggest this 
composite outcome to be the outcome of choice in future studies on the surgical 
treatment of pelvic organ prolapse. 
We have also shown in this thesis that the composite outcome failure in a large 
cohort of mesh treated patients did not significantly differ from the anatomic outcome 
failure rate of the treated compartment only, but was very significantly different from 
failure in overall POP outcome according strict NIH criteria. This finding also underlines 
the statement that in future studies, and particularly in randomized controlled trials 
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that compare two surgical POP procedures, the composite outcome should be used 
as the primary outcome measure, since it is the best reflection of patient’s reported 
outcomes. Since all anatomical and functional data presented in this thesis have 
been collected in a standardized manner and are stored in the Radboud University 
database, it is very well possible to perform re-assessments of the outcomes of the 
studies performed, using this new composite outcome measure.17 
Re-assessment of important randomized controlled trials that so far demonstrated 
significant anatomical benefits for one procedure, in this case vaginal mesh insertion, 
could come to different conclusions when using this new outcome measure, since 
most of these studies could not demonstrate a significantly superior functional 
outcome.19-21 One important trial already showed very different outcomes after re-
-assessing the original data with the new composite outcome measure.22, 23
Part of the composite outcome is the presence of a re-intervention. But what 
do we consider is a relevant re-intervention? Re-surgery in the prolapse-treated 
compartment is an obvious re-intervention that will not be prone to any discussion, 
but what about de novo prolapse in an untreated and previously well supported 
vaginal compartment, or urinary stress incontinence that appeared occult prior to 
surgery, but is unmasked postoperatively as a consequence of appropriate reduction 
of one of the prolapsed vaginal compartments.24, 25 It is necessary therefore, when 
using the proposed composite outcome, to predefine clearly what is considered a 
re-intervention after prolapse surgery as well.
So which aspects of scientific insight have been optimized? 
In chapter 2 we have shown that midline fascial plication for posterior vaginal 
wall prolapse is an effective anatomic treatment with considerable symptom relief 
as shown by improvements in UDI, DDI and IIQ domain scores. Two third of patients 
that suffered from obstructed defecation experienced relief of bother or cure after 
the procedure. The effect size of symptom relief was large (1.5). We also learned that 
predictors of anatomic failure of this procedure were a posterior vaginal wall prolapse 
stage ≥ III and a prior colposuspension. In these cases one might consider to treat 
patients with a trocar-guided mesh insertion of the posterior vaginal wall.
The augmentation of traditional colporrhaphies with a synthetic Titanium coated 
mesh has not resulted in better anatomic outcomes when compared with plain native 
tissue colporrhaphies without augmentation at the short-term follow-up (chapter 3). 
Although the observational cohort study presented in this thesis lacked a control 
group, POP-Q comparison with historical research articles supports that conclusion. 
The tension-free vaginal mesh insertion between bladder and vagina and/or bowel 
and vagina is a revolutionary and more causal way of treating the hernia that occurs 
with POP. 
Although results of the total Prolift™ procedure for post hysterectomy vaginal 
vault prolapse showed excellent anatomic results, as shown in chapter 4, these have 
to be counterbalanced against potential adverse effects, such as mesh exposure, pain 
and dyspareunia, not only at the one-year follow up, but at longer term evaluation as 
well. Although the functional results showed favorable outcomes in our two center 
experience of this paper as well, scientific evidence of superiority can only be obtained 
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by well-designed randomized controlled clinical trials, comparing this procedure with 
the established golden standard procedure, the laparoscopic sacral colpopexy.26 
Both procedures have comparable and considerable learning curves and it hardly 
ever happens that one surgeon is equally experienced in both procedures, so fair 
comparison remains troublesome.27 It has been shown that every decade of clinical 
experience significantly reduces the risk of complications in vaginal mesh surgery.28 
Therefore results of such controlled trials will be influenced and are hampered by the 
experience of the surgeon in either of these techniques. 
In chapter 5 we could demonstrate the low rate of de novo dyspareunia and 
absence of clinically relevant shrinkage of the partially absorbable polypropylene 
mesh in Prolift+M, which is an encouraging improvement in the development of 
mesh-reinforced surgery. 
In chapter 6 we could demonstrate that mesh exposure, a fairly frequent 
complication of vaginal mesh surgery, has been found to be independently associated 
with deterioration in sexual function. Although we could not detect a difference 
in mean sexual function scores, measured with the PISQ-12 at 12 months, we did 
observe that sexual function was affected differently by either trocar-guided mesh 
insertion or by native tissue repair. Improvement in the sexual function scores of the 
native tissue arm was entirely attributed to improvements in the physical and partner 
related subscales, while in contrast with this, slight improvements in the physical 
subscale in the mesh arm were nullified by deteriorations in the behavioral/emotive 
subscale. The fibrotic reactions to the vagina caused by the mesh could possibly be 
responsible for a hampered physiological response of the vagina to sexual stimuli. 
Furthermore there could be a difference in perceived body image by women, but 
also by their spouses, between mesh insertions and native tissue repairs.29, 30 Male 
sexual function following prolapse repair of their sexual partners needs to be more 
thoroughly examined in the future as well. 
We have demonstrated in chapter 7 that outcome of prolapse surgery in trocar-
-guided tension free vaginal mesh insertion clearly depends on outcome definition. 
Conventional (NIH) mesh treated and newly suggested composite outcomes did not 
differ at one year. We could however demonstrate that a combined anterior/posterior 
vaginal mesh insertion with the uterus in situ is a risk factor for failure in all of the 
predefined outcomes.
cOncluding answers tO the research questiOns 
•	 Anatomic and functional outcomes of midline fascial plication under continuous 
digital transrectal control for posterior compartment prolapse were good. Overall 
anatomic success was 80% (95% CI 75-86). Risk factors for anatomic failure were 
initial size of posterior vaginal wall prolapse (stage ≥ III) and prior colposuspension.
•	 Ultra lightweight titanized polypropylene mesh to augment conventional prolapse 
repair surgery showed minimal morbidity, but no additional value compared to 
conventional surgery at short-term follow-up.
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•	 Trocar-guided total tension-free vaginal mesh (ProliftTM) repair with one continuous 
piece of mesh for post-hysterectomy vaginal vault prolapse is well tolerated and 
anatomically and functionally highly effective. Anatomic success was 91% (95% 
CI 83-99). Mesh exposure rate was 15%.
•	 The use of a partially absorbable mesh in trocar-guided mesh repair of POP stage 
≥ III showed improved anatomic support at one-year, with excellent functional 
improvements, without apparent safety concerns. Rate of the novo dyspareunia 
was 2% at one-year follow-up. Sexual function scores, measured with the PISQ-12 
increased significantly post-surgery.
•	 Sexual function scores, measured with the PISQ-12 were not different at one-
year in patients with recurrent prolapse who were surgically treated with either 
a trocar-guided mesh insertion or by vaginal native tissue repair. Mesh exposure 
appeared independently associated with deterioration in sexual function.
•	 In a comparison of outcomes of a large cohort of trocar-guided vaginal mesh 
surgery conventional mesh treated outcome did not differ significantly from a 
newly suggested composite outcome. Treated compartment outcome failure 
was 15% (95% CI 12-19), Composite outcome failure was 9% (95% CI 7-13). 
A combined anterior/posterior mesh insertion with the uterus in situ appeared to 
be a risk factor for failure in all outcomes.
general cOnclusiOn
In conclusion one can say that good research starts with well-designed observational 
cohort studies with proper anatomic and functional outcome measures. The composite 
outcome with adjusted anatomic criteria (leading edge of prolapse < hymen) with 
the postoperative absence of vaginal bulge symptoms and the absence of prolapse 
retreatment should be the outcome of choice. The results of these observational 
studies can subsequently be used for the power calculations that are necessary for the 
search of the supremacy of one of either technique in a Randomized Controlled Trial. 
Although we admit that well designed randomized controlled trials are necessary, we 
believe and we have demonstrated that well designed prospective cohort studies with 
considerable sample size can offer us very valuable information, particularly on certain 
risk factors, and are not necessarily considered an inferior clinical research tool. 
hOw abOut the future?
Future research, with regard to the perspective of this thesis, should focus on the 
validation of the internationally used PFDI-20 and PFIQ-7 and PISQ-R. The impact of 
body image on sexual function following POP surgery, as well as the impact of this 
surgery on male sexual function deserves further research. In a broader perspective, 
and considering the sharp rise in the aging population, further research should focus 
on the development of a durable, safe and patient friendly solution to pelvic organ 
prolapse in general. Longer-term observation of mesh treated patients is absolutely 
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mandatory, but in the mean time further improvements in the biocompatibility of 
synthetic meshes are warranted. One might also think of protective coatings on 
meshes, such as silver to prevent infection, or for example partially, or delayed 
absorbable meshes that serve as scaffolds and are pre-seeded with (stem?) cells 
to improve collagen quality and improve durability of prolapse repairs without the 
potential negative side effects of mesh contraction for example.31, 32 
Another important subject of research should focus on the prevention of 
pelvic organ prolapse, and more in particular on research of the molecular and 
biochemical genetic basis of pelvic organ prolapse, so that our understanding of 
genetic predispositions may expand and possibly and hopefully will provide us in the 
future with means and tools to modify these genetic predispositions in one way or 
another.33 With the expected epidemic of pelvic organ prolapse to come, as a result 
of the aging population, there will be and will remain enough challenging topics for 
basic and clinical research of pelvic organ prolapse.  
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summary
This thesis is about optimizing outcomes of vaginal prolapse surgery with and without 
mesh.
Chapter 1 provides a general introduction on the subject of pelvic organ prolapse 
(POP). The definition, history, prevalence, aetiology and riskfactors, pathophysiology, 
clinical presentation and management of POP are being discussed. The second part 
of the general introduction focuses on the ‘Why-Question’ of this thesis. The two 
challenges that were the inspiration of this thesis are being discussed.
The first challenge was: is it possible to reduce recurrence rates and increase 
durability of POP repairs. The second challenge was: is it possible to optimize assessment 
of symtomatology and anatomical and functional outcomes of POP repairs? 
After a brief description of the trocar-guided tension-free vaginal mesh technique 
and an explanation of the use of the POP-Q system and Symptom Bother and Health 
related Quality of Life questionnaires, the main research questions are formulated in 
the outline of this thesis. 
Chapter 2 provides the detailed description of the surgical procedure and the 
anatomical and functional results of the midline fascial plication under continuous 
digital transrectal control of 233 patients with a posterior vaginal wall prolapse stage 
≥ II. Posterior colporrhaphy is one of the most commonly performed gynecological 
procedures in over 40% of women undergoing surgical correction of pelvic organ 
prolapse. The described surgical procedure is actually a hybrid of the defect discrete 
repair that was ‘en vogue’ in the nineteen nineties of the last century and the classical 
midline plication of the posterior vaginal wall. The addition of the digital transrectal 
control is thought to aid in identifying ‘fascial’ defects and in checking whether the 
repair is ‘solid’ enough. 
The anatomic success rate, according strict NIH criteria (POP stage < II), was 
80.3% (95% CI 75-86). 
Functional results were good as shown by the decrease in patient bother as 
expressed by various significant improvements in mean domain scores of the UDI, DDI 
and IIQ. Effect sizes were calculated as well, with the intention to further objectify 
the clinical relevance of statistically significant findings. Large effect sizes were 
demonstrated for the domain of genital prolapse and pain of the UDI in particular, and 
for the domains of physical functioning and mobility of the IIQ. Only 25% of patients 
were bothered by obstructed defecation, while 75% were not. Sixty-three percent 
of patients, that were significantly bothered by obstructed defaecation, experienced 
cure or relief from their symptoms one year post-surgery. In that subgroup of patients 
the effect size of surgery on obstructed defecation symptoms was particularly high 
(effect size: 1.5). 
Logistic regression analysis identified two independent predictors of anatomic 
failure: a posterior vaginal wall prolapse stage ≥ III and a prior colposuspension.
Chapter 3 provides a detailed description of the surgical technique and 
anatomical and functional outcomes of 71 patients who underwent vaginal prolapse 
repair surgery augmented by ultra lightweight titanium coated polypropylene mesh. 
In contrast with the tension-free vaginal mesh insertion, this technique merely aims 
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to augment traditional vaginal colporrhaphies. No full thickness incision was made, 
but a cleavage of the vaginal wall after hydro dissection and consequently a plication 
took place of what is called the ‘fascial’ remnants of the vagina. The mesh, compared 
to the polypropylene meshes used at that time, was, and still is ultra lightweight 
(16 gr/m2) and covered with a thin layer of titanium to reduce foreign body reactions 
that could be the cause of mesh contraction and subsequently pelvic pain. 
Outcome measures were conventional NIH criteria; POP stage < II.  Anatomic failure 
in the anterior vaginal compartment was 36%, which is not significantly different 
from historical anatomic data after anterior vaginal wall repairs. Remarkably, though 
defined as failures, the prolapse domain scores of these ‘failed’ patients dropped 
dramatically from 50 (range 0-100) before surgery to 7 after mesh augmentation. 
For the posterior vaginal compartment the failure rate was 18%. A weakness of this 
study was the fairly short follow-up period; comments on the durability of the repair 
are therefore difficult to make. Furthermore apical restoration was not systematically 
performed in this patient series, which could be one of the explanations for the 
relatively high failure rate in the anterior compartment. 
Mesh exposure was 5.6 %, which is low if compared to conventional heavier 
weight polypropylene. Whether augmentation with this type of synthetic mesh could 
have contributed to the durability of prolapse repairs can only be determined after 
well designed randomized controlled trials, comparing conventional native tissue 
repairs and repairs with titanium coated mesh augmentation. The evolution in mesh 
surgery however, has taken a slightly other direction. 
Chapter 4 offers a detailed description of the trocar-guided total tension-free 
vaginal mesh repair of post-hysterectomy vaginal vault prolapse. Anatomical and 
functional outcomes of a cohort of 46 patients are presented. This medium weight 
synthetic mesh (45gr/m2) is inserted by the use of trocars through the obturator 
foramen for the anterior compartment and bilaterally through the buttocks and 
sacrospinous ligaments for the posterior compartment, and is inserted underneath 
the full thickness layer of the vagina. This is in contrast with the augmentation 
technique described in chapter 3. This total TVM technique uses only one piece of 
mesh, which simultaneously treats the anterior and posterior vaginal compartments, 
and by passing under an apical bridge of the vagina does provide apical suspension 
by the use of both sacrospinous liagaments. 
Anatomical outcome, defined as overall POP stage <II was 91% (95% CI 83-99). 
Mesh exposure occurred in 15% of patients and was slightly higher than the 10% 
seen in all trocar-guided mesh procedures together at that time, but was mostly 
asymptomatic. A slight, though statistically significant shortening of the vagina was 
observed and is probably related to mesh contraction. 
De novo dyspareunia rate was 18%, but in 28% of patients pre-existing 
dyspareunia resolved after surgery. Patients’ Global Impression of Improvement was 
high: 93% of patients experienced the present situation with respect to prolapse to 
be much or very much better at one-year post-surgery. 
Chapter 5 provides one-year anatomic and functional outcomes of trocar-guided 
mesh repair of vaginal prolapse using a partially absorbable mesh. This observational 
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cohort study comprised 128 patients and was performed in 11 urogynecological 
sites across Europe and the United States. The technique of mesh placement was 
the same as in the original Gynecare Prolift Pelvic Floor repair system, but the 
mesh was entirely different: partially absorbable and more elastic, particularly in 
the longitudinal direction. This mesh contains equal parts of monofilament non-
-absorbable polypropylene and absorbable polyglecaprone 25. Before absorption this 
mesh weighs approximately 57 gr/m2 and after full absorption after 90-120 days only 
31 gr/m2.  
At one year follow-up anatomic outcome, defined as POP stage < II for the mesh 
treated compartment, was 77.4 % (95% CI 69-84). Functional outcomes showed 
significant improvements in all subscales of disease-specific symptoms and Quality 
of Life scores from baseline to one-year. Sexual function scores, measured with the 
PISQ-12 increased significantly at one year with an average of 5.2 points. 
De novo dyspareunia rate was only 2 %. Eighty-nine percent of patients 
experienced the result post-surgery to be ‘much better’ compared to their situation 
before surgery. There were no apparent safety concerns with this new lighter weight 
mesh and the absence of clinically relevant shrinkage combined with the low rate of 
the novo dyspareunia was particularly encouraging.
Chapter 6 provides the results of a study on sexual function in patients with 
recurrent POP, who were treated surgically by either trocar-guided mesh insertion 
or vaginal native tissue repair. Sexual function was measured with the PISQ-12 at 
baseline and at one-year post-surgery. This study was a secondary analysis of study 
VROUW I, a randomized controlled trial, that primarily aimed to compare anatomic 
outcomes of the treated vaginal compartments in patient with recurrent POP, who 
were randomly assigned to either a conventional native tissue repair or tension-free 
vaginal mesh insertion with the Prolift mesh kit. Of the 194 original patients, 78 in 
the mesh arm and 50 in the native tissue arm were ‘ sexually active’. A total of 60 
patients completed the PISQ-12 both at baseline and at one-year and were included 
in the present analysis. Fifty-eight patients were labeled as ‘incomplete responders’ 
since they only completed the questionnaire at baseline or at one-year.
In this study we could not observe a difference in mean total PISQ-12 scores at 
one-year between the two treatment arms. However sexual function was affected 
differently. The native tissue repair arm showed an increase in mean total PISQ-12 
score, which could be entirely attributed to significant improvements in the physical 
and partner related subscales. Total PISQ-12 scores virtually remained unchanged in 
the mesh group though. Subscale analysis revealed that improvements in the physical 
subscale were nullified by deteriorations in the behavioral/emotive subscale, which 
was attributed to significant declines in the frequencies of orgasm and being sexually 
excited. 
The explanation for this difference is sought in the potentially adverse effect that 
insertion of a synthetic mesh could have on the physiological response of the vagina 
to sexual stimuli, a possibly altered body image after a prolapse repair with a mesh 
and/or a different perception that the male partner could have of his sexual partner 
after a prolapse repair with a mesh. 
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The presence of a mesh exposure appeared to be independently associated with 
deterioration of sexual function scores.
Chapter 7 deals with the comparison of different outcome definitions for 
failure in prolapse surgery. Conventional NIH Workshop failure outcomes (pelvic organ 
prolapse stage ≥ II) were compared with a newer, clinically more relevant, composite 
failure outcome (pelvic organ prolapse in any compartment beyond the hymen with 
bulge symptoms or repeat surgery for pelvic organ prolapse). In this prospective 
observational cohort of 433 patients treated by trocar-guided vaginal mesh insertion, 
failure rates varied from 9% (95% CI 7-13) for the composite outcome to 41% 
(95% CI 36-45) for NIH failure outcome of POP in any vaginal compartment. The 
composite failure outcome appeared not statistically different from the NIH failure 
outcome of the mesh treated compartment only (15%, 95% CI 12-19). Since the 
composite outcome includes patients’ bulge symptoms we strongly recommend to 
use this outcome measure in future studies.
The second objective of this study was to identify independent predictors of 
failure for these outcomes by means of logistic regression analysis. Independent 
predictor for failure in all outcomes was the combined anterior/posterior mesh 
insertion with the uterus in situ.
Chapter 8 is a general discussion on the findings of this thesis and provides the 
answers to the research questions posed in the outline of this thesis. Furthermore it 
discusses some challenging aspects of future research that comprehend the aetiology, 
prevention and future alternative treatments of pelvic organ prolapse.  
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samenVatting
Dit proefschrift handelt over het optimaliseren van uitkomsten van prolapschirurgie 
met en zonder het gebruik van mesh.
hoofdstuk 1 geeft een algemene inleiding over het onderwerp genitale prolaps. 
De definitie, geschiedenis, prevalentie, etiologie en risicofactoren, pathofysiologie, 
klinische verschijningsvorm en behandeling van prolaps komen ter sprake. Het tweede 
deel dan de algemene inleiding richt zich op de waarom-vraag van dit proefschrift. 
De twee uitdagingen die de bron van inspiratie voor dit proefschrift waren worden 
besproken.
De eerste uitdaging betrof de vraag: is het mogelijk de recidiefkans van 
prolaps na chirurgische behandelingen te verlagen en de duurzaamheid van de 
plastieken te verhogen? De tweede uitdaging betrof de vraag of het mogelijk 
is de  symptomatologie van genitale prolaps en de anatomische en functionele 
uitkomsten meer gestandaardiseerd in kaart te brengen.
Na een korte beschrijving van de introductie van de ‘spanningsvrije mesh 
techniek’ en een uitleg over het gebruik van POP-Q en Symptoom- en Kwaliteit van 
Leven vragenlijsten, worden de belangrijkste onderzoeksvragen van dit proefschrift 
geformuleerd.
hoofdstuk 2 geeft een gedetailleerde beschrijving van de chirurgische 
procedure en de anatomische en functionele uitkomsten van de ‘fascie plicatie 
onder voortdurende digitale transrectale controle bij 233 patiënten met een 
achterwandprolaps stadium II of hoger. Een achterwandplastiek is een veelvuldig 
uitgevoerde prolapsoperatie en is verantwoordelijk voor 40% van het totaal aantal 
uitgevoerde vaginale prolapsoperaties. De beschreven ingreep is eigenlijk een hybride 
van het zogenaamde defectspecifieke herstel van de achterwand, die in de jaren 
’90 van de vorige eeuw ‘en vogue’ was en de klassieke plicatie van de fascie van de 
vagina-achterwand. De toegevoegde controle met de intra-rectale vinger vergroot 
de kans op het herkennen van fasciedefecten en helpt bij het controleren van de 
stevigheid van de plastiek. 
Het anatomische succespercentage van deze behandeling van het achterste 
compartiment is volgens de strikte NIH criteria (prolaps stadium < II) 80.3% (75-86).
Functionele resultaten waren eveneens zeer bevredigend. Er was een significante 
reductie in prolapsgerelateerde klachten, te meten in meerdere domeinen van de 
Plas Klachten Lijst (UKL), de Defaecatie Klachten Lijst (DKL) en in de Kwaliteit van 
Leven Impact Klachten Lijst (IKL). Klinisch relevante effecten werden waargenomen in 
de domeinen prolaps en pijn van de UKL en in de domeinen fysiek functioneren en 
mobiliteit van de Kwaliteit van Leven Impact Lijst.
Slechts 25% van de behandelde patiënten vertoonde preoperatief symptomen 
van ‘faeces evacuatiestoornissen’. Tweederde van deze groep patiënten ervoer 
verbetering of genezing van hun klachten na chirurgische behandeling. 
Met behulp van Logistische regressie konden twee risicofactoren voor anatomisch 
falen worden geïdentificeerd: 1. een achterwandprolaps stadium III of hoger en 
2. een voorafgaande suspensie van de blaashals.
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hoofdstuk 3 beschrijft de chirurgische techniek en de anatomische en 
functionele resultaten bij 71 patiënten die een versteviging van een conventionele 
voor en/of achterwandplastiek ondergingen met een ultra lichtgewicht getitaniseerde 
polypropyleen mat. De gedachte achter de titanium coating is een mogelijk geringere 
vreemd-lichaam reactie en minder littekenvorming  en mat-krimp met als gevolg 
minder kans op pijn dan bij het gebruik van zwaarder polypropyleen meshmateriaal 
dat in die tijd werd gebruikt.
Volgens de voor die tijd gebruikelijke strikte anatomische uitkomstmaten, was 
het anatomisch ‘faal’ percentage 36% voor de vagina voorwand. Dit percentage 
verschilde niet van studies die geen matversteviging gebruikten. Voor het achterste 
compartiment was het ‘faal’ percentage 18%; eveneens niet verschillend van gebruik 
zonder matversteviging. Een zwakte van het onderzoek is de betrekkelijke korte 
periode tot na controle en het te weinig aandacht schenken aan het belang van 
middelste compartiment suspensie. Dit kan een van de redenen zijn dat de succes 
cijfers matig waren. Ondanks het matige anatomische succescijfer, was bij het 
overgrote deel van de patiënten het verzakkinggevoel postoperatief verdwenen, zich 
uitend in een zeer lage prolaps domein score van de UKL bij na controle.
Mesh exposure, ofwel  het ‘zichtbaar worden van de mat’ in de vagina werd 
waargenomen bij 5.6 % van de patiënten. Dit percentage is laag vergeleken bij cijfers 
over het gebruik van conventioneel, zwaarder polypropyleen mesh materiaal. Of de 
toevoeging van deze getitaniseerde mesh een duurzamer prolaps plastiek resultaat 
oplevert, kan alleen worden vastgesteld na een goed uitgevoerd gerandomiseerd en 
gecontroleerd onderzoek.
hoofdstuk 4 geeft een gedetailleerd beeld van de trocar-geleide totale 
spanningsvrije mesh behandeling voor vagina-top prolaps na voorafgaande 
verwijdering van de baarmoeder. Van 46 patiënten die deze behandeling ondergingen 
en die de jaar controle hadden voltooid worden de anatomische en functionele 
resultaten beschreven. Bij deze techniek wordt een aansluitend stuk polypropyleen 
mesh gebruikt dat dient ter ondersteuning van zowel het voorste, het achterste, als 
het middelste compartiment. Het anatomisch succespercentage was 91 % (83-99). 
Bij 15% van de patiënten echter werd een meshexposure waargenomen. 
Bij 18% werd pijn bij het vrijen gesignaleerd die voor de operatie niet was 
gerapporteerd. Bij 28% van de patiënten echter, was de pijn die voor de operatie 
bij het vrijen aanwezig was, na deze operatie geheel verdwenen. Bij 93% van de 
patiënten was de situatie ten aanzien van de prolaps een jaar na de operatie beter of 
heel veel beter dan voor de operatie.
hoofdstuk 5 beschrijft de 1-jaar resultaten van 128 patiënten die voor een stadium 
III prolaps werden behandeld met een gedeeltelijk oplosbare polypropyleen mesh. Dit 
observationele onderzoek werd uitgevoerd in 11 centra verspreid over Europa en de 
Verenigde Staten. Het betrof ook hier ook een trocar-geleide spanningsvrije mesh 
behandeling, maar met een mesh die enigszins elastisch was, met name in lengte 
richting en bestond uit gelijke delen van onoplosbaar polypropyleen en oplosbaar 
polyglecaprone 25. Voor volledige resorptie is het mesh gewicht 57 gr/m2 en na 
volledige absorptie na 90-120 dagen slechts 31 gr/m2.
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Anatomisch succespercentage na één jaar was 77.4% (69-84); niet significant 
verschillend van de tot die tijd gebruikte niet resorbeerbare polypropyleen mesh. De 
functionele uitkomsten waren eveneens goed en seksuele functie, gemeten met de 
PISQ-12 vragenlijst, was significant verbeterd een jaar na de ingreep.
Bij slechts 2% van de patiënten kon de novo pijn bij het vrijen worden 
gedocumenteerd. Negenentachtig procent van de patiënten ervoer haar prolaps 
situatie een jaar na de ingreep als beter of heel veel beter. De behandeling bleek 
veilig en er waren geen klinische aanwijzingen voor het bestaan van zogenaamde 
‘mat-krimp’.
hoofdstuk 6 vergelijkt het seksueel functioneren, uitgedrukt in gemiddelde 
PISQ-12 scores, bij patiënten die wegens een recidief verzakking een spanningsvrije 
mesh behandeling ondergingen of een klassieke behandeling met lichaamseigen 
weefsel. Deze studie was een secundaire analyse van studie VROUW I, een 
gerandomiseerd onderzoek dat tot doel had anatomische uitkomsten te vergelijken 
van het behandelde vaginale compartiment bij patiënten met een recidief prolaps, 
die of een conventionele prolaps plastiek met lichaamseigen weefsel ondergingen of 
een trocar-geleide spanningsvrije mesh behandeling (de ProliftTM procedure). Van de 
194 geincludeerde patiënten waren er 78 in de mesh arm en 50 in de lichaamseigen 
arm seksueel actief. Zestig patiënten hadden zowel voor als een jaar na de operatie 
de PISQ-12 vragenlijst geheel ingevuld, 58 slechts voor of na, maar niet beide. De 
laatste 58 werden geclassificeerd als uitvallers en vergeleken met de groep die wel 
volledig had gerespondeerd. 
Wij konden na een jaar geen verschil in totale PISQ-12 score waarnemen tussen 
beide groepen. Wel observeerden wij een verschillend effect van de behandelingen 
op seksuele functie. De ‘lichaamseigen’  groep vertoonde een hogere postoperatieve 
totale PISQ score, die geheel kon worden verklaard door significante verbeteringen in 
de fysieke en partnergerelateerde subschalen. De totale PISQ-12 score bleef pre- en 
postoperatief gelijk in de mesh groep. Verbeteringen in de fysieke subschalen werden 
hier teniet gedaan door verslechteringen in de gedrag/emotie gerelateerde subschalen. 
Het waren vooral afnamen in de frequentie van orgasme en het opgewonden raken 
die hiervoor verantwoordelijk waren.
De verklaring voor deze bevinding wordt gezocht in het mogelijk negatieve effect 
dat de insertie een synthetische mesh heeft op de fysiologische respons op seksuele 
stimuli van de vagina. Verder werd geopperd als verklaring dat het lichaamsbeeld 
dat patiënten van zichzelf hebben in de mesh arm ten nadele was veranderd, of het 
lichaamsbeeld dat de mannelijke partner kreeg van zijn vrouw die met mesh werd 
behandeld.
Het bleek dat de aanwezigheid van een mesh ‘exposure voorspellend was voor 
verslechtering van de seksuele functie score, gemeten met de PISQ-12. 
hoofdstuk 7 handelt over de vergelijking van verschillende anatomische 
uitkomst definities voor falen in prolaps chirurgie. De traditioneel gebruikelijke NIH 
Workshop uitkomstmaten voor falen (POP stage ≥ II ) werden vergeleken met een 
nieuwe, klinisch meer relevante, samengestelde uitkomstmaat voor falen (prolaps 
van enig vagina compartiment voorbij het hymen met de aanwezigheid van een 
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balgevoel of een re-interventie voor prolaps). In deze prospectieve cohort studie 
van 433 patiënten, die werden behandeld met trocar-geleide spanningsvrije mesh, 
varieerden de faal uitkomsten van 9% (7-13) voor de samengestelde uitkomst tot 
41% (36-45) voor de conventionele NIH uitkomst voor prolaps in enig compartiment 
van de vagina. De samengestelde uitkomstmaat voor falen verschilde niet significant 
van de NIH uitkomst voor het met mesh behandelde vaginale compartiment (15%, 
12-19). Aangezien de samengestelde uitkomstmaat de aanwezigheid van balgevoel 
bij patiënten meeneemt, bevelen wij het gebruik van deze uitkomstmaat sterk aan in 
toekomstig wetenschappelijk onderzoek.
Het tweede doel van de studie was het identificeren van voorspellers voor falen 
in deze verschillende uitkomstmaten met de hulp van logistische regressie analyse. 
Onafhankelijke voorspeller voor falen in alle uitkomstmaten bleek de gecombineerde 
anterior/posterior mesh behandeling met behoud van de baarmoeder te zijn.
hoofdstuk 8 is een algemene discussie over de onderzoek bevindingen van dit 
proefschrift. Ook worden uitdagende nieuwe onderzoek mogelijkheden rondom 
genitale prolaps geopperd, die o.a. betrekking hebben op de etiologie, de preventie 
en de behandeling.
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list Of abbreViatiOns in alphabetical Order
CI  Confidence Interval
DDI  Defecatory Distress Inventory
DKL  Defaecatie Klachten Lijst
EQ5D  Euroquol-5D
FSFI  Female Sexual Function Index
IIQ  Incontinence Impact Questionnaire
IKL  Impact Klachten Lijst
NIH  National Institute of Health
PGI-I  Patients’ Global Impression of Improvement
PISQ  Prolapse and Incontinence Sexual Function Questionnaire
PFDI  Pelvic Floor Distress Inventory
PFIQ  Pelvic Floor Impact Questionnaire
POP  Pelvic Organ Prolapse
POP-Q  Pelvic Organ Prolapse Quantification
TVM  Tension-free Vaginal Mesh
UDI  Urinary Distress Inventory
UKL  Plas Klachten Lijst
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questiOnnaires 
instructie
Geachte mevrouw,
Voor u ligt de vragenlijst die u hebt ontvangen van uw behandelende gynaecoloog. 
De vragenlijst is bedoeld om meer inzicht te krijgen in uw problematiek en om het 
effect van de voorgestelde behandeling te kunnen meten. In Nederland wordt het 
gebruik van deze vragenlijst aanbevolen door de Werkgroep Bekkenbodem van de 
Nederlandse Vereniging voor Obstetrie en Gynaecologie. De vragenlijst bestaat uit 
een aantal onderdelen. Deze onderdelen bevatten soms vragen waarvan u misschien 
denkt dat ze niet van belang zijn. Wij verzoeken u echter wel om alle vragen in te 
vullen tenzij anders vermeld. Het invullen duurt ongeveer 10 minuten
Naam:
Geboortedatum:
Lengte:
Gewicht:
Datum van invullen:
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-----------------------------------------------------------------------------------------------------------
Dit deel van de vragenlijst bevat een aantal algemene vragen. Omcirkel het bij 
u passend antwoord of vul het getal in.
-----------------------------------------------------------------------------------------------------------
1. Wat is uw leeftijd?  jaar
2. Welke opleiding(en) heeft u voltooid? (meer dan één antwoord mogelijk)
1. basisonderwijs / lagere school (of een deel daarvan)
2. lager beroepsonderwijs (lts, lhno, leao, huishoudschool etc.)
3. mavo, (m)ulo etc.
4. middelbaar beroepsonderwijs (mts, meao, opleiding tot verpleegkundige etc.)
5. vwo, havo, gymnasium, mms etc.
6. hoger beroepsonderwijs (hts, heao, sociale academie etc.)
7. wetenschappelijk onderwijs (doctoraal examen)
3. Wat is uw huidige beroep of zijn uw werkzaamheden? 
4. a. Hebt u kinderen?
 1. Ja  0 Nee (ga door met vraag 5)
b. Hoeveel kinderen heeft u?  (aantal)
c. Hebt u een keizersnede gehad? 1 Ja (    keer) 0 Nee 
d. Hebt u een tang verlossing gehad?  1 Ja (    keer) 0 Nee
e. Hebt u een vacuüm cup verlossing gehad? 1 Ja (    keer) 0 Nee
f. Bent u tijdens de bevalling “ingeknipt” 1 Ja (    keer) 0 Nee
g. Bent u tijdens de bevalling “ingescheurd” 1 Ja (    keer) 0 Nee
h. Wanneer was uw laatste bevalling?   (dag/maand/jaar)
e. Hoe oud was u tijdens de eerste bevalling   (leeftijd in jaren)
-----------------------------------------------------------------------------------------------------------
Bij de volgende vraag loopt de antwoordcategorieën op van 1 (erg slecht) tot 6 
(uitstekend).
Wilt u het getal omcirkelen dat het meest op u van toepassing is?
-----------------------------------------------------------------------------------------------------------
5. Hoe zou u uw algehele kwaliteit van leven gedurende de afgelopen week beoordelen?
 1 2 3 4 5 6
Erg slecht uitstekend
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-----------------------------------------------------------------------------------------------------------
De volgende 5 vragen hebben betrekking op uw huidige gezondheidstoestand. 
Omcirkel bij elke vraag de zin die het best past bij uw eigen gezondheidstoestand 
vandaag.
-----------------------------------------------------------------------------------------------------------
6a. Mobiliteit
1. Ik heb geen problemen met lopen
2. Ik heb enige problemen met lopen
3. Ik ben bedlegerig
6b. Zelfzorg
1. Ik heb geen problemen om mijzelf te wassen of aan te kleden
2. Ik heb enige problemen om mijzelf te wassen of aan te kleden
3. Ik ben niet in staat mijzelf te wassen of aan te kleden
6c. Dagelijkse activiteiten( bv werk, studie, huishouden, gezin- en vrijetijdsactiviteiten)
1. Ik heb geen problemen met mijn dagelijkse activiteiten
2. Ik heb enige problemen met mijn dagelijkse activiteiten
3. Ik ben niet in staat mijn dagelijkse activiteiten uit te voeren
6d. Pijn/klachten
1. Ik heb geen pijn of andere klachten
2. Ik heb matige pijn of andere klachten
3. Ik heb zeer ernstige pijn of andere klachten
6e. Stemming
1. Ik ben niet angstig of somber
2. Ik ben matig angstig of somber
3. Ik ben erg angstig of somber
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6f.
Om mensen te helpen bij het aangeven hoe goed of 
hoe slecht een gezondheidstoestand is, hebben we een 
meetschaal (te vergelijken met een thermometer) gemaakt. 
Op de meetschaal hiernaast betekent “100” de beste 
gezondheidstoestand die u zich kunt voorstellen, en “0” de 
slechtste gezondheidstoestand die u zich kunt voorstellen. 
We willen u vragen op deze meetschaal aan te geven hoe 
goed of hoe slecht volgens u uw eigen gezondheidstoestand 
vandaag is. Trek een lijn van het hokje hieronder naar het 
punt op de meetschaal dat volgens u aangeeft hoe goed of 
hoe slecht uw gezondheidstoestand vandaag is.
 4
 
1. Ik ben niet angstig of somber 
2. Ik ben matig angstig of somber 
3. Ik ben erg angstig of somber 
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-----------------------------------------------------------------------------------------------------------
Vrouwen met ongewenst urineverlies en / of een verzakking hebben aangegeven dat 
ze de volgende klachten hadden. Kunt u aangeven welke klachten u op dit moment 
ook heeft en hoeveel last u daar van heeft. Beantwoord svp alle vragen, ook als u 
geen klachten heeft.
-----------------------------------------------------------------------------------------------------------
7. a. Vindt u dat u vaak moet plassen?
 1. Ja 
 2. Nee (ga naar 7c.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Hoe veel keer plast u gemiddeld per dag?: keer
8. a. Als u moet plassen voelt u dan altijd een sterke aandrang?
 1. Ja
 2. Nee (ga naar 9.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
9. a. Hebt u ongewenst urineverlies als u aandrang voelt om te plassen?
 1. Ja
 2. Nee (ga naar 10.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Zo ja, hoe vaak verliest u ongewild urine?
 1. dagelijks
 2. paar keer per week
 3. 1 keer per week
 4. 1 keer per maand
 5. 1 keer per jaar
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10. a. Hebt u ongewenst urineverlies bij lichamelijke inspanning, hoesten of niezen?
 1. Ja
 2. Nee (ga naar 11.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Zo ja, hoe vaak verliest u ongewild urine?
 1. dagelijks
 2. paar keer per week
 3. 1 keer per week
 4. 1 keer per maand
 5. 1 keer per jaar
11. a. Hebt u moeite uw blaas leeg te plassen?
 1. Ja
 2. Nee (ga naar 12.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
12. a. Hebt u wel eens het gevoel dat de blaas na het plassen niet helemaal leeg is?
 1. Ja
 2. Nee (ga naar 13.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
13. a. Hebt u wel eens een drukkend gevoel onder in de buik?
 1. Ja
 2. Nee (ga naar 14.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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14. a. Hebt u wel eens pijn onder in de buik of in de schaamstreek?
 1. Ja
 2. Nee (ga naar 15.)
b. Zo ja, hoeveel last heeft u hier van? 
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
15. a. Hebt u wel eens het gevoel dat er iets uit de vagina stulpt?
 1. Ja
 2. Nee (ga naar 16.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
16. a. Hebt u wel eens gezien dat er iets uit de vagina stulpt? 
 1. Ja
 2. Nee (ga naar 17.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
17. Hoe vaak hebt u het afgelopen jaar een blaasontsteking gehad?
1. Nooit
2. 1 keer
3. tussen de 2 en 4 keer
4. meer dan 4 keer
18. a. Moet u ‘s nachts meer dan 1 keer plassen?
 1. Ja
 2. Nee (ga naar 19.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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-----------------------------------------------------------------------------------------------------------
De navolgende verschijnselen zijn beschreven door vrouwen met klachten van de 
stoelgang. Geeft u aan welke verschijnselen u tegenwoordig herkent en hoeveel last 
u daarvan heeft. 
-----------------------------------------------------------------------------------------------------------
19. a. Hebt u minder dan driemaal per week ontlasting?
 1. Ja
 2. Nee (ga naar 20.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
20. a. Moet u om ontlasting te krijgen in meer dan een kwart van de keren persen?
 1. Ja
 2. Nee (ga naar 21.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
21. a.  Hebt u wel eens aandrang tot ontlasting terwijl er dan op het toilet geen ontlasting 
komt?
 1. Ja
 2. Nee (ga naar 22.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
22. a. Hebt u wel eens het gevoel dat er iets uit de anus hangt of er iets voor zit?
 1. Ja
 2. Nee (ga naar 23.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
153
CHAPTER 10
23. a. Ervaart u pijn tijdens de aandrang tot ontlasting?
 1. Ja
 2. Nee (ga naar 24.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
24. a. Ervaart u pijn tijdens of vlak na de ontlasting?
 1. Ja
 2. Nee (ga naar 25.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
25. a. Verliest u wel eens dunne ontlasting zonder dat u daar controle over heeft?
 1. Ja
 2. Nee (ga naar 26.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Hoe vaak komt het voor?
 1. dagelijks
 2. paar keer per week
 3. 1 keer per week
 4. 1 keer per maand
 5. 1 keer per jaar
26. a. Verliest u wel eens vaste ontlasting zonder dat u daar controle over heeft?
 1. Ja
 2. Nee (ga naar 27.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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c. Hoe vaak komt het voor? 
 1. dagelijks 
 2. paar keer per week 
 3. 1 keer per week 
 4. 1 keer per maand 
 5. 1 keer per jaar
27. a. Verliest u wel eens windjes zonder dat u daar controle over heeft?
 1. Ja
 2. Nee (ga naar 28.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Hoe vaak komt het voor? 
 1. dagelijks 
 2. paar keer per week 
 3. 1 keer per week 
 4. 1 keer per maand 
 5. 1 keer per jaar
28. a. Moet u wel eens via de schede mee drukken om ontlasting te krijgen?
 1. Ja
 2. Nee (ga naar 29.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
29. a. Moet u de ontlasting wel eens met de vingers via de anus verwijderen?
 1. Ja
 2. Nee (ga naar 30.)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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-----------------------------------------------------------------------------------------------------------
Sommige vrouwen vinden dat ongewenst urineverlies en/of een verzakking en/
of problemen met de ontlasting hun activiteiten, relaties en gevoelens kunnen 
beïnvloeden. De vragen in onderstaande lijst gaan over aspecten van uw leven die 
door uw probleem beïnvloed of veranderd kunnen zijn. Geef voor iedere vraag het 
antwoord aan dat het beste beschrijft hoe zeer uw activiteiten, relaties en gevoelens 
beïnvloed worden door uw urineverlies en/of verzakking en/of problemen met de 
ontlasting.
-----------------------------------------------------------------------------------------------------------
Hoeveel invloed heeft ongewenst urineverlies en/of verzakking en/of problemen met 
de ontlasting gehad op:
30. Uw vermogen om huishoudelijk werk te doen (koken, schoonmaken, wassen) 
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
31. Uw vermogen om klein onderhoud of reparaties te verrichten in en om het huis 
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
32. Boodschappen doen en winkelen
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
33. Reizen met auto of openbaar vervoer over een afstand van minder dan 20 minuten
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
34. Ergens naar toe gaan als u niet helemaal zeker weet of er daar toiletten zijn
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
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35. Bezoek krijgen van vrienden en kennissen
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
36. Relaties met vrienden en kennissen
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
37. Vermogen om een seksuele relatie te hebben
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
38. Geestelijke / emotionele gezondheid
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
39.Wordt u in uw activiteiten beperkt door angst dat anderen u ruiken?
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
Hebt u als gevolg van uw probleem de volgende gevoelens?
40. Nervositeit of ongerustheid 
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg 
41. Frustratie
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
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42. Zich gegeneerd voelen
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
-----------------------------------------------------------------------------------------------------------
De volgende vragen gaan over de seksualiteit. Het is de bedoeling dat u bij het 
beantwoorden denkt aan de situatie van de afgelopen maand. Wilt U het voor u 
meest passende antwoord omcirkelen.
-----------------------------------------------------------------------------------------------------------
 
43. a.  Hebt u wel eens seksueel contact met uw partner? (Denk hierbij aan alle vormen 
van seksueel contact en niet alleen aan geslachtsgemeenschap)
 1. Ja (beantwoord ook vraag b)
 2. Nee (beantwoord ook vraag 43c)
b. Zo ja, hoe tevreden bent u daarover?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Zo nee, hoe vervelend vindt u dat?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
44. Hoe vaak hebt u geslachtsgemeenschap?
1. Nooit 
2. minder dan 1 keer per maand
3. 1 tot 2 keer per maand
4. 1 keer per week
5. meerdere keren per week
45. a. Verliest u wel eens urine tijdens de geslachtsgemeenschap?
 1. Ja
 2. Nee (ga naar 46.) 99 Niet van toepassing (geen seks)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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46. a. Ervaart u pijn tijdens de geslachtsgemeenschap?
 1. Ja
 2. Nee (ga naar 47.) 99 niet van toepassing (geen seks)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
47. a. Is de vagina zo nauw dat geslachtsgemeenschap daardoor niet mogelijk is?
 1. Ja
 2. Nee 99 niet van toepassing (geen seks)
b. Zo ja, hoeveel last heeft u hier van?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
Heeft u alle vragen ingevuld?
Hartelijk dank!
©Werkgroep Bekkenbodem 2006
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Vragenlijst seksueel functioneren bij verzakking 
en ongewenst urineverlies (korte versie: PISQ-12) 
Vraag vooraf: Bent u seksueel actief? 
Ja; ga verder met het lezen van de instructie en invullen van de vragenlijst 
Nee; deze vragenlijst is niet voor u van toepassing 
Instructie. Voor u ligt een lijst met vragen over het seksueel leven van u en uw 
partner. Alle informatie is strikt vertrouwelijk. Uw vertrouwelijke antwoorden zullen 
alleen worden gebruikt om artsen inzicht te geven in wat belangrijk is voor patiënten 
in hun seksueel leven. Kruist u alstublieft aan wat voor u het beste antwoord is op de 
vraag. Bij het beantwoorden van de vragen gaat u uit van uw seksueel leven van de 
afgelopen 6 maanden. Bedankt voor het invullen. 
1. Hoe vaak verlangt u naar seks? Dit verlangen kan bestaan uit het willen hebben 
van seks, het plannen van seks, gevoelens van frustratie door een gebrek aan seks, 
enzovoorts. 
Dagelijks 
Wekelijks 
Maandelijks 
Minder dan 1 keer per maand 
Nooit 
2. Heeft u een orgasme tijdens geslachtsgemeenschap met uw partner? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
3. Voelt u zich seksueel opgewonden tijdens seksuele activiteiten met uw partner? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
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4. Hoe tevreden bent u over de afwisseling in seksuele activiteiten in uw huidige 
seksleven? 
Zeer tevreden 
Redelijk tevreden 
Noch tevreden, noch ontevreden 
Redelijk ontevreden 
Zeer ontevreden 
5. Heeft u pijn tijdens geslachtsgemeenschap? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
6. Heeft u ongewenst urineverlies tijdens seksuele activiteiten? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
7. Wordt u in uw seksuele activiteiten beperkt door angst voor ongewenst verlies van 
ontlasting of urine? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
8. Vermijdt u geslachtsgemeenschap vanwege een uitstulping in de vagina (verzakking 
van blaas, endeldarm of vagina)? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
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9. Wanneer u seks heeft met uw partner, heeft u dan negatieve emotionele reacties, 
zoals angst, afkeer, schaamte of schuldgevoel? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
10. Heeft uw partner een erectieprobleem dat uw seksuele activiteiten beïnvloedt? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
11. Heeft uw partner een probleem met voortijdige zaadlozing dat uw seksuele 
activiteiten beïnvloedt? 
Altijd 
Meestal 
Soms 
Zelden 
Nooit 
12. Hoe intens zijn de orgasmen die u in de afgelopen 6 maanden heeft gehad in 
vergelijking met orgasmen in het verleden? 
Veel minder intens 
Minder intens 
Dezelfde intensiteit 
Meer intens 
Veel meer intens 
13. a. Bent u tevreden met uw seksueel functioneren? 
 Ja, ik ben tevreden 
 Neen; ga door met beantwoording van vraag 13b 
b.  Levert dit stress op voor u en/of stress in uw relatie? (alleen invullen als u 13. a 
met neen hebt beantwoord) 
 Altijd 
 Meestal 
 Soms 
 Zelden 
 Nooit
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instructie 
Geachte mevrouw, 
deze vragenlijst is bedoeld om de situatie na de behandeling die u hebt ondergaan 
te vergelijken met de situatie zoals die vóór de behandeling bestond. Daarom begint 
deze vragenlijst met een algemene vraag naar de mate van verbetering die de 
behandeling bij u heeft teweeg gebracht. De overige vragen zijn identiek aan die uit de 
eerste vragenlijst, waarbij de eerste vier daar gestelde vragen om begrijpelijke redenen 
niet behoeven te worden herhaald. Daarom gaat deze vragenlijst hierna voort met 
vraag 5. Wij verzoeken u dus om na beantwoording van de eerste vraag door te gaan 
met vraag nummer 5 en ook dit keer weer alle volgende vragen in te vullen. 
Naam: 
Geboortedatum: 
Lengte: 
Gewicht: 
Datum van invullen:
-----------------------------------------------------------------------------------------------------------
Deze vraag geeft een globale indruk over de mate van verbetering die de behandeling 
bij u heeft teweeg gebracht. Omcirkel het getal dat het meest op uw huidige situatie 
van toepassing is. 
-----------------------------------------------------------------------------------------------------------
U heeft een behandeling ondergaan voor uw plas- en/of verzakkingsklachten. 
Kies uit het onderstaande rijtje het antwoord dat het beste weergeeft hoe uw situatie 
nu is ten opzichte van de situatie zoals die was vóórdat u werd behandeld. 
1. heel veel beter 
2. veel beter 
3. beetje beter 
4. geen verandering 
5. beetje slechter 
6. veel slechter 
7. heel veel slechter 
Hierna is de vragenlijst identiek aan de intake vragenlijst vanaf vraag 5
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pfdi-20
-----------------------------------------------------------------------------------------------------------
Vrouwen met ongewenst urineverlies en/of een verzakking hebben aangegeven dat 
zij de volgende klachten hadden. Kunt u aangeven welke klachten u op dit moment 
ook heeft en hoeveel last u daarvan heeft. Beantwoord svp alle vragen, ook als u geen 
klachten heeft. 
-----------------------------------------------------------------------------------------------------------
1. a. Voelt u vaak een drukkend gevoel in uw onderbuik?
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
2. a. Heeft u vaak een zwaar of dof gevoel in uw bekken? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
3. a. Voelt of ziet u vaak dat er iets uit het gebied rond de vagina stulpt of valt? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
4. a.  Moet u vaak op de vagina of rond het rectum drukken om uw ontlasting eruit 
te helpen? 
 1. Ja
 2. Nee
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b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
5. a. Heeft u vaak het gevoel dat uw blaas na het plassen niet helemaal leeg is? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
6. a.  Moet u wel eens met uw vingers op een uitstulping in het gebied rond de 
vagina drukken om ervoor te zorgen dat u kunt beginnen met plassen of uit 
kunt plassen?
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
-----------------------------------------------------------------------------------------------------------
De navolgende verschijnselen zijn beschreven door vrouwen met klachten van de 
stoelgang.
Geeft u aan welke verschijnselen u tegenwoordig herkent en hoeveel last u daarvan 
heeft. 
-----------------------------------------------------------------------------------------------------------
7. a.  Heeft u wel eens het gevoel dat u te hard moet persen om uw ontlasting kwijt te 
raken? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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8. a. Heeft u wel eens het gevoel dat uw darmen na de stoelgang niet helemaal leeg zijn? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
9. a. Verliest u wel eens vaste ontlasting zonder dat u daar controle over hebt? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Hoe vaak komt dit voor?
 1. dagelijks
 2. paar keer per week
 3. 1 keer per week
 4. 1 keer per maand
 5. 1 keer per jaar
10. a.  Verliest u wel eens dunne of vloeibare ontlasting zonder dat u daar controle 
over hebt?
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Hoe vaak komt dit voor?
 1. dagelijks
 2. paar keer per week
 3. 1 keer per week
 4. 1 keer per maand
 5. 1 keer per jaar
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11. a. Laat u wel eens windjes zonder dat u daar controle over hebt?
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Hoe vaak komt dit voor?
 1. dagelijks
 2. paar keer per week
 3. 1 keer per week
 4. 1 keer per maand
 5. 1 keer per jaar
12. a. Heeft u tijdens de stoelgang pijn? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
13. a.  Voelt u vlak voor de stoelgang sterke aandrang en moet u dan zo snel mogelijk 
een wc opzoeken?
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
14. a.  Komt het tijdens of vlak na de stoelgang wel eens voor dat een stukje darm uit 
het rectum naar buiten stulpt? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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15 a. Moet u vaak plassen? 
 1. Ja
 2. Nee (ga naar 15c.)
b. Zo ja, hoeveel last hebt u hiervan? 
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Hoeveel keer plast u gemiddeld per dag?:  keer
16. a. Heeft u ongewenst urineverlies als u aandrang voelt om te plassen? 
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Zo ja, hoe vaak verliest u ongewild urine? 
 1. dagelijks
 2. een paar keer per week
 3. één keer per week
 4. één keer per maand
 5. één keer per jaar.
17. a. Verliest u urine als u moet hoesten, niezen of lachen? 
 1. Ja
 2. Nee
 b. Zo ja, hoeveel last heeft u hiervan?
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
c. Zo ja, hoe vaak verliest u ongewild urine? 
 1. dagelijks
 2. een paar keer per week
 3. één keer per week
 4. één keer per maand
 5. één keer per jaar. 
18. Verliest u vaak kleine hoeveelheden urine, dat wil zeggen druppeltjes? 
 1. Ja
 2. Nee
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b. Zo ja, hoeveel last heeft u hiervan? 
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
19. Heeft u vaak moeite om uw blaas te legen?
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan? 
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
20. Ervaart u vaak pijn of ongemak in de onderbuik of de schaamstreek?
 1. Ja
 2. Nee
b. Zo ja, hoeveel last heeft u hiervan? 
 1. Helemaal niet
 2. Een beetje
 3. Nogal
 4. Heel erg
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-----------------------------------------------------------------------------------------------------------
Sommige vrouwen vinden dat ongewenst urineverlies en/of een verzakking en/
of problemen met de ontlasting hun activiteiten, relaties en gevoelens kunnen 
beïnvloeden. De vragen in onderstaande lijst gaan over aspecten van uw leven die 
door uw probleem beïnvloed of veranderd kunnen zijn. Geef voor elke vraag het 
antwoord aan dat het beste beschrijft hoe zeer uw activiteiten, relaties en gevoelens 
beïnvloed worden door uw urineverlies en/of verzakking en/of problemen met de 
ontlasting. 
-----------------------------------------------------------------------------------------------------------
Hoeveel invloed heeft ongewenst urineverlies en/of verzakking en/of problemen met 
de ontlasting gehad op: 
1. Uw vermogen om huishoudelijk werk te doen (koken, schoonmaken, wassen)?
1. Helemaal niet 
2. Een beetje 
3. Nogal 
4. Heel erg
2. Uw vermogen lichamelijke activiteiten te ondernemen zoals wandelen, zwemmen 
of andere oefeningen? 
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
3. Het bezoeken van een uitvoering zoals een film of een concert?
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
4. Uw vermogen met de auto of de bus te reizen, langer dan 30 minuten van huis? 
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
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5. Uw deelname aan sociale activiteiten buitenshuis?
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
6. Uw emotionele gezondheid (nervositeit, depressie enz.)?
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
7. Gevoelens van frustratie?
1. Helemaal niet
2. Een beetje
3. Nogal
4. Heel erg
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Lorenzo Milani (*12.01.1929). In 1972 he graduated from high school (HBS-B: Titus 
Brandsma College) in Dordrecht. Unfortunately he was eliminated ‘by lottery’ for 
Medical School in the Netherlands, but could start this study at the University of 
Antwerp (RUCA) in Belgium. After completing the propaedeutic course cum laude, 
he was offered a restart of study in the Netherlands at the Erasmus University Medical 
School Rotterdam. During this study he was a student-assistant in Physics and Neuro-
-Anatomy. The latter created the opportunity to follow a junior residency Neurology 
at the Albert Einstein College of Medicine, New York in 1976. 
After graduation from Medical School in 1979, he prepared himself for Tropical 
Medicine. After finishing the necessary residencies in Obstetrics & Gynecology 
(Ikazia Hospital Rotterdam) and Surgery (Hofpoort Hospital Woerden), as well as a 
Postgraduate Course in Tropical Medicine and Kiswahili language course at the Royal 
Institute for the Tropics in Amsterdam, he left for Tanzania in 1982. There he worked 
at the Rubya Designated District Hospital in Northwest Tanzania for 4 years. His eldest 
daughter and son were born on African soil.
Having become motivated for Obstetrics & Gynecology in Africa, he started his 
Training residency at the Ikazia Hospital Rotterdam -where his youngest son was born- 
and the Erasmus University Medical Center. At the Ikazia Hospital Mark Vierhout 
started sowing the seeds for his later interest in Urogynecology. After obtaining his 
registration as consultant in Obstetrics & Gynecology in 1993 he started working as 
general gynecologist at the Reinier de Graaf Hospital Delft, where he still is working 
today. 
In 1998 he was invited by Mark Vierhout to participate in the organization of the 
National Urogynecology Course for last year residents in Obstetrics & Gynecology. He 
has been a board member since. In 2002 Mark Vierhout initiated a differentiation-
-year Urogynecology for last year residents and started the cooperation between the 
Erasmus University Medical Center and the Reinier de Graaf Hospital Delft. One of 
the residents that followed this differentiation-year was Mariella Withagen. In 2005 
Mark Vierhout became the first professor in Pelvic Floor Pathology at the Radboud 
University and invited Mariella Withagen to become his staff member. That created 
the foundation for consistent and sound scientific cooperation between Nijmegen 
and Delft. This scientific cooperation and friendship forms the base of the work 
presented in this thesis.
Since 2010 he is president of the board of the Pelvic Floor Society of the Dutch 
Gynecologists and since 2011 registered as subspecialist in Urogynecology.
He is the blessed father of three children: Sara Zawadi (*01.11.1983), David Byera 
(*09.10.1985) and Nathan Lorenzo (*20.05.1992) and the partner of Bart Broekman.
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aan mijn ouders, omdat jullie er waren,
aan mijn kinderen, omdat jullie er zijn,
aan Mark voor je vertrouwen,
aan Mariella voor je ‘maat’- schap,
en aan Bart voor je geduld.
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